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In the late 1700s, Edward Jenner described induced immunity in which he 
demonstrated that inoculation with cowpox prevented one from developing 
disease against smallpox. A century later, Emil Adolf von Behring explored 
the potential of passive immunity as an anti-toxin therapy against tetanus. 
These pioneer works laid the cornerstones for subsequent vaccine and 
therapeutic antibody development as well as for today’s exploding 
immunotherapy research. The first half of this thesis is dedicated to the 
cloning, expression, and characterization of monoclonal antibodies obtained 
from two naturally infected dengue patients. This led to the subsequent 
discovery and further characterization of an antibody that possesses potent 
neutralization capacity against all four dengue virus serotypes. In parallel, an 
attempt to design antibodies that can cross-neutralize all four dengue virus 
serotypes by an engineering approach was made and will be described in the 
second half of this thesis. This thesis ends with the exploration of yeast display 
technology platform for epitope mapping.   
 
A panel of 65 human monoclonal antibodies (hMabs) was isolated from 
dengue patients at the acute phase of disease by single B cell PCR cloning. A 
major fraction of the isolated antibodies were dengue virus (DENV) specific 
that also displayed reactivity to envelope protein and broad cross-reactivity 
against all four DENV serotypes. However, they only possessed poor to 
modest neutralization capacity. In addition, a unique antibody, clone 50_3C, 
characterized by its ability to recognize a quaternary structure epitope was 
identified. Unlike the other antibodies, this antibody was found to possess 
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potent neutralization capacity across all four DENV serotypes.  Furthermore, 
viral neutralization in vitro was found to translate to protection from infection 
in a mouse model against at least two DENV serotypes. Our studies also 
revealed blockade of both attachment and membrane fusion as the 
mechanisms of neutralization by this novel antibody.  As expected, this 
antibody mediates a slight antibody-dependent enhancement (ADE) in all four 
DENV serotypes both in vitro and in vivo.   
 
In parallel, an artificial antibody construct that can neutralize all four DENV 
serotypes potently was proposed. The design principle aimed to stop the 
envelope protein from undergoing the drastic conformation change necessary 
for viral infection and led to the exploration of the use of a bispecific antibody 
that “locks” the dimeric envelope protein subunits.  Although initial tests of a 
small number of the bispecific antibodies did not result in enhanced 
neutralizing potency as compared their corresponding parent antibodies, 
further analysis of the properties of these molecules should aid refining the 
design.     
 
In this thesis we also explored a high throughput approach for epitope 
mapping.  This was achieved by employing the yeast display technology in 
which a library of envelope protein variants with single mutations across the 
entire protein is expressed on the surface of the yeast cells. We have 
demonstrated functional expression of the wild type, full-length dengue virus 
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Chapter 1: Introduction 
1.1 Dengue 
1.1.1 Re-emergence of a century old virus as a global health problem  
Dengue is an arthropod-borne viral disease transmitted predominantly by the 
Aedes aegypti vector. The first probable case of Dengue was recorded as 
‘water poison’ in association with flying insects and water in a Chinese 
medical encyclopedia, which dates back to the Jin Dynasty (265-420AD) 
(Gubler 1998). Following the first confirmed case report of Dengue by Dr 
Benjamin Rush in 1780 (Rush 1789), many epidemics have since been 
described between the late 1700s to mid-1900s over the Asia, Africa and 
America continents simultaneously. 
 
Major dengue epidemics before the 19th century rarely resulted in mortality 
and were relatively infrequent, possibly due to the slow transport of the 
etiological agent and vector by sailing vessels used primarily for commerce 
and slave trade (Smart 1877). However, following the end of World War II in 
1945, dengue epidemiology in the South East Asia took a drastic change as a 
direct result of the unprecedented global population growth which led to the 
unplanned and uncontrolled urbanization, creating densely populated areas 
with poor sanitation which provided an ideal breeding environment for the 
highly domesticated anthropophilic vector Aedes aegypti. On top of this, troop 
movement around the continent facilitated the spread and circulation of all 
four virus serotypes leading to hyperendemicity (Halstead 1980). Along with 
the increase in epidemic transmission and hyperendemicity, a newly described 
disease, Dengue Haemorrhagic Fever (DHF), emerged.  
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The first DHF epidemic was reported in Manila in 1954 (Hammon, Rudnick et 
al. 1960). Since then, the disease has spread throughout South East Asia in a 
short span of two decades. By the mid-1970s, DHF has become a leading 
cause of hospitalization and death among children in the region (Halstead 
1980). In 1981, the first outbreak of a DHF epidemic outside of South East 
Asia was described in Cuba. This epidemic saw a total of 344, 203 cases, of 
which 10,312 had DHF with 158 deaths over just three months (Kouri, 
Guzman et al. 1989). By the 20th century, the America continent which has 
been spared from the disease for decades owing to the successful eradication 
of Aedes aegypti in the region to curb yellow fever between 1947-1970 
(PAHO, 1997), experienced unprecedentedly high numbers of occurrences of 
DF/DHF. This coincided with the re-infestation of its principal vector, Aedes 
aegypti and the co-circulation of all four virus serotypes. 
 
Taken together, it appears that the spread of dengue was largely contributed by 
human behavior (urbanization, international air travel) and fueled further by 
the unsustainable vector control programs. Globally, it is estimated that over 
2.5 billion people are at risk of infection (Gubler 1994, Gubler 2002) WHO, 
2014), making Dengue infection the most significant arthropod-borne human 
disease (Figure 1.1). However, infection with any of the serotypes confers 
only short term cross-protection against the other serotypes, with life-long 
immunity only towards that particular infecting serotype (Sabin 1952). At 
present, specific treatment does not exist beyond palliative care nor does an 




















































































































































1.1.2 Origin and Transmission 
The etiological agent for Dengue, the dengue virus, was first identified as a 
filterable agent transmitted by arthropods in 1907 by Ashburn and Craig 
(Ashburn, Craig et al. 2004). It was subsequently isolated in 1943 by Ren 
Kimura and Susumu Hotta (Hotta 1952). Four antigenically distinct serotypes 
of Dengue exist and they are all members of the DEN antigenic complex of 
the genus Flavivirus, family Flaviviridae (Calisher, Karabatsos et al. 1989). 
 
A phylogeny tree based on sequences of the non-structural 5 (NS5) gene from 
flaviviruses showed three major groups corresponding to their transmission 
mode; by ticks, those without known vectors and lastly in majority, by 
arthropods, including dengue (Figure 1.3) (Holmes and Twiddy 2003).  Many 
other arthropod-borne viruses belonging to the Flavivirus genus also cause 
diseases in humans of significant magnitude globally, with yellow fever and 
Japanese encephalitis as the classical examples.  
 
Traditionally, viruses are grouped based on their genome organization, 
sequence homology and antigenic cross reactivity in various serological tests. 
Nucleic acid sequencing allowed their precise classification within each 
serotype (Rico-Hesse 1990) into genetically distinct groups or genotypes 
defined as clusters of DENV with sequence divergence not exceeding 6% in 
the E/NS1 junction. Phylogeny studies suggests that among the four dengue 
virus serotypes, serotype 4 appeared to be the first to diverge followed by 
serotype 2 with the final split between serotypes 1 and 3 (Figure 1.4) (Holmes 
and Twiddy 2003, Weaver and Vasilakis 2009).  Subsequently, E gene 
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sequences were used as the benchmark for phylogenetic studies until the 
advent of whole genome sequencing which provided a more robust 
phylogenetic study of dengue virus evolution (Weaver and Vasilakis 2009). 
 
Two distinct dengue transmission cycles exist: (1) Sylvatic: enzootic cycle 
between non-human primates and arboreal mosquitos of the genus Aedes, (2) 
Urban: epidemic/endemic cycle between Aedes aegypti and human reservoir 
hosts (Figure 1.2). The first evidence of the existence of a sylvatic cycle 
dengue virus came from Rico-Hesse in 1990 when he showed that strains from 
sylvatic habitats were genetically distinct from the endemic strains. A 
comprehensive phylogenetic study utilizing complete E genes sequences from 
DENV1, -2 and -4 isolated during the 1960s in Malaysia and DENV-2 in 1980 
in West Africa further substantiated the hypothesis of a sylvatic DENV origin 
(Wang, Ni et al. 2000) which were part of the enzootic transmission cycle 
involving the Aedes mosquitoes and lower primates found in the forests of 
Asia and West Africa. 
 
Cross-species transmission to humans only occurred following encroachment 
into the forest, encouraging the virus to break free from its original sylvatic 
cycle with the continuous supply of susceptible hosts. Transmission in humans 
was sustained as a result of vector adaptation to the highly domesticated Aedes 




Figure 1.2: Dengue transmission cycles. Two distinct transmission cycles exists 
for dengue virus. Sylvatic: Enzootic cycle between non-human primates and 
arboreal mosquitos. Urban: Epidemic/Endemic cycle between humans and the 
Aedes genus mosquitos. Adapted from Whitehead et al. Prospects for a dengue 
virus vaccine, Nature reviews Microbiology, 2007. 
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Figure 1.3: Phylogeny tree of Flaviviruses. The Flaviviruses are categorized into 
three major groups based on their transmission mode by ticks, mosquitos and 
those with no-known vectors. The major group of viruses is transmitted by 
mosquitoes which the Dengue viruses are part of. Adapted from Holmes & 
Twiddy. The origin, emergence and evolutionary genetics of dengue virus, 
Infection, Genetics and Evolution, 2003.
8 
 
Figure 1.4: Phylogeny tree of Dengue viruses. Dengue virus exists in four 
antigenically distinct serotypes. Dengue serotype 4 appears to be the first to 
diverge followed by Dengue serotype 2 and the final split between Dengue 
serotypes 1 and 3. Both sylvatic strains and endemic strains exist, although 
phylogeny studies suggest that Dengue viruses are of sylvatic origin. Adapted 
from Weaver & Vasilakis. Molecular Evolution of Dengue Viruses: Contributions 
of Phylogenetics to Understanding the History and Epidemiology of the 
Preeminent Arboviral Disease. Infectious Genetics Evolution, 2009.
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1.1.3 Dengue virus structure and genome organization 
Dengue virus particles are small (~50nm) enveloped viruses with a positive 
single stranded RNA genome approximately 11 000 nucleotides in length. The 
presence of an RNA species other than the genomic mRNA has been 
documented in infected cells. A product of incomplete genomic RNA 
degradation by cellular 5’-3’ exoribonuclease (EXRN1), the subgenomic 
flavivirus RNA (sfRNA) has been implicated in modulating several cellular 
pathways to facilitate viral pathogenicity (Pijlman, Funk et al. 2008, Liu, Yue 
et al. 2010, Moon, Anderson et al. 2012).  
 
A single ORF exists within the genome which directs the synthesis of three 
structural and seven non-structural viral proteins necessary for viral replication 
in the following order; Capsid(C)-Membrane(prM)-Envelope(E)-NS1-2A-2B-
3-4A-4B-NS5 as a single polyprotein precursor cleaved by a combination of 
host and viral enzymes co- and post-translationally (Figure 1.6) (Lindenbach 
2007). Translation of the ORF is dependent on the typical type I cap 
(m7GpppAmp) found at the 5’end; the mRNA, however, lacks the usual 
polyadenylated tail at its 3’ end (Wengler and Gross 1978). Non-coding 
regions flank the ORF at the 5’ and 3’ends whose secondary structures aids in 
genome translation. Virus replication genome translation efficiency is thought 
to influence flavivirus infectivity. The N-termini of prM, E and NS1 follow 
predicted host signalase cleavage sites contributed by the C-terminal 
hydrophobic regions of anchored C, prM and E (von Heijne 1984). This is also 
true for NS4B. Although the N-terminal of NS2A also follows the host 
signalase cleavage site, it lacks the requisite upstream hydrophobic region; 
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hence, the enzyme responsible for cleaving between NS1 and NS2A remains 
unknown. Cleavage sites of NS2B, NS3, NS4A and NS5 are highly conserved 
among flaviviruses and cleavage is mediated by the flavivirus-encoded 
protease. 
 
The genome is enclosed within a nucleocapsid about 30 nm in diameter 
surrounded by an envelope consisting of a lipid bilayer of host origin with two 
viral glycoproteins, E and M. The E protein mediates binding to host cell 
receptors and membrane fusion required for virus entry.  It is also the major 
antigenic determinant. The M protein is a small proteolytic fragment produced 
as part of the precursor prM during maturation of nascent virus particles 
within the secretory pathway. Two types of virion particles exist characterized 
by the association of E with prM or M. Intracellular immature viral particles 
have 180 copies of prM which form heterodimers with E and give the 
immature viral particles their ‘spiky’ appearance with 60 of such spikes each 
composed of three prM-E monomers (Zhang, Corver et al. 2003). 
Extracellular mature viral particles have M although extracellular immature 
viral particles with prM can also be found (Figure 1.5). Cleavage of the prM 
precursor is mediated by the Golgi resident host enzyme furin that results in 
the release of pr peptides with E trimers dissociating and re-forming into 
homodimers (Allison, Schalich et al. 1995, Rey, Heinz et al. 1995). prM 
cleavage precedes virus release from infected cells and appears to trigger 
structural changes in the E protein that dictates virus maturation and 







Figure 1.5: Structures of the immature and mature Dengue viral particles. (a) 
Immature viral particles are characterized by the presence of prM in association 
with E protein which give them the ‘spiky’ appearance. (b) This is in contrast to 
the mature virion which has the pr cleaved prior to its release and has a smooth 
surface. Adapted from Yu et al. Association of the pr peptides with dengue virus 
at acidic pH blocks membrane fusion, Journal of Virology, 2009. 







   







   
 

















































































































































































































































































































































































































































































































































1.1.4 Envelope (E) protein 
The E protein is the major structural surface protein of the virus with 
functional roles in virion assembly, receptor binding and membrane fusion 
(Kielian, Klimjack et al. 1996, Allison, Schalich et al. 2001, Kuhn, Zhang et al. 
2002). In addition, the E protein appears to be the primary target of the 
humoral immune response with studies showing antibodies against E protein 
are able to inhibit virus attachment and neutralize viral infectivity in vitro 
(Roehrig, Bolin et al. 1998).  Also, passive transfer of antibodies against the E 
protein is able to protect mice from subsequent DENV challenge (Kaufman, 
Summers et al. 1987) in vivo. Furthermore, antibodies raised in mice against 
envelope protein also possess neutralizing activity (Kitano, Suzuki et al. 1974).  
 
The E protein is synthesized as a typical Type I membrane protein in which a 
single transmembrane alpha-helix links the ectodomain and the cytoplasmic 
tail. Disulfide bonds formed by 12 conserved cysteine residues (Mandl, 
Guirakhoo et al. 1989) are present on the E protein along with two N-linked 
glycosylation sites at Asn67 and Asn153, which have been implicated in virus 
infectivity and tissue tropism (Mondotte, Lozach et al. 2007). The N terminus 
ectodomain is dominated by β-sheet structures (Rey, Heinz et al. 1995) 
followed by a stem-anchor region made up of two conserved α-helices 
essential for fusogenic structure assembly and stabilization (Stiasny, Allison et 
al. 1996) and a transmembrane segment at the C terminus (Mandl, Guirakhoo 




The native form of E folds into three domains (termed DI-DIII), which 
correspond to the three antigenic domains C, A and B, respectively, in a 
previous study by Mandl et al, (Mandl, Guirakhoo et al. 1989) (Figure 1.7). 
Domain I forms the central β-barrel linking Domain II, which contains an 
elongated dimerization region and houses the putative fusion loop, to Domain 
III that assumes an immunoglobulin-like fold. DIII appears to be involved in 
receptor binding due to the occurrence of such immunoglobulin-modules in 
cell adhesion proteins; not surprisingly EDIII is the major target of 
neutralizing antibodies as demonstrated in various studies utilizing mouse 
monoclonal antibodies (Roehrig, Bolin et al. 1998, Gromowski and Barrett 
2007, Lisova, Hardy et al. 2007, Sukupolvi-Petty, Austin et al. 2007). Two E 
monomers form a head-to-tail homodimer that lies parallel to the virion 
surface, with slight curvatures to accommodate the spherical viral membrane 
(Rey, Heinz et al. 1995). Three homodimers make a set and assume a 
‘herringbone’ configuration of icosahedral symmetry with a total of 90 copies 
of homodimers (Figure 1.7) (Kuhn, Zhang et al. 2002). However, this 
arrangement of the E homodimers does not reflect the true T = 3 structure at 
neutral pH as the environment of the dimers differs significantly between the 
icosahedral 2-fold axes and the quasi-2-fold axes. It is at lower pH that 
weakened association between the homodimers drives the re-arrangement of 
each E monomer to produce a true T = 3 structure in which every monomer 








E mediates virus entry by facilitating its attachment to host cells through 
multiple receptors (Rey, Heinz et al. 1995). Virus internalization occurs 
through clathrin-coated pits and traffic to a prelysosomal endocytic 
compartment where the lower pH initiates fusion of the virus and host cell 
membranes, thus releasing the viral genome to the cytoplasm. There is 
significant structural rearrangement of the E protein during this phase 
characterized by the dissociation of homodimers to monomers followed by the 
irreversible re-association of the monomers to form the fusogenic trimer 
structure (Figure 1.8) (Allison, Schalich et al. 1995, Stiasny, Allison et al. 
1996). Fusion peptides located at the distal ends of Domain II are exposed 
following trimer formation and extend outward from the virion surface (Kuhn, 
Zhang et al. 2002) towards the host cell membrane to form the closed β-barrel 
structure required for membrane fusion. Similar to the alphaviruses, class II 
Figure 1.7: Structure of the whole dengue virus. (A) Each E monomer folds into 
3 domains with domains I, II, and III in red, yellow, and blue, respectively. (B) 
Each E monomer form head-to-tail homodimers that lie parallel to the virion 
surface. Scale bar represents 100 A. Adapted from Kuhn et al. Structure of 





fusion mechanism based on insertion of β-barrel structure into the host cell 




Figure 1.8: Proposed Rearrangement of E Dimers in Flaviviruses upon Exposure 
to low pH. The E protein dimers in mature virus (A) are shown undergoing a 
rearrangement to the predicted T = 3 fusogenic structure (C) with a possible 
intermediate (B). Arrows in (B) indicate the direction of E rotation. The solid 
triangle in (C) indicates the position of a quasi-3-fold axis. Adapted from Kuhn et 
al. Structure of Dengue Virus: Implications for Flavivirus Organization, 
Maturation, and Fusion. Cell, 2002. (D) Schematic of E undergoing pH induced 
structural changes necessary to mediate fusion. L-R: E homodimer mediates 
binding to host cell receptors, dissociation of E homodimers to monomers 
exposing fusion loop, E monomers form homotrimer fusion structure upon 
insertion into cell surface, homotrimers mediate virus: host cell membrane. 
Adapted from Modis et al. Structure of the dengue virus envelope protein after 




1.1.5 Clinical features 
Following the bite of a susceptible human host by an infected vector 
(predominantly Aedes aegypti), disease manifestation occurs following an 
incubation period which usually spans between 3-7 days. Infection with any of 
the four antigenically distinct dengue virus serotypes results in a broad 
spectrum of disease. In about 80% of those infected, patients either do not 
present any symptoms of the disease or suffer from an undifferentiated fever 
not readily diagnosed as dengue fever (Burke, Nisalak et al. 1988). However, 
the disease can also manifest with a very different clinical presentation that 
can be divided into three phases: Febrile, Critical and Recovery Phase (WHO 
2009) (Figure 1.9).  
 
In these patients, there is a sudden onset of high fever (about 40oC) which is 
often biphasic in nature accompanied by symptoms including but not limited 
to severe headache, myalgia, arthralgia, retro-orbital eye pain or a maculo-
papular rash with minor hemorrhage manifesting as petechiae. A positive 
tourniquet test usually differentiates dengue from other non-dengue febrile 
diseases. This is known as the classical Dengue Fever (DF) and constitutes the 
febrile phase which lasts 2-7 days. A small percentage of patients presenting 
the classical DF symptoms may develop a more severe and occasionally life-
threatening form of the disease in the next 24-48 h; the critical phase of the 
disease which coincides with defervescence when there is a drop in body 
temperature to 37.5-38oC or below. During this period, leukopenia is observed 
along with thrombocytopenia owing to the increase in vascular permeability 
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evidenced by the equivalent increase in hematocrit levels preceding plasma 
leakage.  
 
This clinical feature distinguishes the more severe form of the disease known 
as Dengue Hemorrhagic Fever (DHF) from the classical DF (WHO 2009). 
Under the WHO guidelines, DHF is further categorized into four grades 
differentiated by severity: Grades I-IV with grades III and IV classified as 
Dengue Shock Syndrome (DSS) which occurs when there is a significant loss 
of plasma volume through leakage, leading to hypovolemic shock, organ 
impairment and finally resulting in death of the patient. Patients without signs 
of shock are classified under Grades I or II.DSS is the most severe outcome of 
the disease and is the leading cause of mortality in dengue infected patients. In 
patients who survive the critical phase, they enter the recovery phase where 
there is a gradual re-absorption of fluid from the extravascular spaces into the 
bloodstream in the next 48-72 h (Figure 1.9). General well-being improves 
tremendously during this period although fatigue which lasts several weeks 
has been reported in adults (Seet, Quek et al. 2007). There is however, a risk 
of fluid overload during this period which may result in pulmonary oedema. 






Figure 1.9: Clinical course of DHF manifestation over three phases, Febrile, 
Critical and Recovery. Febrile stage is characterized by a sudden onset of fever 
corresponding to high viremia load (DF). Critical stage kicks in at defervescence 
when body temperature and viraemia levels drop followed by an increase in 
vascular permeability. Plasma leakage ensues leading to DHF and shock sets in 
when there is extensive plasma fluid loss (DSS). Recovery stage follows the 
reabsorption of fluids into blood stream from extravascular spaces. Adapted 





Vascular permeability with accompanying vascular leakage, 
thrombocytopenia, microvascular hemorrhage and dysfunction of the 
coagulation cascade is the hallmark of severe disease (Murgue, Cassar et al. 
2001, Butthep, Chunhakan et al. 2006). However, it is notable that no 
inflammatory response against the vascular endothelium is observed (Halstead 
1989) and that disease modification appears to be inclined towards functional 
rather than morphological changes (i.e. there is no damage to the 
microvasculature integrity). Besides, the phenomenon is transient and 
completely reversible with fluid replacement, suggesting that the endothelial 
cells are not damaged, evidenced by the lack of endothelial cell death. In vitro, 
endothelial cells are permissive to DENV infection (Andrews, Theofilopoulos 
et al. 1978). However, no evidence exists that is suggestive of endothelial cell 
infection in vivo (Halstead 1989). In addition, oedema is not generalized but 
appears to be selective only in the pleural and abdominal cavities. Currently, 
the mechanisms which lead to disease exacerbation characterized by vascular 
fragility are neither well-defined nor understood. 
 
The human skin resident immature (Langerhans cells) but not mature DCs 
have been proposed to be the first target cells to be infected upon feeding by 
an infected mosquito which delivers the virus subcutaneously (Wu, Grouard-
Vogel et al. 2000). Infection of the immature DCs was more efficient than 
infection of macrophages and monocytes in the absence of antibodies against 
DENV (Wu, Grouard-Vogel et al. 2000). The infected Langerhans cells then 
migrate from the site of infection, first to the draining lymph nodes and then to 
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remote lymph nodes, establishing a systemic infection through the lymphatic 
system. Viremia becomes detectable in the blood where there is infection of 
several cells of the mononuclear lineage, which includes monocytes, dendritic 
cells (DCs), splenic and liver macrophages (Halstead 1989). Anti-viral 
responses is initiated within the DENV infected DCs through their TLR3 
signaling cascade leading to the production of pro-inflammatory cytokines 
which include TNF, Type I IFNs, and IL-8 (Tsai, Chang et al. 2009).  
 
Since the onset of severe disease coincides with defervescence, it is plausible 
to hypothesize that effector functions of the immune system mediates the 
pathogenesis of severe disease. Mechanisms which lead to vascular 
dysfunction have been proposed in association with the observed ‘cytokine 
storm’ at or near defervescence. A transient disruption in the function of the 
primary endothelial glycocalyx layer which serves as a molecular sieve has 
also been proposed. Consistent with the filtration characteristics of the 
glycocalyx, hypoalbuminemia and proteinuria are observed along with 
increased heparan sulfate excretion in the urine of children with severe disease 
(Wills, Oragui et al. 2004). Heparan sulfate is a key structural element of the 
glycocalyx and is known to interact with the virus and its NS-1 protein 
(Avirutnan, Zhang et al. 2007). 
 
High levels of IFN-α level had been recorded between 1-2 days after fever 
onset (Kurane, Innis et al. 1993) followed by an increase in soluble receptors 
IL-2R, CD4 and CD8 indicative of T cell activation along with an increase in 
various cytokines such as IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, TGF-β and 
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IFN-ᵧ levels (Kurane, Innis et al. 1991). High levels of the chemoattractant CC 
chemokine ligand 2 (CCL2) and monocyte chemoattractant protein-1 (MCP-1)  
which are capable of altering endothelial cell permeability by reducing tight 
junctions between the vascular endothelium cells have also been recorded in 
patients with DHF/DSS (Lee, Liu et al. 2006). In vitro studies demonstrated 
that the T lymphocytes are the main contributors of the observed cytokine 
storm by incubating human T lymphocytes with dengue-infected cells (Kurane 
and Ennis 1987). Original antigenic sin hypothesis is also suggested for 
detrimental T cell responses which suggest that there is preferential expansion 
of pre-existing lower avidity memory T cells. These memory T cells dominate 
the secondary response and yet, are less effective at eliminating infected cells 
over naïve T cells which possess higher avidity for the infecting DENV 
serotype. In addition, these activated T cells tend to be apoptotic and seem to 
die prematurely without effectively controlling infection leading to the 
sustained viral load (Mongkolsapaya, Dejnirattisai et al. 2003).  
 
It is also shown that as plasma leakage becomes apparent, elevated levels of 
complement cascade activation products C3a and C5a are measured in the 
plasma (Churdboonchart, Bhamarapravati et al. 1983).  NS1 appears to be an 
important trigger for complement activation (Avirutnan, Punyadee et al. 2006). 
Binding of heterotypic antibodies to membrane bound NS1 expressed on 
infected cells may result in complement activation, leading to the production 
of inflammatory cytokines associated with disease exacerbation. In addition, 
anti-NS1 antibodies were shown to cross-react with human endothelial cells 
and platelets (Lin, Lei et al. 2003, Lin, Chiu et al. 2005) leading to the 
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activation of inflammatory responses that contribute further to the pro-
inflammatory cytokines milieu and coagulopathy seen in DHF/DSS patients as 
a result of platelets sequestration (Figure 1.10). The fact that DHF only occurs 
in a minority of the secondary infected dengue patients and in primary 
infections with seemingly highly virulent strains suggests that both viral and 
host factors influence disease outcome, with the latter probably playing a 
dominant role.  Individual risk factors including age, gender, ethnicity, host 
genetic factors, nutritional state and the presence of underlying chronic 
diseases have been suggested. However there is no strong correlation between 
these factors and disease severity.  
 
Viral risk factors such as virulence, sequence of infection and interval between 
each successive infection have also been implicated in disease pathogenesis. 
Studies demonstrating the ability of only certain viral genotypes to cause 
severe disease have been described by a few independent investigators (Rico-
Hesse, Harrison et al. 1997, Watts, Porter et al. 1999, Messer, Vitarana et al. 
2002, Messer, Gubler et al. 2003). This is supported by epidemiological 
studies involving the first DHF outbreak in Cuba, 1981 which coincided with 
the introduction of the possibly more virulent DENV2 Southeast Asian 
genotype while the less virulent DENV2 genotype was already circulating in 
the region. Intraepidemic evolution of circulating DENV has been proposed to 
be responsible for increased disease severity. This is demonstrated by the 1981 
and 1997 epidemics in Cuba and also in Townsville, Australia, 1992 where 
severity of disease manifestations and case-fatality rates increased towards the 
end of the epidemic with genomic analysis supporting DENV evolution during 
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an epidemic. In 1970, Halstead suggested that infections ending with DENV2 
tend to result in an increased incidence of severe disease and the interval 
between each successive infection, with a longer interval associated with 
disease severity (Halstead 2007) observed from epidemiology studies of the 





Figure 1.10: Immunopathogenesis of Severe Dengue. Early in infection, 
antibody-dependent enhancement (ADE) is thought to increase viral load 
resulting in the characteristic cytokine storm seen in DHF/DSS patients. The 
activation, proliferation, and secretion of cytokines in tissues by memory T 
lymphocytes add to the inflammatory milieu. Collectively, the host 
immunologic response is thought to create a physiological environment that 
promotes capillary permeability when the viral burden is in rapid decline. 
Interactions between dengue nonstructural protein 1 (NS1) and the surface 
glycocalyx layer may result in release of heparan sulfate into the circulation, 
thereby altering the filtration characteristics of the layer and resulting in 
leakage of proteins. Loss of essential coagulation proteins probably plays a 
major role in the development of the typical coagulopathy. Adapted from 
Simmons et al. Dengue, NEJM, 2012. 
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1.1.7 Antibody Dependent Enhancement (ADE) 
The birth of the immune enhancement hypothesis for dengue severe disease 
pathogenesis was built on two key observations in children made by Halstead 
and co-workers in 1977. First, DHF/DSS incidence peaked in infants between 
the ages of 6-9 months born to mothers who had been previously infected with 
a different serotype; this age group coincided with maternal antibodies which 
had waned to non-protective levels. Second, DHF/DSS incidence also peaked 
in young children between 3-4 years old who had a previous dengue infection 
of a different serotype but only presented with mild clinical symptoms. This 
led to the hypothesis that pre-immune individuals were susceptible to 
developing DHF/DSS in which pre-existing antibodies raised against a 
serotype that is different from the current infecting one are mediators. This 
phenomenon was coined Antibody Dependent Enhancement (ADE). 
 
The immune enhancement hypothesis was further substantiated by 
epidemiological studies which demonstrated a positive association between 
disease exacerbation and individuals with pre-immune antibodies 
(Sangkawibha, Rojanasuphot et al. 1984, Burke, Nisalak et al. 1988, Kliks, 
Nimmanitya et al. 1988). Experimentally, passive transfer of antibodies raised 
against DENV increased viremia titers in nonhuman primates (Halstead 1979) 
in vivo with the same observation made in peripheral blood mononuclear cells 
from non-immune monkey or human donors in vitro (Halstead and O'Rourke 
1977). The same results were reproduced with antibodies which do not possess 
any neutralizing capacity against DENV in the same study. On top of this, the 
antibody isotype responsible for this phenomenon was identified to be IgG 
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with IgM having no enhancing effect on virus infection. This mechanism was 
also shown to be Fc dependent with immune-complex formation as pre-
requisite. Virus neutralization by antibodies requires coating the virus 
pathogen with sufficient antibody molecules beyond a certain threshold and is 
largely influenced by antibody affinity. In the case of DENV infection, 
heterotypic antibodies generated during secondary infection bind to the virus 
and form virus-antibody immune complex. These heterotypic antibodies fail to 
neutralize virus infectivity but instead allow the immune complexes to cross-
link FcᵧRs found on the mononuclear cells through interaction with the Fc 
region of the virus-bound antibodies leading to virus internalization and 
infection establishment in these cells (Figure 1.11) (Halstead and O'Rourke 
1977). Infection of DENV permissive cells in this way was hypothesized to 
result in the high viremia loads observed in the DHF/DSS patients with a 
positive correlation between peak viremia titer and disease severity in humans 
being observed (Murgue et al, 2000; Libraty et al, 2002). 
Figure 1.11: Mechanism of Antibody Dependent Enhancement (ADE). Cross-
neutralizing heterotypic antibodies bind to dengue virus and form immune-
complexes. Binding does not lead to virus neutralization but instead leads to its 
uptake via interaction with FcRs expressing cells resulting in high levels of 
viremia. Adapted from Whitehead et al. Prospects for a dengue virus vaccine, 
Nature reviews Microbiology, 2007. 
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The human IgG isotype is further classified into four subgroups (IgG1, 2, 3 
and 4), with each subgroup demonstrating different affinities for the FcᵧRs. 
Studies have shown that IgM, IgG1 and IgG3 were the predominant 
immunoglobulin groups present throughout the course of infection in patients 
with DF, DHF and DSS with IgG1 associated with disease progression to 
DHF/DSS (Thein, Aaskov et al. 1993, Koraka, Suharti et al. 2001). This 
finding is in agreement with IgG being the only Ig group shown by Halstead 
with the ability to mediate immune enhancement. Not surprisingly, IgG1 has 
the strongest affinity for FcᵧRs compared to the other Ig subclasses and thus 
further supports the mediation of immune enhancement via FcᵧRs. 
 
A second hypothesis supporting the role of ADE in immunopathogenesis 
suggests that viral entry via FcᵧRs suppresses the associated antiviral immune 
response by suppressing the expression of IFN-ᵧ (Interferon-gamma), TNF-α 
(Tumor Necrosis Factor–alpha), IL-12 (Interleukin-12) and NO (Nitric oxide) 
but upregulating IL-6 and IL-10 as shown in vitro with THP-1 cells 
(Chareonsirisuthigul, Kalayanarooj et al. 2007). These findings were further 
substantiated in another independent study demonstrating the anti-viral 
responses down-regulation mechanism mediated through leukocyte 
immunoglobulin-like receptor B1 (LILRB1) co-ligation by the opsonized 
dengue virus complex (Chan, Ong et al. 2014). Virus entry through the 
activating FcᵧRs without LILRB1 co-ligation induces type-I interferon genes 
(ISGs) expression to produce an environment unfavorable for virus replication 




Although ADE is the most widely accepted hypothesis for DHF/DSS 
pathogenesis by far, itself alone is not sufficient to account for the variation in 
immunopathogenesis observed among DENV infected patients since disease 
exacerbation can also manifest in primary infected DENV patients and not all 




1.1.9 Protection against  Dengue Infection  
The contribution of the human immune response towards disease pathogenesis 
is not all inclusive since lifelong immunity against homologous serotype with 
transient immunity against heterologous immunity has been demonstrated by 
Sabin in 1952. Humoral response to DENV infection mediated by antibodies 
has been shown to inhibit virus attachment and neutralize viral infectivity in 
vitro (Roehrig, Bolin et al. 1998).  
 
Epitopes associated with dengue virus neutralization using mouse monoclonal 
antibodies (mAb) have been described by a few investigators (Dittmar, Haines 
et al. 1980, Gentry, Henchal et al. 1982, Henchal, Gentry et al. 1982, Henchal, 
McCown et al. 1985, Crill and Roehrig 2001, Crill and Chang 2004). In a 
study by Henchal et al in 1982, antigenic determinants of dengue virus were 
first categorized into four groups; flavivirus group reactive, dengue complex 
specific, dengue sub-complex specific and dengue serotype specific. Based on 
the E protein of the tick-borne encephalitis (TBE) virus, an epitope model was 
established based on competitive binding studies (Heinz, Berger et al. 1983, 
Mandl, Guirakhoo et al. 1989). Three non-overlapping antigenic domains A, B 
and C, each made up of several epitopes, were defined. Domain A (EDII) 
consists of epitopes that were cross-reactive among flaviviruses (group-
specific) and subtype-specific. Domain B (EDIII) had epitopes which were 
predominantly complex (type) specific and elicited the most neutralizing 
antibodies while domain C (EDI) contains subtype-specific epitopes. The most 
potent neutralizing mouse monoclonal antibodies are serotype specific and are 
directed against the lateral ridge of EDIII (Roehrig, Bolin et al. 1998, 
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Gromowski and Barrett 2007, Lisova, Hardy et al. 2007, Sukupolvi-Petty, 
Austin et al. 2007, Gromowski, Barrett et al. 2008). Epitopes that define sub-
complex specific neutralization are attributed to those found on the A-strand 
of EDIII (Sukupolvi-Petty, Austin et al. 2007). 
 
While it is recognized that EDIII is the main target of potent serotype specific 
neutralizing mAbs, studies with human monoclonal antibodies (hMabs) and 
polyclonal serum have suggested that the human immune response to dengue 
infection is rather complex and differs significantly from that of the mouse. 
Cross-reactive antibodies of weak neutralizing capacity dominate the human 
immune response whereas hMabs with potent neutralization capacity 
constitute a very small fraction of the overall antibody response (Lai, Tsai et al. 
2008, Crill, Hughes et al. 2009, Wahala, Kraus et al. 2009, Beltramello, 
Williams et al. 2010, Dejnirattisai, Jumnainsong et al. 2010, de Alwis, Smith 
et al. 2012). The human antibody response to dengue is comprised of those 
directed against the structural proteins prM, C and E, as well as the non-
structural protein NS1and NS3 (Beltramello, Williams et al. 2010). While 
much attention has been focused on E as it is the major surface glycoprotein 
on the virion and is in line with results from mAbs, it appears that the response 
against prM is also dominant with neutralizing as well as enhancing capability 
(Beltramello, Williams et al. 2010, Dejnirattisai, Jumnainsong et al. 2010, de 
Alwis, Smith et al. 2012).  
 
Potent hMabs against E are not restricted to just EDIII, neutralizing antibodies 
against EDI/II have also been described. The importance of EDIII and its 
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correlation to protective neutralizing antibodies in humans remains 
controversial. Crill and co-workers (Crill, Hughes et al. 2009) demonstrated 
the correlation with dengue immune serum samples in studies involving the 
depletion of EDIII antibodies from human serum, whereas Wahala et al  
(Wahala, Kraus et al. 2009) observed only a minute difference in 
neutralization capacity of the EDIII antibodies depleted serum. However, both 
studies are in agreement that EDIII antibodies make up only a small 
proportion of the human antibody response. On the other hand, the 
significance of EDI/II is gaining recognition in which both the fusion loop and 
hinge regions of E are responsible for membrane fusion resides. The fusion 
loop was identified as the major target of the human antibody response by Lai 
et al (Lai, Tsai et al. 2008), in which he showed that mutations in the 
conserved residues resulted in a significantly reduced binding of immune sera 
against E. In a study by Alwis (de Alwis, Smith et al. 2012), epitope mapping 
studies of a potent neutralizing hMab had its footprint mapped to the hinge 
region of EDI/II. In another very recent study by Messer (Messer, de Alwis et 
al. 2014), the EDI/II hinge region has been implicated as the target site of 
long-lived serotype specific antibodies. They demonstrated that 
‘transplantation’ of the EDI/II from DENV4 onto DENV 3 (rDENV3/4) 
resulted in a gain in neutralization capacity against the ‘donor’ virus serotype 
(DENV4) with loss of neutralization capacity against the ‘host’ virus serotype 
(DENV3).  
 
In the most recent paper by (Dejnirattisai, Wongwiwat et al. 2015), the authors 
described a new class of antibodies isolated from the plasmablasts of naturally 
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infected dengue patients. These antibodies were directed against an antigenic 
determinant that was preserved on whole viral particles and coined as 
envelope dimer epitope (EDE). In contrast to the collection of human 
antibodies isolated to date, this class of antibodies possessed potent 
neutralization capacity across all four DENV serotypes in vitro. 
 
Despite the knowledge gained from the expanding collection of hMabs 
generated from humans naturally infected with dengue, a significant gap in the 
understanding of the human antibody response to dengue infection remains 




1.2.1 Introduction to antibodies 
Antibodies (Ab), also termed immunoglobulins (Igs) are a group of 
structurally related glycoproteins produced in humans by only one specific 
immune cell subtype, the B lymphocytes. Adaptive humoral immunity, 
mediated by this group of glycoproteins, was demonstrated in 1890 by Emil 
Adolf von Behring through the treatment of diphtheria patients by 
administering serum from horses immunized with the diphtheria toxin. 
 
Antibody molecules exist as membrane bound or secreted forms. The antibody 
molecules function as receptors for antigen recognition in their membrane-
bound form on the B lymphocytes constituting the recognition phase which 
leads to the initiation of B cell responses. In the effector phase, antibodies that 
recognize the same antigens are secreted by activated B cells and trigger 
effector mechanisms that lead to their elimination. These effector functions 
include neutralization of foreign microbes or their associated toxins, activation 
of the complement system, opsonization for enhanced phagocytosis, antibody 
dependent cellular cytotoxicity (ADCC) and immediate hypersensitivity, 
mediated by components of the innate immune system such as complement 
proteins and immune cells such as mononuclear phagocytes, natural killer (NK) 
cells and mast cells which express receptors specific for antibodies. 
 
Antibodies can be found in the plasma, mucosal secretions and interstitial fluid 
of the tissues, biological fluids which circulate the body. This component of 
the adaptive immunity serves to defend the host against extracellular 
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pathogens and their associated toxins, if any. Initial antibody response occurs 
in the lymphoid tissues such as the spleen, lymph nodes and mucosal 
lymphoid tissues whereas long-lived antibody-producing cells appear to reside 
in the bone marrow. 
 
1.2.2 Antibody structure and isotypes 
All antibody molecules share a common symmetrical structure made up of two 
identical heavy and light chains held together by disulfide bonds found 
between each heavy and light chain pair, and between both heavy chains. Each 
chain comprises of a series of repeating homologous units that fold 
independently into a globular motif termed an Ig domain. The heavy chain is 
made up of one variable region Ig domain with three or four constant (C) 
region Ig domains designated CH1, CH2, CH3 and CH4. The light chain is 
made up of one V region domain with one C region domain. Each antibody 
molecule is about 150 kDa with each heavy and light chain approximately 55 
kDa and 24 kDa respectively. 
 
The amino terminal V regions of heavy (VH) and light (VL) chains form the 
antigen recognition site which displays remarkable diversity of up to 109, 
accounting for their capability to bind a vast number of structurally diverse 
antigens. Antibody diversity is concentrated in what is known as the 
complementarity determining regions (CDRs) of the antigen recognition sites. 
Each antibody molecule consists of two identical antigen binding sites. 
Effector functions of antibodies are mediated by the carboxy terminal constant 
(C) regions which display relatively fewer variations among different 
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antibodies. C regions mediate biological functions of the antibodies by 
interacting with molecules and cells of the innate immune system and are 
separate entities with the antigen binding sites. This is demonstrated by 
Rodney Porter in the late 1950’s who suggested that each antibody molecule 
took a Y shape with the carboxy terminal C regions of the heavy chains 
making up the base of the Y shape and spread apart towards the amino 
terminal V regions where a light chain is attached in parallel (Figure 1.12). 
Under limited proteolysis conditions with the enzyme papain, the rabbit IgG 
was cleaved into one major component along with two smaller fragments.  
 
Antigen binding capacity was restricted to the smaller fragments (arms of the 
Y); the largest component (base of Y) had no active antigen binding sites. 
Porter named the arms which displayed significant variation among different 
antibodies as fragment antigen-binding (Fab) and the fairly conserved base 
which had a tendency to self-dimerize and crystallize as fragment crytallizable 
(Fc).Antibody molecules are flexible structures with the ability of orienting its 
antigen binding sites for efficient antigen engagement. The flexibility is 
conferred by the presence of a hinge region capable of assuming random 




Five distinct classes (isotypes) of antibodies named IgG, IgA, IgM, IgE and 
IgD exists based on structural differences in their heavy chain C regions. In 
humans, IgG can be further subdivided into subtypes called IgG1, IgG2, IgG3 
and IgG4 while IgA consists of subtypes IgA1 and IgA2. Lights chains 
associated with the heavy chains of a single Ig molecule are either of the 
kappa (κ) or lambda (λ) isotypes; and like the heavy chains, is distinguished 
by their carboxy terminal constant regions. In humans, 60% of antibodies have 
κ light chains and the remaining 40% have λ light chains. 
 
  
Figure 1.12: Structure of an antibody molecule. The antibody molecule is a ‘Y’ 
shaped structure made up of two identical heavy and light chains held together 
by disulfide bonds. The arms of ‘Y’ termed Fragment antigen-binding (Fab) 
contains antigen binding sites formed by the N-terminal variable regionsof each 
heavy and light chains pair, thus each antibody molecule has two antibody 
binding sites. The C-terminal constant region is the mediator of downstream 
effector mechanisms and is termed Fragment crystallizable (Fc). Adapted from 
Weiner et al. Building better magic bullets-improving unconjugated monoclonal 
antibody therapy for cancer. Nature reviews Cancer, 2007. 
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IgA is the predominant class of antibody produced at mucosal surfaces such as 
the gastrointestinal and respiratory tract walls and provides the first line of 
defense against pathogens invading through these tissues. IgA makes up two-
thirds of the total antibodies secretion reflecting the large surface area covered 
by the mucosal surfaces. IgG is the main Ig isotype found in circulation along 
with IgE and IgM. The only class of antibody that is able to cross the placenta 
to the developing fetus, IgG mediates the clearance of extracellular pathogens 
such as bacteria and viruses that have entered the bloodstream in which IgM 
also appears to have a role. IgE helps to clear parasitic helminths infections 
whereas the role of IgD remains unclear. 
 
1.2.3 Fc and its associated FcR effector functions 
Notwithstanding the neutralization role of antibodies which is conferred solely 
by antigen binding, the other effector mechanisms mediated by antibodies 
requires a coordinated effort along with the other immune cells. Immune cell 
mediators of phagocytosis and ADCC such as macrophages, neutrophils and 
NK cells express receptors termed Fc receptors (FcRs) specific for the Fc 
region of antibodies. Different classes of FcRs exist that are specific for each 
class of immunoglobulins, FcᵧR, FcαR, FcεR bind IgG, IgA and IgE, 
respectively. FcRs are members of the immunoglobulin gene superfamily and 
each is comprised of a unique ligand binding α-chain. Fcᵧ-chains possess 
activation domains termed immunoreceptor tyrosine-based activation motifs 
(ITAMs) in their cytoplasmic regions or whose α-chain associate with ITAMS 
of a ᵧ-chain in its transmembrane region. Association with ITAMS is essential 
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for the initiation of downstream signaling events that lead to effector cell 
activation and subsequent elimination of the invading pathogens.  
 
Three classes of FcᵧRs, FcᵧRI (CD64), FcᵧRII (CD32) and FcᵧRIII (CD16) 
have been described (Figure 1.13). Different classes of FcRs have been 
described for IgA and IgE, but they are not discussed further due to their 
irrelevance in this study. Each class of FcᵧRs differs in their structure, cellular 
distribution and affinity for different classes of antibodies. FcᵧRI has the 
highest affinity for IgG and is the only FcR with three extracellular Ig-like 
domains in its α-chain, while the other FcRs have two domains designated D1 
and D2. In addition, variants for FcᵧRII and FcᵧRIII have been described with 
three such variants for FcᵧRII (FcᵧRIIa, FcᵧRIIb and FcᵧRIIc), and two 
variants for FcᵧRIII (FcᵧRIIIa and FcᵧRIIIb). With the exception of FcᵧRII 
where their cytoplasmic regions possess either ITAMS (FcᵧRIIA/C) or ITIMS 
(FcᵧRIIB), the cytoplasmic regions of FcᵧRI and FcᵧRIIIA are associated with 
ITAMS of the gamma chain. In comparison to FcᵧRI, FcᵧRII and FcᵧRIII have 





FcR mediated cellular response requires the cross-linking of two or more 
receptors achieved by the formation of immune complexes (i.e. antibodies 
coated pathogens). Activation of immune cells leads to internalization 
(phagocytosis) and subsequent degradation of the pathogens in 
phagolysosomes. Pathogens are broken down by the release of proteolytic 
enzymes or through the activation of potent reactive oxygen species. 
Phagocytosis is mediated by monocytes, macrophages and neutrophils that 
express FcᵧRI with high affinity for IgG1 and IgG3. Another effector 
mechanism of FcR engagement is the antibody dependent cell-mediated 
cytotoxicity (ADCC) mediated primarily by natural killer (NK) cells that 
express FcᵧRIII. NK cells activation results in the release of cytotoxic 
molecules such as perforin and granzymes to induce apoptosis of target cells. 
Figure 1.13: Human FcᵧRs. FcᵧRs are members of the immunoglobulin gene 
superfamily and each is comprised of a unique ligand binding α-chain. There 
are 5 classes of activating FcᵧRs (FcᵧRI, IIA, IIC, FcᵧRIIIA and IIIB) where ITAMS 
are present in their cytoplasmic regions or are associated with ITAMS of the Fc 
common ᵧ-chain. FcᵧRIIB is the only inhibitory FcᵧR that contains ITIM instead of 
ITAM. Adapted from Smith et al. FcᵧRIIb in autoimmunity and infection: 
evolutionary and therapeutic implications. Nature reviews Immunology, 2010.  
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1.2.4 Antibody Engineering and Therapy 
The advent of monoclonal antibodies technology put forward by Georges 
Kohler and Cesar Milstein in 1975 expanded the development and application 
of passive immunotherapy since its inception in 1890 when an effective anti-
toxin (later known as antibody) was used to treat diphtheria patients. Passive 
immunotherapy is the transfer of antibodies to treat diseases for which neither 
effective drugs nor vaccines are available. Currently, the uses of monoclonal 
antibodies in humans encompass a wide spectrum ranging from autoimmune 
diseases, immune suppression in organ transplantation, tumor targeting to 
infectious diseases. Not surprisingly, monoclonal antibodies outperform small-
molecules as the best-selling biological drugs (Scolnik 2009).  
 
The first report of the successful application of mAb in humans was in the 
treatment of neoplasm described in 1982 (Waldmann 2003). For nearly a 
decade after the first FDA approved drug in 1986, no other mAbs were 
approved for use in humans. Although antibodies possess inherent specificity 
that gives it its edge over the use of small molecules, there are however 
limitations which resulted in lower therapeutic efficacy such as 
immunogenicity elicited by human anti-mouse antibody (HAMA) response. 
(Miller, Oseroff et al. 1983, Shawler, Bartholomew et al. 1985). Next, 
antibody mediated effector mechanisms were severely impaired as the murine 
mAbs can neither fix human complement nor elicit ADCC. This led to 
attempted modifications to the mouse monoclonal antibodies to reduce 
immunogenicity without compromising their antigen specificity and to 
improve downstream effector functions in humans.  
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The first modified version of a mouse mAb, or chimeric antibody, is a fusion 
protein which essentially involved the ‘swapping’ of the mouse mAb C region 
for human C region by means of genetic engineering (Boulianne, Hozumi et al. 
1984). Although effector functions were improved (Liu, Robinson et al. 1987), 
there remained a significant immune response to these chimeric antibodies 
presumably contributed by the mouse origin V regions (Jaffers, Fuller et al. 
1986). In 1986, Winter and co-workers took a bold approach to antibody 
engineering by ‘grafting’ the CDRs required for antigen recognition from 
mouse monoclonal antibodies onto the human antibody framework, creating 
the first humanized antibody (Figure 1.14). Although xenogeneic elements 
were significantly reduced to a minimum, this approach resulted in loss of the 
original affinity displayed by the parent mouse antibody (Riechmann, Clark et 
al. 1988). Queen et al (Queen, Schneider et al. 1989) introduced refinements 
to the humanized antibodies with the help of computer modeling taking into 
account framework regions that were also essential for antigen binding and 
maintenance of the CDRs integrity. This approach proved to be very 
successful in maintaining the original antibody’s affinity. 
 
Today, fully human antibodies are possible with various techniques such as 
transgenic mice (Jakobovits, Moore et al. 1993), phage display (McCafferty, 
Griffiths et al. 1990) or through the direct immortalization of isolated 
monoclonal human B cells with Epstein Barr Virus (EBV) (Steinitz, Klein et 
al. 1977), although each technique possess its own limitations. In addition, 
more sophisticated modifications also exist to improve serum-half life, 
effector functions, ligand affinity and target site penetration. 
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Figure 1.14: Monoclonal antibodies engineering. Although highly specific in 
antigen recognition, the application of murine monoclonal antibodies in 
humans was severely hampered by its immunogenicity and inability to trigger 
antibody mediated effector mechanisms. To circumvent these problems, the 
first modification of the murine monoclonal led to a chimeric antibody which 
retained its antigen binding specificity and restored the associated effector 
functions. Further refinements led to the development of humanized 
antibodies, eventually allowing the isolation of fully human antibodies today. 
Adapted from Carter et al. Improving the efficacy of antibody-based cancer 
therapies. Nature Reviews Cancer, 2001.
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1.3 Epitope Mapping 
The concept of vaccination was first introduced in 1796 by Edward Jenner, 
and its protective effects have seen the global eradication of small pox in 1979. 
Although smallpox is the only human disease eradicated through vaccination 
to date, the implementation of vaccination has undoubtedly also brought other 
major human diseases such as polio, measles, tetanus, diphtheria and yellow 
fever under control, with the possibility of polio eradication next in line 
(Carter Center).  
 
Vaccination elicits the humoral arm of the adaptive immunity mediated by 
antibodies that bind to invading pathogens and inactivate them before they can 
establish an infection in their hosts. Historically, vaccine formulations have 
primarily been based on the respective disease’s causative agent that has been 
inactivated by heat or attenuated by serial passages in cell cultures. Gradually, 
we learn that the same strategy is not applicable to all other diseases simply 
because the same degree of protection is not generated against all epitopes of 
the antigen. Some epitopes appear to elicit a dominant immune response 
which does not correspond to their neutralization capacity. To circumvent this 
problem, subunit vaccines aided by recombinant DNA technologies were 
introduced whereby immunogenic fragments of the antigen were utilized 
(Andersen 1994, Babai, Samira et al. 1999, Nemchinov, Liang et al. 2000). 
The possibility of using selected epitopes in vaccine formulations also exists 
(Sun, Seyer et al. 1991). It is proposed that immunization of an individual with 
the epitope that elicits an antibody response with potent neutralization capacity 
may result in an immune response of the same magnitude towards the same 
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epitope minus the ‘background’ responses. This consequently results in a 
‘focused’ immune response of increased specificity towards the neutralizing 
epitopes. In order to identify epitopes that can elicit such desirable “focused” 
protective response, reverse engineering is employed.  
 
To date, several methods have been described that cater to antibody 
‘backtracking’. The ‘gold standard’ of which is X-ray crystallography which 
requires co-crystallization of the antigen:antibody complex and solving its 
atomic structure with x-ray diffraction. Although the results obtained this way 
define the antigen:antibody interface with precision, this method is  limited by 
its laboriousness, low efficacy and requirement of a highly skilled personnel. 
Besides biophysical methods, biochemical techniques have also been 
described for epitope mapping. The first such method described is the ‘Geysen 
pepscan’ by Mario Geysen in 1984 (Geysen, Meloen et al. 1984). This method 
requires the generation of a series of overlapping peptides that encompass the 
entire antigen. Peptides that show reactivity to antibody is proposed to 
constitute part of the epitope. These peptides are then used as immunogens 
and tested for their capacity to elicit the desired protective response. Similar to 
pepscan, functional antibody binding to antigen fragments generated by 
proteolysis or chemical synthesis in place of linear peptides is an alternative. 
These techniques work well with antigens whose epitopes are not 
conformation sensitive, however, B cell epitopes are usually highly 
conformational and discontinuous in nature and the use of these techniques is 




Alternatively, protein-protein interaction can be probed with the use of protein 
homologs or through site-directed mutagenesis, circumventing the problem of 
dealing with conformational epitopes while allowing fine-specificity for the 
epitope to be analyzed down to specific residues. The most commonly 
described and systematic method is the alanine scanning mutagenesis (ASM) 
whereby an alanine residue is introduced in place of the original amino acid 
residue throughout the entire antigen protein sequence individually and 
sequentially (Cunningham and Wells 1989). In this case, the corresponding 
amino acid residue of the mutants that result in loss of antibody binding is 
indicative of their role at that particular position. The major drawback of this 
technique lies in the production, purification of all the mutants and the 
evaluation of their structural integrity. Additionally, the results are often 
confounded by false negatives tolerant to mutations as well as mutants 
affecting antibody binding outside the target epitope region (Chao, Cochran et 
al. 2004). 
 
In addition to the systematic approach in which alanine is the only 
replacement, random mutagenesis introduced by error-prone PCR in the 
antigen sequence has also been examined. In this approach, each amino acid 
has the potential of being substituted by any of the 19 other amino acids. The 
advantage of this technique over ASM should reduce the number of false 
negatives where alanine does not influence the properties of the original 




1.3.1 Yeast Display 
First described by Boder & Wittrup in 1997 as a method for affinity 
maturation of antibody fragments and subsequently as a screening platform for 
antibodies isolation in 2003 by Feldhaus et al, application of the yeast surface 
display system was extended to epitope mapping in 2004 (Chao, Cochran et al. 
2004, Cochran, Kim et al. 2004). The main advantage of yeast display is that it 
is an eukaryotic system with intrinsic protein synthesis and folding machinery 
that allows post translational modifications ensuring proper folding of its 
expressed proteins in the endoplasmic reticulum (Ellgaard and Helenius 2003), 
obviating the need for expression, purification and eventual functional 
characterization of each mutant.  
 
Yeast surface display utilizes the yeast surface receptor a-agglutinin that 
mediates cell-cell contact during the mating process by binding to its 
complementary cell receptor, α-agglutinin. Unlike the α-agglutinin, a-
agglutinin is made up of two subunits, Aga1p and Aga2p. Aga1p anchors onto 
the cell wall via covalent linkages while Aga2p is associated with Aga1p via 
two disulfide bonds. In the yeast surface display technology, a single-mutant 
antigen library generated by error prone PCR or other techniques is expressed 
as fusion proteins to the Aga2p subunit. Expression of the mutant library on 
yeast cell surface occurs through covalent linkage of the Aga2p-fused proteins 
to Aga1p. This leads to projection of the fusion proteins away from the yeast 
cell surface, minimizing interaction with other yeast surface molecules and 
therefore enabling mutants to interact with antibody of interest. Binding of the 
displayed antigen and its mutants is detected by flow cytometry. Potential 
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epitope residues are those that lose the affinity to the antibody when replaced 
by other amino acids.  This combinatorial approach allows analysis of tens of 
thousands of antibody-antigen interactions in a one-pot reaction to identify 




Chapter 2: Materials and Methods 
2.1 Cell lines 
Drosophila Schneider 2 (S2) cells were bought from Life Technologies and 
cultured in S2 media supplemented with 10% heat-inactivated fetal bovine 
serum (HI-FBS) at 28oC. C6/36 mosquito cells, Baby Hamster Kidney [(BHK-
21) ATCC CCL-10], K-562 (ATCC CCL-243) and U937 (ATCC CRL-1593.2) 
cells were obtained from American Type Cell Culture (ATCC) and cultured in 
RPMI-1640 (BSF, A*STAR), supplemented with 10% HI-FBS at 37oC, 
except for C6/36 cells which were cultured in RPMI-1640 supplemented with 
5% HI-FBS at 28oC. HEK293-6E cells (licensed from National Research 
Council Biotechnology Research Institute, Montreal, QC, Canada) were 
cultured in F17 supplemented with L-Glutamax, pluronic acid and geneticin 
(G418) at 37oC with shaking at 125 rpm. S2 media, F17 media and all media 
supplements were purchased from Life Technologies. 
 
2.2 Antibodies 
Two mouse monoclonal antibodies against DENV were used as positive 
controls in this study. A dengue serotype 2 specific mouse monoclonal clone 
3H5-1 (ATCC HB-46) which recognizes a linear epitope on EDIII and a pan-
dengue serotype mouse monoclonal antibody clone 4G2 (ATCC HB-112) 
which recognizes a conformational epitope on fusion loop in the DI/II region 
of E were obtained from ATCC. Humanized antibodies of both clones were a 





2.3 Dengue virus strains 
All dengue virus (DENV) strains were propagated in C6/36 mosquito cells 
(ATCC) by infecting C6/36 cells with each dengue serotype at a multiplicity 
of infection (MOI) of 0.1. Virus seed stocks were harvested from the cell 
culture supernatant between 5-7 days post infection, using centrifugation to 
remove the cell debris and the stocks were then stored at -80oC for PRNT 
assay. Virus stocks used in ELISAs screening assays and FACS based 
neutralization assays were concentrated from culture supernatant by adding 
sodium chloride (NaCl) to a final concentration of 0.4 M and 7.5% (w/v) Poly-
Ethylene Glycol (PEG-6000). The precipitated virus particles were collected 
by centrifugation at 7000 x g for 10 min at 4oC, re-suspended in NTE buffer 
and inactivated by exposing to UV for 1 h. DENV stocks used for ELISA 
were DENV1 05K2916 [EU081234] (Schreiber, Holmes et al. 2009), DENV2 
TSV01 [AY037116.1] (McBride et al, 1993), DENV3 VN32/96 [EU482459] 
and DENV4 My04-31586 [FN429925]. DENV3 and DENV4 isolates are 
generous gifts from Dr. Cameron Simmons (Oxford University Clinical 
Research Unit, Ho Chi Minh City, Vietnam) and Prof. Shamala Devi 
(University of Malaya, Kuala Lumpur, Malaysia) respectively. DENV strains 
used for PRNT were DENV3 D3/SG/05K4141/DK1 [EU081214] and DENV4 
2641Y08 HQ875339.1 clinical isolates from Singapore obtained from EHI, 
Singapore. DENV strains used for challenge studies were DENV1 08K3126 





2.4 Virus Tittering 
Virus seed stocks were diluted 10-fold over 6 dilutions in RPMI-1640 and 
added to BHK-21 cell monolayer in a 24-well tissue culture plate. Plates were 
incubated at 37oC for 1 h to allow cell infection to take place, after which an 
overlay was added and the plates were further incubated for 4.5 days. The 
overlay was discarded and the cells were fixed and stained with 1X crystal 
violet by incubating at RT with rocking overnight. Plates were washed with 
tap water and plaques were enumerated by eye. The virus titer was determined 
as the dilution that gave a reasonable number of plaques multiplied to that 
particular dilution. 
 
2.5 General methods 
2.5.1 Infusion cloning 
Cloning was achieved by homologous recombination using Infusion HD 
cloning kit (Clontech). Briefly, PCR products were treated with cloning 
enhancer and incubated at 37oC for 15 min, followed by 80oC for 15 min. The 
treated PCR products were then incubated with the linearized vector at 37oC 
for 15 min, followed by 50oC for 15 min. The cloning reaction mix was 
diluted 10-fold with 1X TE buffer and transformed into the commercially 
available E.coli XL-10 gold (Stratagene) competent cells. The transformed 
cells were plated onto LB plates and incubated at 37oC overnight. Individual 
colonies were picked for screening by colony PCR (primers listed in Tables 
2.3 and 2.4). Plasmid DNA was extracted using QIAprep Spin Miniprep Kit 
(Qiagen) following manufacturer’s protocol and sent off for DNA sequencing 
(Axil Scientific Pte Ltd). 
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2.5.2 Western blot and Coomassie stain 
Protein samples were diluted with 4X LDS sample buffer (Life Technologies) 
and denatured at 95oC for 5 min. The samples were then fractionated on a 
NUPAGE Novex Bis-Tris 4-12% gradient polyacrylamide gel (Life 
Technologies) along with the pre-stained protein standard SeeBlue Plus2 (Life 
Technologies) in 1X MOPS running buffer (Life Technologies) at 150 V 
constant voltage for 90 min. Gels were then stained with Coomassie Brilliant 
Blue R-250 (Bio-Rad) for 15 min at room temperature (RT) and destained 
with Coomassie destaining solution at RT overnight to assess the expression 
and purity of the proteins. For Western blot, proteins were transferred onto a 
0.45 um nitrocellulose membrane (GE) using a semi-dry transfer system (Bio-
Rad) at 20 V constant voltage for 1 h. The membrane was blocked with 
blocking buffer for 1 h at RT and washed 3 times with PBST, with 5 min of 
shaking between each wash. Proteins of interest were probed with the 
respective primary antibody, binding was detected by adding anti-human IgG 
conjugated to HRP (Jackson Immuno Research), diluted 1:5000 in blocking 
buffer at 4oC overnight. The membrane was then incubated with SuperSignal 
West Pico chemiluminescent substrate (Pierce), followed by exposure to X-ray 
film (Konica Minolta, Japan) for detection. 
 
2.5.3 Antibody biotinylation 
A 20 mM solution of the EZ-Link NHS PEG4-Biotin (Pierce) was prepared by 
reconstituting 2 mg of biotin in 170 µl of DMSO (Sigma). Biotin was added to 
200 µg of monoclonal antibody to achieve a final concentration of 100 µM 
biotin, corresponding to a 25 fold molar excess of biotin to antibody. 
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Biotinylation was allowed to proceed at RT for 3 h with rotation. The reaction 
was stopped by adding 1 M Tris, pH 8.0 to a final concentration of 100 mM 
and incubated at RT for 20 min. Biotinylated antibodies were buffer-
exchanged into 1X PBS (Phosphate Buffered Saline) with a 10 kDa cutoff 
concentrator (Sartorius). 
 
2.5.4 Antibody labeling 
Purified antibodies were diluted to 1 mg/ml in 1XPBS and pH adjusted to 8.0 
with 1 M sodium bicarbonate. The diluted antibodies were then conjugated to 
either Dylight 488 (Pierce) or Alexa Fluor 647 (Life Technologies) dye and 
incubated at RT for 3 h in the dark. The excess free dye was removed with the 
purification columns and resin (supplied with the labeling kit). Resin was first 
added to the column and centrifuged to remove the storage solution. The 
labeling reaction mix was then added to the packed resin column and the 
labeled antibodies were collected by centrifugation at 1100 g for 5 min. 
 
2.5.5 Ethanol precipitation 
Restriction enzyme digestion reaction volume was topped up to 50 µl with 
nuclease free water. Sodium acetate (NaOAc, pH 5.2) was added at 1/10th the 
reaction volume, followed by 2 volumes of 100% ethanol. DNA precipitation 
was carried out at -80oC for 1 h. DNA was collected by centrifugation at 
16000 g at 4oC for 15 min. The DNA pellet was washed twice with 500 µl of 
ice-cold 70% ethanol and collected by centrifugation at 16000 g for 10 min. 




2.6 Generation of recombinant human immunoglobulin G (IgG) 
2.6.1 Patients 
Adult patients (age>21 years) presenting at community primary care clinics 
with acute onset fever (>38.5oC) and without clinically obvious alternative 
diagnoses were included in the study, as part of the collaborative “STOP 
DENGUE” program. Patients were diagnosed by DENV-specific RT-PCR; 
DENV specific IgM and IgG antibodies (Abs) were detected by ELISA 
(Panbio kit, Inverness Medical, Queensland, Australia). Both patients 
described in this study had DENV specific serum IgG Abs at the time of fever 
onset and were therefore classified as having secondary infections. Whole 
blood samples were collected into EDTA vacutainer tubes (Becton Dickinson) 
at recruitment (acute phase). The research involving patients enrolled in the 
Early Dengue Infection and Outcome study was approved by the Institutional 
Review Board of Singapore National Healthcare Group Ethical Domain 
(DSRB B/05/013), and written consent had been sought from patients. 
  
2.6.2 Single B cell sorting 
Peripheral blood mononuclear cells (PBMCs) were obtained by layering 
whole blood on top of Ficoll-paque (GE). PBMCs which are present in the 
buffy coat after centrifugation without brakes at 400 g for 30 min at room 
temperature (RT), were removed and washed with 1X PBS. These cells were 
then labeled with antibodies against CD20, CD27, CD19 (Biolegend), and 
CD138 (BD Pharmingen). Plasmablasts (CD19low, CD20low, CD27hi and 
CD138hi) were sorted as single cell by FACS Aria into each well of 96-well 
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PCR plates containing catch buffer. The plates were incubated on dry ice 
immediately after sorting and stored at -80oC. 
 
2.6.3 Isolation and cloning of human immunoglobulin genes 
The cDNA (complementary deoxyribonucleic acid) of human 
immunoglobulin G (IgG) variable regions were amplified from single B cells 
by reverse transcription-polymerase chain reaction (RT-PCR), using a set of 
primers (listed in Table 2.15) comprising the leader sequences of human Ig. A 
second round of nested PCR was performed to amplify the cDNA obtained 
from RT-PCR and to introduce cloning sites SalI/NheI into the heavy chain 
sequence and SalI/BbvCI into the light chain sequence respectively (Table 
2.16). The PCR products were then cloned into the mammalian expression 
vector pTT5 (licensed from National Research Council Biotechnology 
Research Institute, Montreal, QC, Canada) separately for heavy and light 
chains by homologous recombination using Infusion kit bought from Clontech 
(described in Section 2.3.1). cDNA synthesis and PCR conditions are as 





2.6.4 Expression and purification of human IgGs 
HEK293-6E cells were seeded at 0.5 x 106 cells/ml 24 h prior to transfection, 
in media supplemented with valproic acid (VPA) in place of G418. At a cell 
density of 1 x 106 cells/ml, DNA constructs with productive sequences were 
transfected into the HEK293-6E cells. For each transfection sample, lipid-
DNA complexes were prepared by diluting equal amounts of heavy and light 
chain plasmid DNA in Opti-MEM reduced serum medium (Life 
Technologies). 293fectin (Life Technologies) was diluted in Opti-MEM and 
incubated at RT for 5 min. The diluted DNA was then added to the diluted 
293fectin and incubated at RT for 30 min. The DNA-293fectin complex was 
added dropwise to the cells. The cells were subsequently incubated at 37oC 
with 5% CO2, with shaking at 125 rpm on an orbital shaker. At 24 h post-
transfection, the culture media was supplemented with TN1 (Tryptone N1, 
Organotechnie) and G418 (Gibco). Five days post-transfection, the 
supernatant containing immunoglobulins (Igs) was harvested by centrifugation 
at 4500 rpm. Protein G agarose beads (Millipore) were added to the 
supernatant and allowed to bind to the Igs at 4oC overnight. Beads were then 
collected by centrifugation at 150 g for 5 min at 4oC and added to a 1 ml 
polypropylene column (Qiagen). The supernatant was allowed to flow through 
the column by gravity flow. The column was then washed with 20 bead 
volumes of wash buffer (1X PBS) and the Igs were eluted with 0.1 M Glycine, 
pH 2.7 and neutralized with 1/5th volume of 1 M Tris. The eluted Igs were 
buffer exchanged into 1X PBS with a 10 kDa cutoff concentrator (Sartorius) 





2.7  Construction of DENV2 recombinant Envelope (rENV) protein 
2.7.1 Cloning of TSV01 rENV 
The S2 insect cell expression vector pMT/BiP/V5-HisA (Figure 2.3) is a 
component of the Drosophila expression system (DES) purchased from Life 
Technologies. This vector contains a Drosophila secretion signal (BiP) which 
allows inducible expression of secreted proteins from the metallothionein (MT) 
promoter with copper sulfate. 5 µg of pMT/BiP/V5-HisA was digested with 
20 U of XhoI (NEB) and 10 U of BglII (NEB) at 37oC for 4 h. 1 U of TSAP 
(Promega) was added to remove the free 5’ phosphate groups and the reaction 
was carried out at 37oC for 1 h, followed by heat-inactivation at 74oC for 15 
min. DNA sequence corresponding to DENV2 strain TSV01 prM-Envelope 
ectodomain (Figure 2.1) was amplified from the plasmid 5’DENV2-TSV01 
(obtained from Dr Roland Zuest, Singapore Immunology Network, Singapore) 
(Figure 2.2) using primers listed in Table 2.4 with PCR conditions shown in 
Table 2.5. The PCR product was cloned into BglII and XhoI sites of 
pMT/BiP/V5-HisA vector (Life Technologies, CA, USA) by Infusion cloning 
(as described in Section 2.3.1).  
 
   C  prM               E        NS1          NS2A   NS2B         NS3          NS4A   NS4B                NS5 
 
1            52              132           193            280  296                  394   495 
     EDI                 EDII                   EDI                 EDII                                   EDIII                         TM 
 
 
Figure 2.1: Schematic diagram of the dengue virus open reading frame (ORF) 
which encodes all viral proteins as a single polyprotein. For the construction of 
recombinant E protein, sequence corresponding to prM right through to E 









2.7.2 Expression and purification of rENV 
Expression of rENV was achieved with the DES. Stable cell line expressing 
the rENV protein was generated by seeding S2 cells at 1 x 106 cells/ml in each 
well of a 6-well plate for 24 h (log phase). 19 µg of the DNA construct and 1 
µg of pCoBLAST (Figure 2.3) was mixed with 2 M CaCl2 and added with 
continuous mixing to 2X HEPES-buffered saline. The transfection mix was 
incubated at RT for 30 min and then added to log phase S2 cells dropwise with 
swirling. 24 h post transfection, calcium phosphate was removed and cells 
were washed twice in S2 complete medium by centrifugation at 100 g for 5 
min. Blasticidin was added at 25 µg/ml to select for resistant colonies 48 h 
post removal of calcium phosphate. Resistant clones were then re-plated into 
T-25 flasks. For large-scale rENV expression, the S2 stable cell line was 
expanded to a 500 ml culture and expression was induced by adding copper 
sulfate to a final concentration of 750 µM. Culture supernatant was harvested 
Figure 2.2: Plasmid map. Plasmid was obtained from Dr Roland Zuest, from 
which sequences corresponding to prM through envelope ectodomain was 




5 days post induction. To purify rENV protein, an empty column (GE) was 
packed with 500 µl of Chelating Sepharose Fast Flow (GE) and attached to the 
Profinia system (Bio-Rad). After the culture supernatant was passed through 
the column, the column was washed with 14 column volumes of wash buffer. 





Figure 2.3: Plasmid maps. Plasmid maps were obtained from Life Technologies. 
(A) pMT/BiP/V5-His A. Sequence encoding the envelope ectodomain was cloned 
into BglII/XhoI sites of pMT/BiP/V5-HisA. This vector allows the transient, 
inducible, secreted expression of rENV-fusion protein upon transfection into S2 
cells, under the control of the metallothionein promoter (pMT) and the 
Drosophila BiP secretion signal for secretion. (B) pCoBlast. This selection vector 


























2.8 Characterization of human recombinant IgG  
2.8.1 Whole virus particles binding Enzyme Linked ImmunoSorbent 
Assay (ELISA) 
MaxiSorp plates (Nunc) were coated with 5 µg/ml mouse monoclonal 4G2 at 
4oC overnight and blocked with casein (Thermo Scientific). Whole viral 
particles of dengue serotypes 1-4 were added at 2 x 105 pfu per well and 
incubated at room temperature (RT) for 2 h. Purified antibodies were added to 
the plates at 1 µg/ml and incubated at RT for 1 h. Dengue virus specific 
binding Abs were detected by adding goat anti-human IgG-HRP (Jackson 
Immuno Research) and incubation at RT for 1 h. Reaction was developed with 
Tetramethylbenzidine (TMB) substrate (SurModics) by incubation at RT for 
5-10 min and stopped by adding 1 M HCl. The optical density (OD) was 
measured at 450 nm wavelength on the microplate reader (EnSpire, 
PerkinElmer). 
 
2.8.2 Plaque reduction neutralization titre (PRNT) 
BHK cells were seeded at 1 x 105 cells/ml in 0.5 ml per well of a 24-well plate 
and incubated at 37oC with 5% CO2 overnight. Purified antibodies were 
diluted four folds over 6 dilutions, starting from 30 µg/ml to 0.03 µg/ml and 
then added to the virus suspension. Virus-antibody mixtures were incubated at 
37oC for 1 h. Infection was carried out by adding 100 µl to each well in 
triplicates for each antibody dilution and incubating at 37oC for 1 h, with 
rocking at every 15 min interval. An overlay was added 1 h post-infection and 
the plates were incubated at 37oC for 4.5 days. The overlay was discarded and 
monolayer was stained with crystal violet + 0.8% PFA by incubating at RT 
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with rocking overnight. Plates were washed with tap water and plaques were 
enumerated by eye. PRNT50 is defined as the concentration of antibody which 
results in a reduction of plaques by 50% and determined by applying a three-
parameter non-linear curve fit in Graphpad Prism. Percentage plaque reduction 
was calculated using the formula as follows: 
 
        Percentage plaque reduction: 
= [100 − [( ୬୳୫ୠୣ୰	୭୤	୮୪ୟ୯୳ୣୱ	୵୧୲୦	ୟ୬୲୧ୠ୭ୢ୷୬୳୫ୠୣ୰	୭୤	୮୪ୟ୯୳ୣୱ	୵୧୲୦୭୳୲	ୟ୬୲୧ୠ୭ୢ୷) × 100] 
 
2.8.3 E protein specificity 
MaxiSorp plates were coated with 150 ng of DENV1-4 rENV protein at 4oC 
overnight and blocked with casein (Thermo Scientific). Purified antibodies 
were added at 1 µg/ml and incubated at RT for 90 min. Secondary goat anti-
human IgG-HRP (Jackson Immuno Research) was added and incubated at RT 
for 1 h. Reaction was developed by adding TMB substrate (SurModics) 
followed by incubation at RT for 5-10 min before terminating with 1M HCl. 






2.8.4 Stage of virus neutralization 
BHK cells were seeded at 1 x 105 cells/ml in 0.5 ml per well of a 24-well plate 
and incubated at 37oC with 5% CO2 overnight. For post-adsorption procedure, 
virus was added to cells at 50 pfu per well and incubated at 4oC for 1 h. The 
cell monolayer was washed with ice-cold PBS thrice. Purified antibodies were 
diluted four-fold over 6 dilutions, starting from 30 µg/ml to 0.03 µg/ml and 
added to cells, with triplicates for each antibody dilution. The plates were 
incubated at 4oC for another hour and washed with ice-cold PBS thrice before 
adding the overlay. For pre-adsorption procedure, virus-antibody mixture was 
incubated at 4oC for 1 h before adding to BHK cell monolayer. The plates 
were incubated at 4oC for 1 h and washed with ice-cold PBS thrice before 
adding the overlay. The subsequent steps that followed were the same as that 
of the PRNT assay described in Section 2.7.2. 
 
2.8.5 Antibody Dependent Enhancement assay 
Dengue virus seed stocks of all four serotypes were diluted to achieve a MOI 
of 0.1 and added to antibodies which were diluted four-fold over 12 dilutions, 
starting from 50 µg/ml and incubated at 37oC for 1 h. K562 cells were then 
added to the virus-antibody suspensions and incubated further at 37oC for 2 h. 
The cells were then washed with 1X PBS twice by centrifugation at 8000 g for 
5 min and re-suspended in 350 µl of RPMI + 2% FBS. After incubation at 
37oC for 72 h, K562 cells were collected by centrifugation at 8000 g and the 
supernatant was added to BHK cells in triplicates at 100 µl per well as per 




2.8.6 Antibody affinity measurement 
Antibody affinity was determined by sandwich ELISA. MaxiSorp plates were 
coated with 5 µg/ml 4G2 in coating buffer at 4oC overnight and blocked with 
casein at RT for 2 h. 2 x 105 pfu of all 4 DENV serotypes were added and Fab 
fragments were added over 8 dilutions starting from 10 µg/ml and incubated at 
RT for 1 h. Binding kinetics was detected by adding secondary anti-human 
IgG (Fab)2 –HRP and incubating at RT for 1 h. Reaction was developed by 
adding TMB substrate (SurModics) followed by incubation at RT for 5-10 min 
before terminating with 1 M HCl. The OD was measured at 450 nm 
wavelength on the microplate reader (EnSpire, PerkinElmer) and fitted to a 
one-site binding hyperbola using GraphPad Prism. (GraphPad Software, La 
Jolla California USA).  
 
2.8.7 In vivo protection assay 
The Type I and II interferon knockout AG129 mice at 8 weeks old were 
utilized to assess antibody efficacy in vivo. In a prophylactic model, varying 
concentrations of antibody starting at 100 µg over 10-fold dilutions to 1 µg 
were administered intravenously (iv) per mouse. Mice were challenged with 
either DENV1 or DENV2 via intraperitoneal (ip) route 24 h post treatment on 
Day 1. In another model to assess anti-viral effects, mice were challenged with 
DENV2 before antibody administration at 48 h post challenge. Blood was 
obtained retro-orbital from mice at Day 3 post challenge/treatment and 
collected into sodium citrate tubes. Serum was collected and viremia load was 




2.8.8 Antibodies stability at pH 5 and pH 7 
Antibodies stability studies were carried out using the ProteOn XPR36 Protein 
Interaction Array System (Bio-Rad). Goat anti-human IgG Fc (Jackson 
Immuno Research) was immobilized at a concentration of 4 µg/ml onto the 
GLC sensor chip (BioRad) by amine coupling at pH 5.5. Antibodies were 
captured by the ligand at a concentration of 2 µg/ml at 30 µl/min for 300 s. 
rENV protein at 1 µg/ml was flowed across at 30 µl/min for 300 s. 
Dissociation was allowed for 1800 s. Measurements were recorded at 25oC in 
1XPBS + 0.05% Tween at pH 5 or pH 7. Stability is assessed by comparing 
the dissociation rate of antibody from rENV. 
 
2.8.9 Epitope mapping by Surface Plasmon Resonance (SPR) 
Epitope mapping studies were carried out on the ProteOn XPR36 Protein 
Interaction Array System (Bio-Rad). 30 nM of DENV2 TSV01 rENV was 
immobilized onto the GLC sensor chip (BioRad) by amine coupling at pH 6.0. 
Antibodies at a concentration of 200 nM were flowed over the rENV ligand at 
a flow rate of 30 µl/min. Upon completion of binding by the first analyte, 
another set of antibodies at 200 nM was used as the second analyte for 
competition. Antibodies are said to be competing if no further binding is 
observed upon binding by the second analyte as reflected on the sensorgram. 
 
2.8.10 Epitope mapping by competition ELISA 
MaxiSorp plates were coated with 150 ng purified rENV protein at 4oC 
overnight. Plates were blocked with casein (Thermo Scientific) at RT for 2 h. 
Antibodies were applied to the plates at 0.05 µg/ml for biotinylated antibodies 
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and 10 µg/ml for non-biotinylated antibodies followed by incubation at RT for 
1 h. Streptavidin-HRP was diluted 1:3000 in casein and added to the plates 
with incubation at RT for 1 h. Reaction was developed by adding TMB 
substrate (SurModics) followed by incubation at RT for 5-10 min before 
terminating with 1 M HCl. The OD was measured at 450 nm wavelength on 
the microplate reader (EnSpire, PerkinElmer). 
 
2.9 Antibody Engineering 
2.9.1 Generation of LALA mutants 
The leucine residues at positions 234 and 235 of the human IgG1 Fc 
(Fragment crystallizable) region were replaced with alanine by site-directed 
mutagenesis to abolish FCγRs (Fc gamma receptors) binding. The Quikchange 
multi-site directed mutagenesis kit used was purchased from Agilent. Mutant 
strand synthesis was carried out with oligonucleotides listed in Table 2.7 and 
using cycling parameters listed in Table 2.8. Following temperature cycling, 
the reactions were incubated on ice and parental strands were removed by 
restriction digest with DpnI at 37oC for 1 h. The DpnI treated reactions were 
then transformed into the commercially available E.coli XL-10 gold 
(Stratagene) chemically competent cells. The transformed cells were plated 
onto LB+Amp plates and incubated at 37oC overnight. Individual colonies 
were picked and inoculated into LB+Amp media. The cultures were incubated 
at 37oC with shaking at 250 rpm overnight. Plasmid DNA was extracted using 
QIAprep Spin Miniprep Kit (Qiagen) following manufacturer’s protocol and 
sent out for DNA sequencing (Axil Scientific Pte Ltd) using the primers listed 
in Table 2.3. 
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2.9.2 Construction of bi-specific antibodies 
Single-chain fragment variable (ScFv) from candidate antibodies were 
synthesized by Genscript and amplified using primers listed in Table 2.9 and 
cycling parameters in Table 2.10. A 20 amino acid linker was also introduced 
by PCR to the 3’ end of each ScFv and cloned upstream to the hinge region of 
the IgG heavy chain via the SalI/NotI sites into the knobs-into-holes constructs 
(Figure 2.4) obtained from Dr Janice Oh (SIgN) by Infusion cloning described 















Antibody 1 Antibody 2 
Bi-specific antibody
Figure 2.4: Schematic of bi-specific antibody construction strategy. ScFv of 
parent antibodies with distinct epitopes were each grafted onto the Fc region of 
an IgG1 backbone via a 20 aa linker determined to provide sufficient binding 







2.9.3 Characterization of bi-specific antibodies 
2.9.3.1 Whole viral particles binding capability 
MaxiSorp plates were coated with PEG precipitated DENV1-4 at 4oC 
overnight and blocked with casein. Purified bi-specific antibodies were added 
at 1 µg/ml and incubated at RT for 90 min. Whole viral particles specific 
binding was detected by adding goat anti human IgG-HRP. Reaction was 
developed by adding TMB substrate (SurModics) followed by incubation at 
RT for 5-10 min before terminating with 1 M HCl. The OD was measured at 
450 nm wavelength on the microplate reader (EnSpire, PerkinElmer). 
 
2.9.3.2 In-vitro neutralization capacity of bi-specific antibodies 
U937 cells stably transfected with DC-SIGN were seeded at 6 x 104 cells per 
well of a 96-well plate and incubated at 37oC overnight. Bi-specific antibodies 
were diluted in serum free media 3-fold over 6 dilutions, starting from 10 
µg/ml and added to the DENV seed stocks. The virus-antibody mixture was 
incubated at 37oC for 30 min and then added to the cells. Plates were 
incubated at 37oC for another 2 h to allow virus adsorption and RPMI 
supplemented with 10% FBS was added. The plates were incubated further at 
37oC overnight. At 24 h post infection, cells were fixed with BD 
Cytofix/Cytoperm (BD) at 4oC for 30 min and washed once with FACS 
permeabilization buffer. Cells were then stained with the mouse monoclonal 
4G2-Alexa Fluor® 647 and NS1-Alexa Fluor® 488 diluted in FACS 
permeabilization buffer at 4oC for 30 min. Finally, the cells were washed once 
with FACS permeabilization buffer and re-suspended in FACS buffer before 
acquiring on the FACS Verse (BD). 
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2.9.3.3 Binding capacity of bi-specific antibodies 
The binding capacity of bi-specific antibodies was carried out using the 
ProteOn XPR36 Protein Interaction Array System (Bio-Rad). DENV2 rE 
protein was immobilized at a concentration of 30nM onto the GLC sensor chip 
(BioRad) by amine coupling at pH 6. Bi-specific antibodies or parent 
antibodies were introduced at 200 nM with a flow rate of 30 µl/min for 300 s. 
Dissociation was allowed for 900 s. Measurements were recorded at 25oC in 
1XPBS + 0.05% Tween at pH 7. Binding kinetics of bi-specific antibodies 
with single or dual specificities and their corresponding parent antibodies were 
compared. 
 
2.10 Epitope mapping by yeast surface display 
2.10.1 Cloning of dengue serotype 2 strain TSV01 Envelope ectodomain 
into the yeast surface display vector pCTCON2 
The yeast Saccharomyces cerevisiae EBY100 strain and the yeast surface 
display vector pCTCON2 were kind gifts from Prof. K. Dane Wittrup 
(Massachusetts Institute of Technology, Cambridge, England) (Figure 2.5). 5 
µg of pCTCON2 vector was digested with 20 U of NheI-HF (NEB) and 20 U 
of XhoI (NEB) at 37oC for 15 h. Free 5’ phosphate groups were removed to 
prevent vector re-circularization by adding 1 U TSAP (Promega) and 
incubating at 37oC for 1 h followed by heat-inactivation at 74oC for 15 min. 
DNA sequence corresponding to DENV2 strain TSV01 Envelope ectodomain 
was amplified from plasmid 5’DENV2-TSV01 (obtained from Dr Roland 
Zuest, Singapore Immunology Network, Singapore) using primers listed in 
Table 2.11 together with PCR conditions shown in Table 2.12. The obtained 
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PCR product was then cloned into NheI and XhoI sites of the pCTCON2 





Figure 2.5: Plasmid map of pCTCON2. Plasmid map was obtained from Prof. K. 
Dane Wittrup. The Envelope mutant library was cloned between the NheI and 
BamHI sites by homologous recombination in the yeast strain EBY100.  
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2.10.2 Construction of dengue serotype 2 strain TSV01 Envelope 
ectodomain mutant library 
GeneMorph II Random Mutagenesis Kit (Stratagene) was bought for the 
construction of the E ectodomain mutant library following manufacturer’s 
protocol. Briefly, 3.5 µg of plasmid DNA obtained from Section 2.9.1 was 
used in each mutagenesis reaction using primers listed in Table 2.13 and with 
cycling parameters listed in Table 2.14. The obtained product was purified 
with Gel Extraction Kit (Qiagen) and amplified with the same set of primers 
and cycling conditions for 20 cycles. The product was purified a second time 
with the Gel Extraction Kit and quantified using Nanodrop. 5 µg of pCTCON2 
vector was digested with 20 U of NheI-HF (NEB) and 20 U of SalI-HF (NEB) 
at 37oC for 15 h. 20 U of BamHI was then added to the reaction and incubated 
further at 37oC for 2 h, following which, the reaction was heat-inactivated at 
65oC for 20 min. Free 5’ phosphate groups were removed to prevent vector re-
circularization by adding 1 U TSAP (Promega) and incubating at 37oC for 1 h 
followed by heat-inactivation at 74oC for 15 min. 
 
2.10.3 Transformation of EBY100 
The yeast strain EBY100 Saccharomyces cerevisiae glycerol stock was 
streaked out on a YPD (Yeast Peptone Dextrose) plate and incubated at 30oC 
for 24 h. A starter culture was prepared by inoculating the EBY100 colony 
into 5 ml YPD media and grown overnight at 30oC with shaking at 250 rpm 
overnight. The starter culture was used to inoculate a 50 ml culture in YPD 
media to an absorbance of A600nm of 0.1 and incubated further at 30oC to an 
absorbance of between 1.3-1.5, corresponding to the mid-log growth phase of 
Saccharomyces cerevisiae. Once the cells have reached mid-log phase, 500 µl 
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of Tris-DTT was added to the culture and incubated at 30oC for 15 min. Cells 
were then collected by centrifugation at 2500 g for 3 min at 4oC and washed 
twice with ice-cold E buffer. The competent cells were then re-suspended in 
300 µl of ice cold E buffer. 0.2-cm electroporation cuvettes (Bio-Rad) were 
pre-chilled on ice, 50 µl of the competent cells along with 2 µg of E mutant 
library insert and 0.4 µg of cut vector pCTCON2 were added to the pre-chilled 
cuvette and kept on ice until it was pulsed. Cells were pulsed by inserting the 
electroporation cuvette into the Gene Pulser Xcell system (Bio-Rad) and 
applying voltage at 0.54 kV with 25 µF capacitance. Warm YPD media was 
added to the pulsed cells immediately and contents were transferred to a 14 ml 
polypropylene tube (BD). Cells were allowed to recover at 30oC for 1 h with 
shaking at 250 rpm. Culture supernatant was removed by centrifugation at 
2500 g for 5 min and cells were re-suspended in 10 ml SDCAA medium. 
Transformation efficiency was determined by plating 5 µl and 50 µl of the cell 
suspension on SDCAA plates. The remaining cell suspension was transferred 
to a 250 ml baffled flask containing 90 ml SDCAA and the antibiotics 
Penicillin/Streptomycin (Gibco) at 1:100 dilution and incubated at 30oC for 48 
h with shaking at 250 rpm. 
 
2.10.4 Surface expression and detection of E mutant library by flow 
cytometry 
A new culture was initiated to remove dead cells from the transformed cells. 
This was done by inoculating 5 x 108 cells in 50 ml of fresh SDCAA media 
and incubating the culture at 30oC overnight. The following day, 5 x 107 cells 
were collected from the freshly passaged library by centrifugation at 2500 g 
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for 5 min. Surface expression was induced by switching cells into media 
containing galactose (SGCAA) at an absorbance of 0.5 at A600nm.  Induction 
was carried out at 20oC for 48 h with shaking at 250 rpm. The induced cells 
were collected by centrifugation at 14000 g for 30 s at 4oC and washed once 
with PBSF buffer. Cells were stained with the mouse monoclonal 3H5 at 1 
µg/ml and chicken anti-c-myc IgY (Life Technologies) at 1:250 dilution in 50 
µl PBSF buffer and incubated at RT for 30 min under rotation.  Following 
primary antibody staining, cells were washed once with 1 ml of cold PBSF 
buffer and stained with goat anti mouse IgG-Alexa Fluor® 568 (Life 
Technologies) and anti-chicken IgY-Alexa Fluor® 488 (Life Technologies) at 
1:100 dilution in PBSF buffer respectively, for 30 min on ice in the dark. Prior 
to analysis by flow cytometry on the MACSQuant VYB (Miltenyi Biotech), 
cells were washed once with ice-cold PBS and re-suspended in 1 ml PBSF 
buffer. 
 
2.10.5 Yeast library freezing 
Freshly grown cells were inoculated into 1 L SDCAA at 1 x 107cells/ml and 
grown at 30oC for 72 h with shaking at 250 rpm. Culture supernatant was then 
removed by centrifugation at 2500 g for 5 min and the cells were re-suspended 






Chapter 3: Generation of human monoclonal antibodies against Dengue 
3.1 Plasmablasts were obtained from two Dengue infected patients at the 
acute phase of disease 
To date, the collection of hMabs available for the purpose of understanding 
the human immune response to Dengue infection was obtained from memory 
B cells immortalized by EBV transformation (Beltramello, Williams et al. 
2010, Dejnirattisai, Jumnainsong et al. 2010, de Alwis, Beltramello et al. 2011, 
de Alwis, Smith et al. 2012, Smith, Zhou et al. 2012, Smith, de Alwis et al. 
2014). All these studies are in consensus that the human immune response to 
dengue consists of predominantly cross-reactive antibodies which possess 
poor to moderate neutralization capacity, while potent serotype-specific 
neutralizing antibodies make up only a small fraction of the overall antibody 
response. Although Dengue infection in humans results in a life-long 
protective response against homologous infections, transient cross-reactive 
immunity against heterologous infections which lasts 2-3 months was also 
described in the same study (Sabin 1952). The transient cross-reactive 
immunity phenomenon suggests the presence of antibodies capable of 
neutralizing all four DENV serotypes by the short-lived antibody producing 
plasma cells.  At present, very few studies are described with regards to 
immune response at the acute phase of DENV infection (Setthapramote, 
Sasaki et al. 2012). In this study, a bold approach is undertaken with the hope 
of shedding new light on the human immune response to dengue which still 
remains elusive. For the purpose of this, we isolated antibodies from the 




As part of the “STOP-Dengue” program, patients above 21 years of age with 
acute-onset fever greater than 38.5oC for less than 72 h were recruited for the 
study. These patients do not present clinically obvious alternative diagnoses at 
point of consultation. Whole blood was collected from patients (acute phase) 
from which diagnosis was made by dengue virus specific RT-PCR. The 
current infecting serotypes for the two patients in this study were determined 
to be DENV2 and DENV3 for patient 10/63 and 10/50, respectively, and their 
pre-existing DENV immune status was determined using a flow cytometry 
based infection neutralization assay (Table 3.1). These data suggested that 
patient 10/63 had a previous DENV1 infection and patient 10/50 had a 
previous DENV2 infection. In addition, both patients had DENV-specific 





Table 2.1: Patient details  
a Neutralizing titers were determined 45h (10/63) and 17h (10/50) after fever onset. 
Bold text indicates assumed DENV serotype of previous infection. 
b Time point after onset of fever 
Source: MXu et al. Plasmablasts Generated during Repeated Infection Are Virus 
Glycoprotein-Specific and Bind to Multiple Virus Serotypes, J Immunol, 2012. 
 
 
To clone the dengue virus-reactive antibody genes from each B cell, peripheral 
blood mononuclear cells (PBMCs) were isolated from the whole blood by 
density gradient ficoll-paque extraction from which plasmablasts (PBs), 
identified as CD19+CD20-CD27highCD138+ lymphocytes, were sorted as single 
cell into each well of the 96-well plates (Figure 3.1) in the presence of Tris-
HCl and RNase inhibitor. Sorted samples not processed on the same day were 

































































Figure 3.1: Sorting strategy for plasmablasts. Freshly isolated PBMCs were 
stained for flow cytometry and the following consecutive gating strategy was 
used: (A) gating on lymphocytes, (B) gating on CD20-CD19+ cells, (C) gating on 














3.2 Amplification of immunoglobulin genes from single B cells 
There exists a repertoire of mouse monoclonal antibodies from which serology, 
topology and neutralizing epitopes are determined for Dengue. However, 
recent studies have shown that the immune response against Dengue infection 
in mouse and humans is starkly different (Wahala, Kraus et al. 2009, Teoh, 
Kukkaro et al. 2012, Smith, de Alwis et al. 2013, Messer, de Alwis et al. 2014). 
For the purpose of dissecting the human humoral immune response to dengue 
virus, an attempt was made to isolate antibodies from naturally infected 
Dengue patients. Previous attempts to isolate human monoclonal antibodies 
were largely obtained through immortalization of memory B cells with EBV 
(Epstein Barr Virus). The major drawback of this technique is the potential 
biasness in which certain B cells subsets may be more efficiently immortalized 
than the others. (Aman, Ehlin-Henriksson et al. 1984, Chan, Stein et al. 1986). 
 
In this study, a novel approach to isolate monoclonal antibodies from single B 
cells of two naturally Dengue infected patients is described (Patient ID 10/63 
and 10/50). Although the generation of monoclonal antibodies from single B 
cells is an established technology (Smith, Garman et al. 2009), the novelty of 
the method described in this study lies in its primers combination. Variable 
regions of the human Ig gamma chain (VH) and kappa light chain (Vk) were 
amplified by nested RT-PCR with a set of degenerate primers each for heavy 
and kappa light chain. The single B cell PCR approach for Ig gene 
amplification appears to be a very efficient process with an overall efficiency 
of 75% for heavy chain, albeit lower at 60% for light chain. It is observed that 
heavy chain amplification appears to be more efficient than light chain 
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amplification from patient 10/50. However, in the wells where heavy chains 
were amplified without light chains, it is also possible that the corresponding 
light chain is of the lambda isotype which is not included in this study. In 
humans, kappa isotype is predominantly used, making up 60% of the total 
light chains usage.  In total, 42 and 36 clones with both heavy and light chains 
amplified from one B cell were obtained from patient 10/63 (Figure 3.2.1) and 
patient 10/50 (Figure 3.2.2), respectively. Finally, wells that resulted in neither 


































































































































































































































































































































3.3 Ig genes were cloned as recombinant antibodies of the IgG1 isotype 
The immune response following DENV infection has been shown to be biased 
towards the induction of Th1 dependent immunity and it has been observed 
that the main IgG sub-classes found in the serum of Dengue infected patients 
are of the IgG1 and IgG3 isotypes (Thein, Aaskov et al. 1993, Koraka, Suharti 
et al. 2001). In addition, IgG1 is the most abundantly expressed antibody in 
human blood and the principle isotype associated with neutralization. 
Therefore, the Ig genes isolated from the patients in this study were cloned as 
recombinant IgG1 antibodies  
 
The heavy and light chain genes obtained from a single well were separately 
cloned into the mammalian expression vector pTT5_SP_H1 (Figure 3.3A). 
Cloning efficiency was greatly increased by homologous recombination over 
the traditional ligation method by using In-Fusion® cloning technology.  
Plasmid DNA was transformed into E.coli XL-10 gold competent cells from 
which circularized plasmid DNA containing the insert were selected by their 
resistance to ampicillin and screened by colony PCR using primers which 
flank the cloning sites. An empty vector yields a product of ~250 bp, whereas 
vector with heavy or light chain insert yields a product of ~1600 bp and 750 
bp respectively (Figure 3.3B). This PCR screening protocol allows efficient 





From the initial 42 and 36 pairs of Ig genes that were amplified from the two 
patients’ plasmablasts, 31 and 34 of them were successfully cloned in-frame to 
the expression vector as determined by DNA sequencing. Where cloning was 
not successful, it was associated with low PCR amplification efficiency in 










































Figure 3.3: Construction of human recombinant IgG1. (A) Restriction enzyme 
digestion of the expression vector pTT5_SP_H1. L-R: Ladder, pTT5_Heavy-uncut, 
pTT5_Heavy-SalI&NheI digested, pTT5_Light-uncut, pTT5_Light-SalI&BbvCI 
digested.  (B) Screening by colony PCR for cloned fragments. L-R: Ladder, heavy 






3.4 A panel of 65 recombinant antibodies was generated from the 
plasmablasts of naturally infected Dengue patients 
Recombinant proteins are routinely expressed in mammalian cells which 
possess molecular chaperons and post translational modification machineries 
necessary to aid in the proper folding of functional glycoproteins (Tate, Haase 
et al. 2003). Two options are available for recombinant proteins expression via 
transient gene expression or stable gene expression. Although stable gene 
expression results in a higher recombinant protein yield, it requires the time 
and labor consuming process of generating stable cell lines. Compared to 
stable gene expression, transient gene expression from extra-chromosomal 
DNA is an alternative to obtaining reasonable amounts of recombinant 
proteins in a much shorter time span.  
 
The human embryonic kidney (HEK) cell line is a widely used tool for 
transient recombinant proteins expression. HEK293E is a variant of the HEK 
cell line that has been transformed by EBV. This variant expresses the 
Epstein-Barr virus nuclear antigen 1 (EBNA1) to allow episomal amplification 
of plasmids containing the viral EBV origins of replication (oriP). Therefore, 
HEK293E is used in this study to complement the expression vector pTT5 for 
recombinant antibody expression. In short, HEK 293E cells were transfected 
with a pair plasmid DNA each containing the Ig heavy or light chain gene, and 
expression levels were aided by the addition of valproic acid (VPA) and the 
supplement Tryptone N1 (TN1). VPA is a histone deacetylase inhibitor that 
delays the loss of extra-chromosomal DNA associated with deacetylated 
histones (Backliwal, Hildinger et al. 2008) while TN1 is a casein peptone 
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shown to increase recombinant protein production by stimulating gene 
expression post-transfection (Pham, Perret et al. 2005). The recombinant 
antibodies secreted into the cell culture medium were then harvested by 
centrifugation to remove cells and debris 5 days post transfection.  
 
Recombinant antibody expression levels were examined by SDS-PAGE 
analysis. We observed differential expression levels across all clones, ranging 
from high expression with a clear band of the correct size on the gel 
corresponding to the molecular weight of the full length IgG to low or 
negligible expression (Figure 3.4). The secreted antibodies were purified from 
the cleared culture supernatant by affinity chromatography using Protein G 
conjugated agarose beads. Purity was determined by SDS-PAGE analysis with 
purified antibodies showing a major band between the 191 kDa and 97 kDa 
protein standards positions on the PAGE gels, suggesting a molecular weight 
size corresponding to that of a full length IgG molecule of 150 kDa. No major 
contaminating bands were observed, indicative of the efficient assembly of the 
recombinant IgG molecule (Figure 3.4). While differential expression levels 





Figure 3.4.1: Expression of recombinant IgG1 from 10/63. Crude supernatant of 
recombinant IgG1 expression on a Coomassie blue stained analytic non-reducing 
SDS-PAGE. IgG expression is reflected as the ~150 kDa band with observed 
expression variation among the clones. Other bands were cellular products which 




























































































































Figure 3.4.2: Expression of recombinant IgG1 from 10/50. Crude supernatant of 
recombinant IgG1 expression on a Coomassie blue stained analytic non-reducing 
SDS-PAGE. IgG expression is reflected as the ~150 kDa band with observed 
expression variation among the clones. Other bands were cellular products which 

























































































































Chapter 4: Characterization of human monoclonal antibodies isolated 
from naturally infected Dengue patients 
4.1 Antibodies isolated from plasmablasts of secondary infected acute 
patients are mostly Dengue specific. 
B cells of the humoral immune response are activated upon encountering 
soluble antigens such as viruses (Cooper and Nemerow 1984). Activation of B 
cells leads to their proliferation and differentiation into plasmablasts and 
memory B cells (Szakal and Tew 1992, Eckl-Dorna and Batista 2009). 
Plasmablasts are effector B cells that secrete antibodies to contain infection by 
various groups of pathogens such as bacteria, viruses and helminthes through 
neutralization and activating effector mechanisms to mediate their clearance. 
Upon successful viral clearance, antigen-specific B cells persist as long-lived 
plasma cells and memory B cells to provide a rapid response in the subsequent 
encounters with the same antigen. 
 
In this study, plasmablasts were isolated from Dengue infected patients and 
sorted directly without DENV specificity discrimination. It is assumed that the 
majority of the plasmablast population isolated should be specific towards 
DENV since the patients were at the acute phase of DENV infection when 
blood was drawn. Nevertheless, it is still essential to screen the panel of 
antibodies for their specificity to DENV since by-stander B cells might also 
have been activated (Lee, Halliley et al. 2011). To this end, crude culture 
supernatant of which the IgG concentration was quantified by ELISA (Figure 
4.1) was used to screen for DENV specificity by ELISA using heat-inactivated 
viral particles of all four DENV serotypes. More than 70% of the antibodies 
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demonstrated specificity to Dengue, with all the Dengue specific antibodies 
showing cross-reactivity to at least 2 or more dengue virus serotypes (Figure 
4.2). Antibodies that cross-react against all four DENV serotypes are classified 
as dengue complex specific while those that cross-reacts to at least two DENV 
serotypes are termed dengue sub-complex specific. Among those that showed 
successful expression, 10 of them did not react with viruses of any serotype. 
None of the antibodies isolated in this study were serotype-specific. 
 
Antibodies with reasonably good binding capacity to DENV as reflected by 
their absorbance values in the ELISA assay had their expression scaled up and 
tested for their in vitro neutralization capacity. In summary, 12 and 15 such 
clones were chosen from patients 10/63 and 10/50, respectively. Antibodies 
were purified from the cleared culture supernatant by affinity chromatography 
using Protein G beads. Purity was also determined by SDS-PAGE analysis. 
All purified antibodies showed a major band between 191 kDa and 97 kDa on 
the non-reduced PAGE gels, suggestive of a size corresponding to a full IgG 
molecule of approximately 150 kDa. Analysis by reducing SDS-PAGE further 
confirmed the integrity of the heavy and light chain compositions. Slight size 
differences corresponding to their respective CDR lengths were observed 









Figure 4.1: Quantitation of IgG in crude culture supernatant. The concentration 
of recombinant IgG antibodies in the crude culture supernatant was quantified by 
ELISA. MaxiSorp plates were coated with capture antibody. Crude culture 
supernatant containing recombinant IgG was then added. Binding was detected 
by adding HRP-conjugated anti-human IgG and absorbance was read at 450 nm 
(A) Concentration of antibodies from patient 10/63. (B) Concentration of 
antibodies from patient 10/50. The respective antibody concentration was 
extrapolated from a standard curve with absorbance readings corresponding to 
known concentrations of IgG standards. Source: Source: MXu et al. Plasmablasts 
Generated during Repeated Infection Are Virus Glycoprotein-Specific and Bind to 
Multiple Virus Serotypes, J Immunol, 2012.
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Figure 4.2.1: Frequency of DENV reactive B cells in secondary infected patient 
10/63. Heat-inactivated viral particles of all four DENV serotypes were coated 
onto MaxiSorp plates followed by addition of crude supernatant IgG preparation. 
Antibody binding was detected by adding HRP-conjugated anti-human IgG and 
measuring absorbance at 450 nm. (A) DENV1, (B) DENV2, (C) DENV3 and (D) 
DENV4. Antibodies which are DENV specific make up 75% of the antibodies 
tested, the remaining 25% of the antibodies did not show any signs of DENV 









   
Figure 4.2.2: Frequency of DENV reactive B cells in secondary infected patient 
10/50. Heat-inactivated viral particles of all four DENV serotypes were coated 
onto MaxiSorp plates followed by addition of crude supernatant IgG preparation. 
Antibody binding was detected by adding HRP-conjugated anti-human IgG and 
measuring absorbance at 450 nm. (A) DENV1, (B) DENV2, (C) DENV3 and (D) 
DENV4. Antibodies which are DENV specific make up 56% of the antibodies 
tested, 26% of the antibodies did not show any signs of DENV specificity although 
antibody expression levels were detectable while expression levels were not 







Figure 4.3: Purity of recombinant antibodies. Recombinant antibodies that 
demonstrate good binding capacity in whole viral particles binding ELISA were 
scaled up for further characterization. Recombinant antibodies were purified 
from cleared culture supernatant by Protein G affinity chromatography. The 
purity of antibodies was assessed by SDS-PAGE stained with Coomassie blue. 12 
and 15 such clones were identified from patient 10/63 (A, D) and 10/50 (B, C, E, F) 
respectively. The major product is the full length IgG molecule that corresponds 
to ~150 kDa under non-reducing conditions (A, B, C). The relative amounts of 
heavy (~50 kDa) and light chains (~25 kDa) as shown under reducing conditions 
(D, E, F). There appears to be a size difference among the various clones and 








































































































































































































4.2 The soluble DENV envelope (E) ectodomain 
The genome of dengue virus directs the synthesis of three structural proteins, 
C, prM and E and seven non-structural proteins, NS1, 2a, 2b, 3, 4a, 4b and 5. 
E is the major surface glycoprotein and is the major target of neutralizing 
antibodies (Crill and Roehrig 2001). The native E protein folds into three 
domains I, II and III and forms head-to-tail homodimers that lie parallel to the 
virion surface. The N-terminus ectodomain is dominated by β-sheet structures 
followed by a stem-anchor region and ends with a transmembrane segment at 
the C terminus (Rey, Heinz et al. 1995). Studies involving mouse monoclonal 
antibodies are in agreement that the most potent serotype-specific neutralizing 
antibody targets the domain III of E, in particular the lateral ridge.  In view of 
this, E is also the focus for dissecting the human antibody response.  
 
To facilitate characterization of the panel of antibodies isolated, the E 
ectodomains, i.e. the C-terminal truncated E protein lacking the stem anchor 
and transmembrane region of all four DENV serotypes were cloned and 
expressed. Expression of the ectodomain has been shown to result in improved 
secretion and immunogenicity with preserved native E conformation (Men, 
Bray et al. 1991). In addition, co-expression of prM with E has been suggested 
to aid in the proper folding of E with prM acting as a chaperone to guide its 
trafficking through the secretory pathway (Lindenbach, 2007). Hence, 
sequences corresponding to the E ectodomain along with prM were both 
amplified and cloned into the pMT/BiP/V5-HisA expression vector as a His-
































Figure 4.4: Construction of dengue recombinant E (rE) protein. (A) Amplification 
of DENV E protein. L-R: Ladder, plasmid DNA with sequence corresponding to ORF 
of DENV2, strain TSV01, amplification of prM-E. (B) Cloning of DENV E protein. 
Screenings by colony PCR to identify clones with desired gene insert. L-R: Ladder, 
pMT/BiP/V5-His with insert corresponding to ~2000 bp, pMT/BiP/V5-His vector 





A stable cell line expressing the recombinant DENV E protein (rE) was 
generated using Drosophila melanogaster Schneider 2 (S2) cells to facilitate 
expression for increased yield. Several expression platforms utilizing E.coli, 
baculovirus vectors, yeast, mammalian cells and insect cells have been 
described in an effort to express DENV rE and were met with various 
challenges such as the lack of native conformation preservation with E.coli 
and low yields with yeast and mammalian expression systems. This bottleneck 
was overcome by the Drosophila melanogaster derived S2 cell expression 
system, which not only preserved the native conformation of DENV rE but 
also resulted in relatively high expression levels.  
 
S2 cells were co-transfected with the pMT/BiP/V5-HisA containing the E 
protein gene and the antibiotic Blasticidin selection vector (pCoBlast). Stable 
cell lines were obtained by Blasticidin selection. The expression vector 
pMT/BiP/V5-HisA contains a metallothionien promoter (pMT) and a 
Drosophila secretion signal (BiP) to allow the inducible expression of secreted 
proteins by addition of copper sulfate. In addition, the vector also contains a 
V5-His tag to facilitate protein detection and purification. Culture supernatant 
was harvested 5 days post induction by centrifugation to remove cells and 
debris. Purification of the secreted proteins from the cleared supernatant was 
achieved by affinity chromatography. Due to the presence of free copper 
sulfate used for protein induction in the supernatant, purification with Ni-NTA 
beads would result in competition for binding between the free copper sulfate 
and the His-tagged rE protein to the Ni-NTA beads. The uncharged chelating 
sepharose beads were used for purification instead to circumvent this problem. 
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This is with reference to Lehr et al (Lehr, Elefante et al. 2000) who showed 
that His-tagged protein had a higher affinity for the chelating sepharose than 
the free copper sulfate ions. The yield of the rE protein obtained was at ~1 mg 
per liter of culture. The purity of rE was assessed by SDS-PAGE with 
Coomassie staining showing a major band corresponding to the size of an E 
monomer (43 kDa) between the 39-51 kDa protein standards (Figure 4.5), 
suggesting that prM is cleaved prior to E secretion. The identity of the protein 
is further verified by Western blot using pooled human serum obtained from 





































































































































Figure 4.5: Expression of DENV E protein. (A) Coomassie stain of soluble E protein 
fractionated by SDS-PAGE under non-reducing conditions. L-R: prM_E-non 
induced, prM_E-induced, Sample flow through, wash fraction, eluate flow 
through, eluate, concentrated eluate. The major bands seen in the induced and 
non-induced lanes is a component of fetal bovine serum (FBS) and share similar 
size with the rE protein monomer of about ~40 kDa. (B) Western blot analysis 
with human anti-dengue serum distinguishes between rE protein and FBS protein 
reflected by a single band seen only in the induced cell culture.
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4.3 More than 80% of the antibodies are specific for the Dengue Envelope 
protein 
The human antibody response to dengue has been shown to target the 
structural proteins C, prM and E as well as the non-structural proteins NS1 and 
NS3 with a bias towards an anti-prM response (Lai, Tsai et al. 2008, Crill, 
Hughes et al. 2009, Beltramello, Williams et al. 2010, Dejnirattisai, 
Jumnainsong et al. 2010, de Alwis, Beltramello et al. 2011). Results from 
whole viral particles binding ELISA suggested that these antibodies bind to 
the virus’s structural proteins that make up the virus protective coat. E is the 
major glycoprotein found on the viral surface and is the target of neutralizing 
antibodies (Kitano, Suzuki et al. 1974, Kaufman, Summers et al. 1987, 
Roehrig, Bolin et al. 1998). The M protein acts as a transmembrane protein 
buried under the E protein shell and is not exposed on the surface, although 
the uncleaved form, prM is exposed on immature viral particles.  
 
The targets of the panel of antibodies which were shown to be dengue specific 
were elucidated first by determining their specificity to E by ELISA. rE 
obtained from Section 4.2 was coated onto ELISA MaxiSorp® plates followed 
by addition of the antibodies. rE specificity was detected by adding a 
peroxidase conjugated secondary antibody and measuring the absorbance at 
OD450nm. The pan-DENV serotype mouse monoclonal antibody 4G2 was used 
as a positive control. An antibody HA4 specific for Influenza virus was 
included as a negative isotype control. Of the 27 antibodies tested, 24 of them 




       
Figure 4.6.1: Antibodies specificity to DENV rE protein. The panel of antibodies 
was tested for their specificity to E protein by ELISA. rE of all four DENV serotypes 
were coated to MaxiSorp plates. Purified antibodies were added at 1 µg/ml, 
reactivity to E was detected by adding HRP-conjugated anti-human IgG and 
measuring absorbance at 450 nm. (A) DENV1, (B) DENV2, (C) DENV3 and (D) 
DENV4. The pan-dengue E protein specific monoclonal antibody 4G2 and the 
influenza specific antibody HA4 were used as positive and negative controls 
respectively. All the antibodies from patient 10/63 were E reactive. 
A.                DENV1  
D.               DENV4 
B.               DENV2 





     Figure 4.6.2: Antibodies specificity to DENV rE protein. The panel of antibodies 
was tested for their specificity to E protein by ELISA. rE of all four DENV serotypes 
were coated to MaxiSorp plates. Purified antibodies were added at 1 ug/ml, 
reactivity to E was detected by adding HRP-conjugated anti-human IgG and 
measuring absorbance at 450 nm. (A) DENV1, (B) DENV2, (C) DENV3 and (D) 
DENV4. The pan-dengue E protein specific monoclonal antibody 4G2 and the 
influenza specific antibody HA4 were used as positive and negative controls 
respectively. All but 3 of the antibodies from patient 10/50 were E reactive. 
A.                DENV1  
D.               DENV4 
B.               DENV2 




4.4 Fusion loop specific antibodies dominate the antibodies repertoire 
Unlike the immune responses in mice, antibodies with potent neutralization 
capacity are not restricted to EDIII in humans. The fusion loop and hinge 
regions which reside in the EDI/II region have been shown to be capable of 
eliciting protective antibody response against Dengue infection in humans (de 
Alwis, Smith et al. 2012, Messer, de Alwis et al. 2014). In the study by Lai et 
al (Lai, Tsai et al. 2008), the fusion loop is identified as the major target of the 
human antibody response as mutations in the conserved residues resulted in a 
significantly reduced binding of immune sera against E.  
 
Here, the binding properties of the panel of antibodies obtained was further 
characterized by employing two independent techniques, a competition ELISA 
and a surface plasmon resonance (SPR) assay with DENV2 rE. In both assays, 
rE was immobilized followed by binding of the first DENV specific antibody. 
Subsequent application of the second DENV specific antibody allowed the 
assessment of any effects of the binding of the first antibody on the second 
antibody.  Results obtained from competition ELISA mirrored that of SPR 
showing that the panel of antibodies can be categorized into 4 main groups 
with a dominating group made up of more than 50% of the antibodies tested 
(Figure 4.7).  
 
To obtain a more specific footprint of these antibodies on the E protein, a 
competition assay was carried out with the fusion loop specific mouse 
monoclonal antibody 4G2. Results showed that 67% of the antibody repertoire 
tested competed with 4G2 for binding as reflected by the significant drop in 
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the absorbance readings at 450 nm compared to 4G2 binding alone (Figure 
4.8). Interestingly, it is the dominant group that was identified by the 
competition assay. This suggests that these antibodies share a common epitope 
with 4G2 in the fusion loop and supports the current understanding that the 
majority of the antibodies produced during a DENV infection are fusion loop 
specific. It is of interest to note that the two antibodies belonging to Group B 













































































































































































































































































































































































































































































4.5 Identifying critical contact residues for antibody binding 
A major fraction of the human immune response to Dengue infection at the 
acute phase of disease is directed to the fusion loop, as suggested by the 
competition assay in Section 4.4. In an attempt to further dissect the human 
antibody responses, critical contact residues that contribute to antibody 
binding were identified by means of a modified alanine scanning mutagenesis 
approach.  
 
A collection of DENV prM/E mutants were generated by shotgun mutagenesis 
in which each E protein mutant contained one residue replaced by an Alanine 
residue. The mutants were then expressed on the surface of the HEK 293T 
cells and used to screen for binding with one representative antibody from 
each group identified in Section 4.4. Antibody binding was detected with an 
AF488-conjugated secondary antibody and quantified by their mean 
fluorescence intensity. Mutations that led to loss of antibody binding were 
identified as potential contact residues. Measurements were made relative to 
wild-type (WT) E transfected cells and normalized to mock-transfected cells. 
A conformation-sensitive antibody was included to account for protein mis-
folding and expression defects.  
 
Antibody representative of Groups A and B had their epitope mapped to EDII 
identified by the residues H209, W212, D215, P217 and A267 whereas the 
footprint of Group C is mapped to EDI (Figure 4.9). Interestingly, the contact 
residues identified are buried in both EDI and EDII and therefore, not readily 
accessible by antibodies. In agreement with the competition assay, the one 
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critical contact residue for Group D, W101, is located in the fusion loop region 




Figure 4.9: Critical amino acid residues for antibody binding. A collection of 
DENV prM/E mutants was generated by shotgun mutagenesis and expressed in 
HEK-293-T cells. Cells were then stained with each test antibody, binding was 
detected by secondary antibody-AF488 and mean cellular fluorescence was 
detected. Mutations which led to loss of test antibody binding were identified as 
critical contact residues.  Top-Bottom: Group A- Epitope footprint in EDII, Group 
B: Epitope footprint in EDII, Group C: Epitope footprint spanning EDI and EDIII, 
Group D: Epitope footprint around fusion loop. EDI, EDII and EDIII are represented 
in red, yellow and blue respectively. Fusion loop is illustrated in grey. Courtesy of 







4.6 Antibodies demonstrated cross-neutralization in-vitro  
E protein is the major target of neutralizing antibodies. So far, studies with 
human monoclonal antibodies suggest that cross-reactive antibodies of low to 
modest neutralization capacity are in abundance whereas serotype-specific 
antibodies that possess potent neutralization capacity are rare. Having shown 
that the majority of the anti-dengue antibodies are E protein specific, they 
were subsequently assessed for their neutralization capacity in-vitro.  
 
Two different assays were employed for this: 1. Plaque reduction 
neutralization test (PRNT), the gold standard for in-vitro neutralization (Figure 
4.10A) and 2. flow cytometry based neutralization, the high throughput 
screening system (Figure 4.10B). The panel of antibodies exhibited cross-
neutralization to at least 2 DENV serotypes in both assays. However, 
while >60% antibodies in this panel showed significantly high neutralization 
potency with EC50<0.5 µg/ml by the flow cytometry method, the mass 
majority of them neutralized Dengue infection poorly, if at all, by PRNT.  
Consistent with literature, antibodies that are cross-reactive with poor to 
moderate neutralizing capacities dominate the human antibody response in the 




 Figure 4.10: In vitro neutralization capacity. The neutralization capacity of the 
panel of isolated antibodies was determined by (A) flow cytometry based 
neutralization assay in comparison with (B) PRNT. Antibody EC50 (µg/ml) was 
plotted against DENV serotype. The antibody clones 63_6C, 63_2C, 63_5D, 50_7A, 
50_7E and 50_7H were not plotted in (B) as they were not neutralizing by PRNT 
assay. The EC50 values did not appear too different between both assays with 





Chapter 5: Identification of an antibody that possess potent neutralization 
capacity across all 4 dengue serotypes 
The absence of serotype-specific antibodies with potent neutralization capacity 
led to the speculation that the initial screen with heat-inactivated virus was an 
issue. Various inactivation methods have been recognized for their individual 
associated pitfalls with perturbation of antigenic epitopes being the primary 
concern. In this chapter, we describe the re-screen of antibodies with live viral 
particles which led to the isolation of a cross-reactive potent neutralizing 
antibody. 
 
5.1 Antibodies that recognized conformational epitopes preserved on live 
viral particles 
The panel of antibodies was then re-screened in an ELISA binding assay using 
whole live DENV virions (Figure 5.1). One major observed difference 
between the use of inactivated and live virus is the cross-reactivity of these 
antibodies; binding was demonstrated against all 4 serotypes for all antibodies 
tested with live viral particles whereas none of the antibodies displayed 
binding to DENV4 with inactivated virus described in Chapter 4 (Figure 4.2). 
Additionally, in comparison to the same panel of antibodies tested for rE 
reactivity described in Chapter 4 (Figure 4.6.2), it was noted that 3 of the 
antibodies (designated 50_3C, 50_5A, 50_9B) which did not bind to rE 




A.     Whole viral particles 
B.     Envelope protein 
Figure 5.1.1: Antibodies that bind quaternary structure epitopes. DENV1 live 
viral particles or rE were coated onto MaxiSorp plates followed by addition of IgG 
at 1 µg/ml. Antibody binding was detected by adding HRP-conjugated anti-
human IgG and measuring absorbance at 450 nm. The pan-dengue E protein 
specific monoclonal antibody 4G2 and the influenza specific antibody HA4 were 
used as positive and negative controls respectively. (A) live viral particles, (B) rE. 
The entire panel but 3 of the antibodies tested reacted to whole viral particles 
but not to rE, suggesting the preservation of their epitopes on whole viral 
particles. Data replicates are expressed as mean ± SD, 3 independent 

























































A.     Whole viral particles 
B.     Envelope protein 
Figure 5.1.2: Antibodies that bind quaternary structure epitopes. DENV2 live 
viral particles or rE were coated onto MaxiSorp plates followed by addition of IgG 
at 1 µg/ml. Antibody binding was detected by adding HRP-conjugated anti-
human IgG and measuring absorbance at 450 nm. The pan-dengue E protein 
specific monoclonal antibody 4G2 and the influenza specific antibody HA4 were 
used as positive and negative controls respectively. (A) live viral particles, (B) rE. 
The entire panel but 3 of the antibodies tested reacted to whole viral particles 
but not to rE, suggesting the preservation of their epitopes on whole viral 




A.     Whole viral particles 
B.     Envelope protein 
Figure 5.1.3: Antibodies that bind quaternary structure epitopes. DENV3 live 
viral particles or rE were coated onto MaxiSorp plates followed by addition of IgG 
at 1 µg/ml. Antibody binding was detected by adding HRP-conjugated anti-
human IgG and measuring absorbance at 450 nm. The pan-dengue E protein 
specific monoclonal antibody 4G2 and the influenza specific antibody HA4 were 
used as positive and negative controls respectively. (A) live viral particles, (B) rE. 
The entire panel but 3 of the antibodies tested reacted to whole viral particles 
but not to rE, suggesting the preservation of their epitopes on whole viral 
particles. Data replicates are expressed as mean ± SD, 3 independent 




A.     Whole viral particles 
B.     Envelope protein 
Figure 5.1.4: Antibodies that bind quaternary structure epitopes. DENV4 live 
viral particles or rE were coated onto MaxiSorp plates followed by addition of IgG 
at 1 µg/ml. Antibody binding was detected by adding HRP-conjugated anti-
human IgG and measuring absorbance at 450 nm. The pan-dengue E protein 
specific monoclonal antibody 4G2 and the influenza specific antibody HA4 were 
used as positive and negative controls respectively. (A) live viral particles, (B) rE. 
The entire panel but 3 of the antibodies tested reacted to whole viral particles 
but not to rE, suggesting the preservation of their epitopes on whole viral 




5.2 Clone 50_3C displays potent neutralization capacity against all 4 
DENV serotypes in-vitro 
The humoral immunity plays an important role in the protection against 
flaviviruses infection. This is demonstrated by their ability to protect mice 
against infection through the passive transfer of antibodies reviewed by 
Roehrig in 2001 (Roehrig, Staudinger et al. 2001).  
 
The panel of antibodies was re-assessed for their neutralization capacity in 
vitro by plaque reduction (PRNT). The presence of an antibody that possesses 
potent neutralization capacity against all four DENV serotypes was observed 
among the pool of antibodies tested. This antibody clone 50_3C was among 
one of the three clones that displayed significant binding to whole viral 
particles but not to the rE protein described in Section 5.1. Clone 50_3C 
displayed potent neutralization against all four serotypes of DENV. The 
PRNT50 of 50_3C range from as low as 0.001 µg/ml to 0.2 µg/ml, in a 
neutralization order of DENV2 >> 1 ≈ 4 > 3 (Figure 5.2B). There were two 
other two antibody clones which shared similar binding characteristics as 
clone 50_3C however, one of the two antibodies clone 50_9B did not exhibit 
the same neutralization potency (Figure 5.2A). The neutralization capacity of 
the other clone 50_5A has not been determined due to lack of antibody sample. 
Since these 3 antibodies only recognized whole live viral particles, it is 
hypothesized that their epitopes are only preserved on the intact virions 
suggesting the recognition of quaternary structure epitope/s.  
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As discussed in the previous chapter, most cross-reactive antibodies derived 
from dengue virus infected patients have been characterized as poor 
neutralizers. However, in this chapter we discovered an antibody that 
displayed very high neutralizing potency against all four DENV serotypes led 













Figure 5.2: In vitro neutralization capacity by PRNT. Three antibodies identified 
as DENV whole viral particles reactive but rE negative were re-assessed for their 
neutralization capacity by plaque reduction neutralization (PRNT). (A) The 
discovery of a cross-reactive antibody clone 50_3C with potent neutralizing 
capacity. 50_3C demonstrated potent neutralization capacity against all four 
serotypes with the EC50 ranging from 0.001 µg/ml (0.006 nM) to 0.2 µg/ml (1 
nM) in the following order of neutralization; DENV2-1-4-3. (B) In contrast, the 
other antibody clone 50_9B with similar binding characteristics did not display 
comparable neutralization capacity. Data replicates are expressed as mean ± SD, 
2 independent experiments were performed. 
B.                                      50_3C  
A.                                      50_9B 
 122 
 
5.3 Clone 50_3C inhibits virus attachment and membrane fusion 
Next, we investigated clone 3C’s mechanism of neutralization.  Antibodies are 
known to incapacitate virus infection by interfering at various stages of its life 
cycle (Cooper and Nemerow 1984). The first and foremost of which is the 
inactivation of viral particles by coating their surface to prevent them from 
attaching to susceptible cells through their surface receptors. Antibodies are 
also known to inhibit virus infectivity following the entry into host cells by 
impairing the membrane fusion mechanism of enveloped viruses. A classic 
example is the neutralization of WNV virus by an antibody that blocks 
membrane fusion (Vogt, Moesker et al. 2009). In the context of dengue virus, 
a low endosomal pH-induced structural change in the E protein is required for 
virus: host membrane fusion, an event that allows for subsequent genome 
release into the cytoplasm.  
 
Here we attempted to differentiate these two distinct neutralization 
mechanisms utilized by clone 3C. In the “pre-attachment” assay, the virus was 
pre-incubated with the antibody at 4oC for 1 h before infecting BHK cells. In 
the “post-attachment” assay, the virus was adsorbed to BHK cells at 4oC for 1 
h followed by the removal of unbound viruses and subsequent addition of 
antibody. Neutralization efficacy is determined by the reduction of the plaque 
formation on the agarose plate when the antibody is present.  Results suggest 
that clone 50_3C appears to inhibit receptor attachment and is also able to 
inhibit at a post-attachment step presumably through antagonizing membrane 





























Figure 5.3: Neutralization capacity and mechanism of inhibition by 50_3C. The 
mechanism of inhibition by 50_3C was assessed in modified plaque reduction 
neutralization (PRNT) assay. In the pre-attachment mechanism, antibody was 
incubated with the virus at 4oC for 1 h before infecting BHK cells. In the post-
attachment assay, virus was allowed to adsorb to BHK cells at 4oC for 1 h before 
adding the antibody. Results showed that this antibody inhibits virus attachment 
at an EC50 of 0.001 µg/ml and also antagonize the membrane fusion mechanism 
post attachment at a four-fold higher concentration of 0.003 µg/ml. Data 




5.4 Construction of 50_3C LALA mutants 
A study by Balsitis et al (Balsitis, Williams et al. 2010) demonstrated that Fc 
modification at the N-linked glycosylation site N297 residue impaired lethal 
enhancement of Dengue disease in mice. Similar findings were documented in 
another independent study by Beltramello et al (Beltramello, Williams et al. 
2010) in the same year where modifications to the Fc region were made at 
sites other than N297. These effects are attributed to the loss of Fc receptors 
(FcRs) binding by the antibody. We expected that the native form of antibody 
3C would also cause ADE, and would like to test if this can be prevented by 
eliminating FcRs binding capability of the antibody.  
 
To this end, we decided to use Fc with mutations at sites other N297.   Here, 
Fc was modified by introducing two mutations that replace the leucine 
residues at positions 234 and 235 with alanine residues in the CH2 region.  
The resulting modification is often referred to as the LALA mutant. LALA 
mutations have been shown to result in a dramatic decrease in FcᵧR binding 
(Hessell, Hangartner et al. 2007). A neutralizing antibody with such mutations 
has demonstrated lack of ADE and its therapeutic potential in a mouse model 
(Beltramello, Williams et al. 2010).   
 
Here, we construct the LALA variant of 50_3C by site-directed mutagenesis. 
Similar to the expression of the native IgG, the LALA variant was also 
expressed in HEK293E cells and purified by Protein G affinity 
chromatography. Expression and purity of the LALA variant was assessed by 
SDS-PAGE stained with Coomassie (Figure 5.4). We found that the LALA 
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variant was expressed at a level similar to that of the parental IgG, and can be 
readily purified by Protein G affinity chromatography.  This suggested that the 























Figure 5.4: Coomassie stain of 50_3C LALA mutant. The 50_3C LALA mutant was 
expressed in HEK-293E cells which were then purified by affinity chromatography 
with Protein G. The proteins were then fractionated by SDS-PAGE and stained 
with Coomassie to assess purity. L-R: Ladder, native (non-reduced) corresponding 










5.5 Clone 50_3C displays Antibody Dependent Enhancement (ADE) 
across all 4 serotypes, which can be abolished by its corresponding 
LALA mutants 
One disease exacerbation seen in Dengue patients has been proposed to occur 
through an immune mediated mechanism termed antibody dependent 
enhancement (ADE). ADE is mediated by antibody-virus complex and is 
facilitated by the interaction between the Fc region of virus-bound antibody 
and cells that expresses the respective FcᵧR.  
 
The monocytic cell line K562, which expresses FcᵧR, was used to assess the 
ADE effect, if any, of 50_3C. The antibody 50_3C was diluted four-fold over 
12 dilutions starting at 50 µg/ml and incubated with each of the four DENV 
serotypes at 37oC for 1 h, to which K562 cells were added to achieve a virus 
M.O.I of 0.1 and incubated further at 37oC for 2 h to facilitate virus uptake. 
The cells were then washed to remove free antibody-virus complex and re-
suspended in RPMI supplemented with 2% FBS. The cell suspension was then 
incubated at 37oC for another 72 h to allow virus replication. Following virus 
replication, the culture supernatant was harvested and used in a plaque assay 
to determine viral titers. Here, we show that clone 50_3C mediates ADE with 
all four DENV serotypes to which it cross-reacts, although the window of 
ADE is narrower compared to antibodies which are poorly neutralizing 
(Dejnirattisai, Jumnainsong et al. 2010). The experiments were carried out 
together with the LALA variant of clone 50_3C was in parallel. As expected, 












Figure 5.5: 50_3C mediates ADE across all four DENV serotypes. 50_3C was 
analyzed for its ability to mediate ADE across all four DENV serotypes to which it 
binds. Antibody-virus complexes were allowed to form at 37oC for 1 h, to which 
K562 cells were then added. Following infection of K562 cells at 37oC for 2 h, cells 
were washed with PBS twice to remove free antibody-virus complexes and re-
suspended in 350 µl RPMI + 2%FBS which were then incubated further at 37oC for 
72 h before adding the virus-containing supernatant to BHK cells for infection by 
plaque assay. ADE is observed across all four DENV serotypes by IgG represented 
by solid circles which is abolished with the LALA mutant which is unable to bind 
to FcᵧR represented by solid squares. Maximum infection in the absence of 
antibody is represented by dash line. Box represents ADE window. (A) DENV1, (B) 
DENV2, (C) DENV3 and (D) DENV4. Data replicates are expressed as mean ± SD, 2 












5.6 Clone 50_3C protects mice against lethal DENV challenge 
The antibody clone 50_3C displayed potent neutralization capacity against all 
four DENV serotypes in vitro. It is then of great interest to determine if the 
same potency can be seen in vivo. Humans and mosquitos are the only known 
natural hosts of DENV, which does not infect any other hosts or produce an 
illness similar to humans.  As a consequence, no experimental animals are 
suitable with which to conduct in vivo models that mimic natural infection. As 
clinical isolates and laboratory strains of dengue virus do not replicate 
efficiently in wild-type mice, administration of mouse-adapted strains at high 
viral titers via the intracranial route is often necessary for efficient replication. 
This route of infection with mouse-adapted strains, however, results in 
irrelevant clinical manifestations, of which one prominent feature is the 
exhibition of neurologic impairment characterized by paralysis. This 
shortcoming led to the exploration of murine models of different genetic 
backgrounds.  
 
Currently, the Type I (α/β) and II (ᵧ) interferon receptors knockout (Kouri, 
Guzman et al.) AG129 mice are the most widely used mouse model for DENV 
infection. Interferon has been shown to be necessary to control infection and 
indeed these mice are highly susceptible to infection. In the first description of 
AG129 as a Dengue model, death of these animals was observed by day 12 
when 1 x 106 pfu mouse-adapted virus was administered intraperitoneally (ip) 
to 8 weeks old mice.  Neither Type I nor Type II ko alone was sufficient to 
cause disease, suggesting that both interferon types in combination was 
necessary (Johnson and Roehrig 1999). 
 129 
 
Clone 50_3C was assessed for its in vivo protection capacity in two models: 
prophylactic and therapeutic. Two DENV2 strains, TSV01 and D2Y98P, and 
one DENV1 strain were used. Infection of AG129 mice by the two DENV2 
virus strains have been characterized and were described by Schul et al (Schul, 
Liu et al. 2007) and Tan et al (Tan, Ng et al. 2010), respectively. The non-
mouse adapted clinical DENV2 strain D2Y98P has been described to be 
highly infectious when administered ip to AG129 mice. At a high viral dose of 
1 x 107, death of the animals correlate with the peak of viremia levels at 5 days 
post infection. The non-virulent DENV2 clinical isolate TSV01was included 
as a comparison. In mice infected with 1 x 107 pfu of TSV01, the peak of 
viremia is observed 3 days post infection followed by clearance by day 9 post 
infection. These mice did not display any signs of overt illness and death was 
not observed for up to 20 days post infection.  
 
In the prophylactic model, AG129 mice at 8 weeks of age were treated with 
three different doses of the antibody 50_3C at 100 µg (5 mg/kg), 10 µg and 1 
µg administered intravenously (iv). Twenty-four hours post treatment; mice 
were challenged with either DENV2 or DENV1 strain at 107 pfu per mouse by 
ip. In the therapeutic model, AG129 mice were challenged with the lethal 
DENV2 strain D2Y98P at 1 x 107 pfu per mouse by ip followed by iv 
administration of the antibody 50_3C 48 h post infection. An isotype control 
antibody HA4 was included as a negative control using the same dosing 
regimen in both models. All mice were bled 3 days post challenge and viremia 
was determined by qPCR.  
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In the prophylactic mouse model, an antibody dose-dependent reduction in 
viremia was observed in mice infected with the non-lethal TSV01 strain. At 
the 100 µg dose a 10,000-fold reduction was observed and, remarkably, 
reduction in viremia by more than 10-fold was achieved at a dose as little as 1 
µg per mouse. In mice infected with the lethal D2Y98P strain, viremia was 
also drastically reduced by 1,000 to 10,000-fold with 10 µg and 100 µg 
antibody, although the difference between these 2 doses appeared to be small 
(Figure 5.6).  
 
In contrast to viremia reduction when TSV01 was used, treatment at 1 µg dose 
resulted in a slight increase in viremia in mice infected with the lethal 
D2Y98P strain.  The observation in the slight increase in viremia led to the 
postulation of an ADE effect. The LALA mutant of 50_3C has been shown to 
abolish ADE in vitro and we ask if the same correlate can be reproduced in 
vivo. Thus, 1 µg each of 50_3C IgG, its LALA mutant and HA4 were 
administered to 8 weeks old AG129 mice following the regimen of the 
prophylactic model. Remarkably, the ADE effect was abolished (Figure 5.7).  
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Figure 5.6: 50_3C treatment reduces viremia titers. Three doses of the antibody 
50_3C was administered iv to 8 weeks old AG129 mice at 100 µg, 10 µg and 1 µg. 
24 h post treatment, the treated mice were challenged with 1 x 107 pfu DENV2 
given ip. An isotype control antibody HA4 was included. All mice were bled on D3 
post infection and viral titers were assessed by qPCR. (A) Mice challenged with 
TSV01; antibody treatment resulted in a dose-dependent reduction in viremia, 
with the most pronounced effect observed with 100 µg of the antibody which led 
to a 4 logs reduction in viremia. (B) Mice challenged with D2Y98P; antibody 
treatment resulted in a dose-dependent reduction in viremia. Interestingly, an 
increase in viremia was observed with 1 µg of antibody. A reduction in viremia by 
4 logs is also observed with 100 µg of antibody. n=3 in each treatment group. 













































Figure 5.7: The LALA mutant of 50_3C abolished antibody dependent 
enhancement (ADE) and promoted survival. A single dose of the antibody 50_3C 
or its LALA mutant was administered at 1 µg iv to 8 weeks old AG129 mice. 24 h 
post treatment, the treated mice were challenged with 1 x 107 pfu of the lethal 
DENV2 strain D2Y98P given ip. An isotype control antibody HA4 was included. (A) 
All mice were bled 3 days post infection and viral titers were assessed by qPCR. 
An increase in viral titers suggestive of ADE was observed in the 50_3C IgG 
treated group. This phenomenon is absent in the group of mice treated with the 
LALA mutant of 50_3C. (B) Lethality was observed slightly earlier in mice treated 
with 50_3C IgG compared to the isotype control antibody HA4 at 4 days post 
infection. In contrast, survival of mice was extended to 7 days post infection with 
























Having demonstrated the efficacy of 50_3C as a prophylactic, the therapeutic 
effect of 50_3C was also evaluated. Viremia and survival of AG129 mice 
treated with 100 µg of 50_3C IgG 48 h post challenge with the lethal D2Y98P 
was assessed. A 2-logs reduction in viremia was observed at 3 days post 
infection and the mice survived for at least 22 days. Of 3 mice, death of the 
last mouse was recorded at 35 days post infection (Figure 5.8).  In contrast, the 
control group which received HA4 died at 4 days post infection. 
 134 
 
Figure 5.8: 50_3C prolongs survival of mice challenged with the lethal DENV2 
strain D2Y98P. AG129 mice were challenged with the lethal DENV2 strain 
D2Y98P given ip at 1 x 107 pfu. 100 µg of the antibody 50_3C was administered iv 
48 h post infection. (A) Mice were bled 3 days post infection and viral titers were 
assessed by qPCR; a 2 logs reduction in viremia was observed. (B) Survival of 
AG129 mice was observed with death of the last animal only occurring at 35 days 
post infection in contrast to death of all animals treated with the isotype control 
antibody HA4 at 4 days post infection. n=3 in each treatment group. Courtesy of 





Finally, the prophylactic efficacy of 50_3C was also assessed in AG129 mice 
challenged with DENV1 serotype. Similar to the findings with the non-lethal 
TSV01 DENV2 challenge, a drastic reduction in viremia was observed at all 
doses, with the most pronounced effect that resulted in non-detectable viral 
load in all 3 mice at the 10 µg dose. Furthermore, a 20-fold reduction of 












































Figure 5.9: 50_3C possesses similar prophylactic efficacy in AG129 mice 
challenged with DENV1. Three doses of the antibody 50_3C was administered iv 
to 8 weeks old AG129 mice at 100 µg, 10 µg and 1 µg. 24 h post treatment, the 
treated mice were challenged with 1 x 107 pfu DENV1 given ip. An isotype control 
antibody HA4 was included. All mice were bled on D3 post infection and viral 
titers were assessed by qPCR. Antibody treatment resulted in a dose-dependent 
reduction in viremia, with the most pronounced effect observed with 10 µg of the 
antibody which led to a 4-logs reduction in viremia. A 1-log reduction in viremia is 




Chapter 6: Engineering an antibody to arrest dengue virus structural 
changes 
To date, a human antibody that possesses potent neutralization capacity 
against all four dengue serotypes has not been described. The great majority of 
the antibodies isolated from naturally infected Dengue patients is generally 
cross reactive but poorly neutralizing and has been attributed to the cause of 
ADE that leads to severe disease.  
 
In this study, we attempted to convert these cross-reactive but poorly 
neutralizing antibodies into potent virus neutralizers by a rational, engineering 
approach. Dengue virus undergoes E-mediated structural changes upon 
endosomal acidification to mediate fusion of its membrane and the host cell’s 
membrane to facilitate the initiation of its replication in the cytoplasm (Figure 
6.1). This conformation transition drives the rationale behind the engineering 
of an antibody that can arrest structural changes at the pre-fusion stage. An 
antibody engineered to possess dual epitope specificities that is able to ‘lock’ 
the 2 subunits of each E dimer to prevent pH-dependent conformational 





6.1 Antibodies demonstrate stability at pH 5 and pH 7 
To enable such rational design, the antibody candidates to be built into the 
bispecific format should thus possess E protein binding capability that is stable 
at both neutral (extracellular) and acidic (endosomal) pH. The panel of 
antibodies that was shown to be envelope protein specific by ELISA was 
tested for their binding stability at both physiological pH 7 and acidic pH 5 by 
SPR. Antibodies were immobilized by amine coupling to the floor of a GLC 
chip followed by the introduction of rE protein. The stability of interaction 
between the antibodies and the E proteins determined by their dissociation rate 
was measured at either pH 5 or pH 7 by introducing a corresponding buffer of 
the same pH. More than 90% of the antibodies demonstrated stability at both 
pHs, with a number of them even displaying increased stability at pH 5 
(Figure 6.3). The antibodies with demonstrated stability at both pH 7 and pH 5 































































































































































































































































































































































































































































































































































































Figure 6.3: Antibodies stability at pH 7 and pH 5. SPR is employed to assess the 
stability of antibodies at pH 7 and pH 5; antibodies are immobilized by amine 
coupling followed by introduction of rE. E protein interaction is then measured at 
pH 7 (A) or pH 5 (B). 3 trends were observed among all the antibodies tested; (1) 
higher stability at pH5 represented by the blue curve, (2) similar binding at both 
pH 7 and pH 5 represented by the green curve and (3) relatively weak binding at 







6.2 Construction of antibodies with dual epitope specificities 
A ‘shotgun’ approach is taken for the bispecific antibody engineering based on 
the footprinting data obtained by competition assay described in Section 4.4 of 
Chapter 4. The resultant engineered antibody with dual specificities is termed 
bi-specific antibody (bsAb). A total of 28 bispecific antibodies were made by 
pairing 7 original antibodies that represented 3 epitope groups.  The antibody 
from Group A was omitted due to its weak binding at both pH. 
 
The antigen binding domains (the V domains) of the heavy and light chains of 
each of the 7 parental antibodies candidates were constructed into the single 
chain (scFv) format by gene synthesis and cloned separately into a modified 
pTT5_SP_H1 vector that contains the Fc region of human IgG1 by 
homologous recombination. A 20 amino acid linker between the ScFv and the 
hinge region of the Fc is included to provide the flexibility necessary for 
binding across the monomers of each E homodimer (Figure 6.4).  This length, 
calculated based on the crystal structure of the E protein dimer, was chosen to 
allow the two binding arms of the bispecific antibody to reach the longest 
possible distance between the two epitopes across the E dimer. Transformants 
which contain the desired insert were screened by colony PCR (Figure 6.5) 
and further confirmed by DNA sequencing. Bispecific antibodies were 
produced by co-transfecting HEK293E cells with a pair of plasmids each 
encoding a scFv-Fc deriving from one of the 7 parental anti-dengue antibodies. 
To circumvent the problem of homodimerization, this bsAb approach 
employed the knobs-into-holes technology to encourage heterodimerization of 
different chains.  
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The knobs-into-holes technology was first described in 1996 by Ridgway et al 
to facilitate heterodimerization among IgG heavy chain homodimers. A heavy 
chain knob variant was created by swapping the smaller Threonine residue for 
the larger Tyrosine residue at position 366 of the IgG CH3 domain. The 
complement hole variant was created by replacing the larger Tyrosine residue 
for the smaller Threonine residue at position 407 of the IgG CH3 domain. 
 
Each of the 7 scFv was cloned in both Fchole and Fcknob plasmids.  A library of 
bsAb of all possible permutations of pairing was achieved by co-transfecting 
the HEK293E cells with one scFv- Fchole and one scFv- Fcknob plasmid.  
Expression and purity were assessed by SDS-PAGE gel analysis. Results 
showed that bsAb can be expressed to high levels as reflected by the 100 kDa 




Figure 6.4: Schematic of antibody engineering. A bi-specific antibody with dual 
specificities is constructed by grafting the antigen binding domains (ScFv) from 
two parent antibodies with different specificities onto the Fc region of a human 
IgG, separated by a 20 aa linker to enable flexibility. Knob-in-holes technology 
was employed to encourage heterodimerization between two different chains. To 
minimize the effect of ADE mediated by antibody binding to FcᵧR, mutations 
termed LALA which substitutes Leucine residues at 234 and 235 to Alanine 

























Figure 6.5: Construction of bi-specific antibodies. (A) Antigen binding domains 
(ScFv) from the selected antibody clones were amplified by PCR which 
corresponds to a size of ~750 bp; L-R: Ladder, 2C, 2F, 5A, 5D, Ladder, 1B, 7A, 7E. 
(B) Restriction enzyme digestion of cloning vector pTT5_SP_H1, L-R: Ladder, 
uncut, double digestion with SalI and NotI. (C) Screening of insert by colony PCR L-
R: Ladder, pTT5 with correct insert corresponding to ~1600 bp, pTT5 without 








































Figure 6.6: bsAb expression and purity was assessed by SDS-PAGE stained with 
Coomassie. (A&B) Assessment of bsAb expression levels in crude supernatant. (C) 
Bi-specific antibodies after Protein G purification; L- non-reducing conditions, full 
length bi-specific antibodies represented as the major band at ~100 kDa, R: with a 
minor fraction of non-assembled chains represented at ~50 kDa under reducing 




























































































































































































6.3 bsAb retained their binding capacity to whole viral particles 
To ascertain that the bsAbs still retained their specificity and binding capacity, 
an ELISA assay was performed. Whole viral particles of all four serotypes 
were coated onto ELISA plates followed by addition of the bsAbs. Results 
showed that these bsAbs still retained their binding capacity and specificity to 
all four DENV serotypes similar to their parental clones in parallel (Figure 
6.7). 
 
6.4 Modest neutralization capacity of bsAb  
Having demonstrated that the bsAbs retained their binding capacity, they were 
tested for their neutralization capacity in-vitro by flow cytometry. In parallel, 
their parental clones were included as controls. Each bsAb or its 
corresponding parent IgG was incubated with each of the four DENV 
serotypes at 37oC for 30 min. The antibody-virus complex was then added to 
the monocytic cell line U937 and incubated at 37oC for 2 h to facilitate 
infection. 24 h post infection; cells were fixed and stained for E and NS1 
proteins which are indicative of virus replication. The percentage of infected 
cells was determined as the population stained positive for both E and NS1. 
No significant difference was observed in the neutralization capacity between 





6.5 Linker length variations did not improve bsAb neutralization capacity 
The absence of any improvement in neutralization capacity by the bsAb led to 
the hypothesis that the 20 aa linker length might not be optimal for restricting 
conformation changes of the E dimers due to the flexibility conferred by the 
length. To test this possibility, bsAbs was reconstructed to adopt varying 
linker lengths at 5, 10 or 15 aa by splicing PCR (Figure 6.9) and expressed in 
HEK293E cells (Figure 6.10). The resultant bsAbs were then re-tested for 
their respective neutralization capacity by flow cytometry as described in 
Section 6.4 and compared to the bsAbs of original 20 aa linker length. 
However, no significant difference in their neutralization capacity was 
observed (Figure 6.11). 
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Figure 6.7: bsAb retained their binding capacity. The binding capacity of bsAbs 
was compared to their parent antibodies in whole viral particles ELISA for all four 
DENV serotypes, (A) DENV1, (B) DENV2, (C) DENV3 and (D) DENV4. Whole viral 
particles were coated onto MaxiSorp plates followed by the addition of bsAb and 
their respective parent IgG. Binding was detected by HRP-conjugated anti-human 
IgG and absorbance was measured at 450 nm. bsAb shared similar binding 
characteristics as their respective parent antibodies 2C, 2F, 5A and 5D. 
A.                     DENV1 
B.                     DENV2 
C.                     DENV3 
D.                     DENV4 
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Figure 6.8: Modest neutralization capacity of bsAb in-vitro. The neutralization 
capacity of bsAbs was compared to their parent antibodies by flow cytometry. 
U937 stably transfected with DC-SIGN were infected with all four DENV serotypes 
pre-incubated with the bsAb or their respective parent IgG. Cells were fixed and 
permeabilized followed by staining for E and NS-1 proteins indicative of virus 
infection and replication. A-D: DENV1-4. bsAb is denoted as 2C/1B, parent IgG is 
denoted 2C, 1B. The neutralization capacity of bsAb closely resembles that of its 
parent IgG observed for all four DENV serotypes.
A.     DENV1 B.         DENV 2 




Figure 6.9: Construction of bsAb with varying linker lengths. Antigen binding 
domains (ScFv) with varying linker lengths were amplified by PCR which 
corresponds to a size of ~800 bp; (A) L-R: Ladder, 2C, 5A, 7A, 7E with a 15 aa 
linker;  2C, 5A, 7A, 7E with a 10 aa linker and 2C, 5A, 7A, 7E with a 5 aa linker. (B) 
L-R: Ladder, 1B, 2F, 5D with 15 aa, 10 aa and 5 aa linkers respectively. (C) 
Screening of insert by colony PCR L-R: Ladder, pTT5 with correct insert 


























































































































































































































Figure 6.10: Expression and purity of bsAb linker length variants. The expression 
and purity of bsAb linker length variants was assessed by SDS-PAGE stained with 
Coomassie. Like the original bsAb, these variants expressed well and a pure 






























Figure 6.11: Minimal effects of linker length variation on neutralization capacity 
of bsAb in-vitro. The neutralization capacity of bsAb variants was compared to 
the original bsAb by flow cytometry. U937 stably transfected with DC-SIGN were 
infected with all four DENV serotypes pre-incubated with the bsAb or their 
respective parent IgG. Cells were fixed and permeabilized followed by staining for 
E and NS-1 proteins indicative of virus infection and replication. (A) 2F/1B bsAb 
linker variants with 15 aa linker 2F (2Fdel06) paired with 1B of different linker 
lengths. (B) 2F/1B bsAb linker variants with 10 aa linker 2F (2Fdel26) paired with 
1B of different linker lengths. The various bsAb variants appeared to have a 
negative effect on neutralization capacity instead; with the original bsAb 





6.6 bsAb binding: Single or dual arms? 
Next, we asked if the lack of improvement in neutralization capacity, which 
appeared to be independent of its linker length, was attributed to the binding 
capacity of the bsAb instead. Although binding assays by ELISA 
demonstrated similar binding capability between the bsAb and its parent IgG, 
it cannot discern whether the ELISA data resulted from binding through only 
one arm or both arms of the bsAb. We attempted to answer this question by 
utilizing SPR backed by the theory that the avidity effect conferred by the 
simultaneous binding of both arms is stronger than binding of one arm alone, 
an effect distinguishable from the SPR sensorgram. Control bsAbs with only 
one arm capable of binding was constructed by replacing DENV E specific 
ScFv on the ‘hole’ chain to an irrelevant ScFv specific to the Chikungunya 
virus (CHIKV) instead (Figure 6.12).  
 
rE was immobilized covalently to the floor of a GLC-chip by amine coupling. 
bsAbs and IgGs were then introduced at equi-molar concentrations. The 
binding capacity of the bsAb was compared to its parent IgG and to its 
respective single-arm bsAb. 2C + 2F (parent IgG) has almost twice the RU of 
2C alone, indicating simultaneous binding of these two antibodies spaciously 
possible.  As such, if 2C/2F (bsAb) bound to the rE via only one arm, it should 
have achieved a RU similar to that of 2C+2F.  However, the data suggested 
otherwise, as 2C/2F only achieved a RU that is only roughly half of 2C+2F, 










































Figure 6.12: Construction of bsAb with an irrelevant arm of Chikungunya 
specificity. The original dual DENV specificity bsAb was adapted to adopt an 
irrelevant arm with Chikungunya specificity instead for use as a control antibody. 
(A) ScFv of the Chikungunya specific antibody was amplified by PCR with a band 
size corresponding to ~750 bp and cloned into the ‘hole’ construct of 
pTT5_SP_H1. (B) Expression and purity of the irrelevant bsAb were assessed by 
SDS-PAGE stained with Coomassie. The major product was the full-length bsAb 
represented at ~100 kDa with a minor fraction of non-assembled chains 























Figure 6.13: Binding capacity of bsAb. An attempt to measure the binding 
capacity of bsAb was made by utilizing SPR. rE was immobilized by amine coupling 
followed by the introduction of the dual DENV specificity bsAb (BiS 2C/2F-pink) 
along with the bsAb of the same specificity on both arms (BiS 2C/2C-blue), bsAb 
with an irrelevant Chikungunya arm (BiS 2C/CHIKV-turquoise), an irrelevant bsAb 
with both arms of Chikungunya specificity (BiS CHIKV/CHIKV-orange) and the 
corresponding parent IgG (Parent 2C and Parent 2C+Parent 2F in green and 
purple respectively) in equimolar concentration at 200 nM.  
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Chapter 7: Establishing a platform for epitope mapping studies by 
employing yeast surface display technology 
7.1 Proof-of-concept 
The epitopes that lead to virus neutralization in human Dengue infections have 
remain elusive despite extensive efforts to decipher the respective immune 
response. Long-term immunity exists for homotypic infections whereas cross-
protective responses are transient despite sharing serologic similarities across 
all 4 serotypes. E protein is the major surface glycoprotein of dengue virus and 
is a major target of the neutralizing antibodies. Using mouse monoclonal 
antibodies, EDIII is implicated as the primary target of neutralizing antibodies. 
Various techniques are available for epitope mapping studies with their 
accompanied pros and cons. In this study, yeast surface display is employed as 
the platform of choice for its protein synthesis machinery that possess 
appropriate post translational mechanisms to aid in proper protein folding 
(Ellgaard and Helenius 2003). Originally described as a platform for affinity 
maturation of antibody fragments and screening, application to the technology 
was extended to epitope mapping. 
 
Yeast surface display utilizes the yeast surface receptor a-agglutinin that 
mediates cell-cell contact during the mating process by binding its 
complementary cell receptor, α-agglutinin. Unlike the α-agglutinin, a-
agglutinin is made up of two subunits, Aga1p and Aga2p. Aga1p anchors onto 
the cell wall via covalent linkages while Aga2p is associated with Aga1p via 
two disulfide bonds. A library of mutants is generated by error prone PCR and 
expressed as fusion proteins to the Aga2p subunit. Expression of the Aga2p-
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fused protein on yeast cell surface occurs through covalent linkage to Aga1p, 
which is anchored onto the cell wall. This leads to projection of the fusion 
proteins away from the yeast cell surface; minimizing interaction with other 
yeast surface molecules and therefore facilitates screening of the mutants 
against the antibody (Figure 7.1A).  
 
The reactivity of each candidate antibody against the mutants was screened by 
staining yeast cells with the fluorophore-conjugated antibody candidate. 
Pooled monoclonal antibodies with distinct epitope specificity, conjugated to a 
different fluorophore, were included to eliminate aberrant mutants. Detection 
of protein expression and loss of antibody binding is easily achieved by flow 
cytometry which also allows for quantitative measurement. The putative 
epitope of the antibody candidate is identified as the collection of amino acid 
residues that result in the loss of binding. Loss of antibody binding is 
represented by the single stained yeast cells with the pooled antibodies (Figure 
7.1B). These were then sorted and enriched for plasmid recovery along with 
sequencing. Epitope mapping by yeast surface has been described with 
success (Chao, Cochran et al. 2004, Cochran, Kim et al. 2004). 
 
Previous epitope mapping studies have utilized EDI/II or EDIII for surface 
display but not the full length E ectodomain. However, we now learn that 
antibodies that recognize interdomain epitopes are present in greater numbers 
than previously appreciated (Lin, Tsai et al. 2012). We therefore propose 
utilization of the full length E ectodomain for epitope mapping.  
 158 
 
Before mutant library construction, we first established surface expression of 
the wild-type E proteins. Similar to the generation of rE protein, sequences 
corresponding to full length, EDI/II, or EDIII ectodomain were amplified and 
cloned in frame to the yeast surface display vector by homologous 
recombination. To identify clones that contain the E protein gene insert, 
colony PCR was employed for screening. Clones which contained the insert of 
expected size (Figure 7.2) were further verified by DNA sequencing and 
subsequently transformed into the yeast strain EBY100.  Transformants were 
selected based on the nutrition marker tryptophan: EBY100 is unable to 
synthesize its own tryptophan whereas the yeast expression vector pCTCON2 
carries the trp1 gene. Hence, only yeast cells which harbor the pCTCON2 
plasmid can survive in the selection media lacking tryptophan. Surface 
expression is regulated by a galactose-inducible promoter with which 
induction is induced by replacing glucose with galactose in the media.  
 
Expression of surface proteins is measured quantitatively by flow cytometry 
where variation in expression levels is easily monitored by detecting either the 
amino-terminus haemagglutinin (HA) or carboxyl terminus c-Myc tag that 
flank the fusion protein. To account for proper folding of the various E 
domains, cells were double-labeled with either 3H5 or 4G2 mouse mAb. 3H5 
is specific for EDIII of DENV2 while 4G2 recognizes all four DENV 





A double positive population based on c-myc staining and the respective 
conformation sensitive antibody is observed in all the dotplots of E 
ectodomain, EDI/II and EDIII as a smear. This observation is suggestive of 





Figure 7.1: Schematic of yeast surface display. (A) Concept of yeast surface 
display technology. The mating mechanism of yeast lays the foundation for 
surface display of heterologous protein. The yeast surface receptor a-agglutinin is 
made up of two subunits, Aga1p and Aga2p. Aga1p anchors onto the cell surface 
via covalent linkages and associates with Aga2p via two disulfide bonds. The 
heterologous protein gene is cloned downstream of Aga2p. Expression of the 
protein is under control of the galactose inducible promoter. Expression of the 
full-length protein is detected by staining either the HA or c-myc tags that flank 
the protein. (B) Concept of epitope mapping by yeast surface display. E mutants 
expressed on the surface of yeast cells are screened against fluorophore 
conjugated antibody candidates. Yeast cells are double stained with pooled 
monoclonal antibodies conjugated to another fluorophore to control for aberrant 
protein expression. Loss of antibody binding identified as a single stained 
population by flow cytometry leads to a collection of mutants expressing yeast 













































































































































































































































































Figure 7.3: Detection of dengue E protein expression on yeast surface by flow 
cytometry. Surface expression of various E domains on yeast cells was induced 
with galactose. Protein expression was detected by staining cells with the mouse 
monoclonal 3H5 or 4G2 and double-stained with chicken anti-c-myc IgY followed 
by secondary antibody staining with goat anti mouse IgG-Alexa Fluor® 568 and 
anti-chicken IgY-Alexa Fluor® 488. (A) Unstained, (B) E ectodomain double stained 
with anti-c-Myc and 4G2, (C) EDI/II double stained by anti-c-Myc and 4G2, (D) 
EDIII double stained with anti-c-Myc and 3H5. A ‘smear’ indicative of differential 











7.2 Optimization of E ectodomain mutant library construction 
Randomized mutagenesis in the ectodomain genes was achieved by error 
prone PCR to create a mutant library. Ideally, mutagenesis rate is controlled at 
one mutation per gene to allow interrogation of individual amino acid’s 
contribution to antibody binding. The required library size worked out to be 
about 1 x 104 based on a size of 400 amino acid residues for the E ectodomain 
with the probability of each residue replaced by any of the 20 amino acid 
residues.  
 
Mutagenesis rate can be controlled by the amount of starting DNA template 
and/or number of amplification cycles. We worked around both parameters to 
achieve the desired mutation rate; DNA template was varied between 3 µg, 3.5 
µg and 4 µg with amplification cycles of 20, 25 or 30 (Figure 7.4). Sequencing 
data from 16 clones of each group suggested that 3.5 µg DNA template with 
25 amplification cycles resulted in at least one mutation per gene in at least 50% 
of the clones sequenced (Table 4.1). The mutant library was created by 
transforming yeast cells with the linearized expression vector pCTCON2 
containing mutant E ectodomain genes to promote plasmid circularization 
through homologous recombination. A library size of ~ 1.676 x 106 was 










Amount of starting DNA template 
3.0µg 3.5µg 4.0µg 
20 
1 31 37 44 
>1 37 12 12 
0 31 50 44 
25 
1 45 57 
ND >1 18 14 
0 36 28 
30 
1 37 37 36 
>1 25 25 21 
0 37 37 43 
Figure 7.4: Construction of E ectodomain mutant library. E ectodomain mutants 
were generated by error-prone PCR. Error-prone PCR conditions were optimized 
to incorporate 1 mutation per gene by controlling the amount of starting DNA 
template and cycle numbers.
30  35  40  30  40  35  30  40  35
20 cycles   25 cycles   30 cycles 
Table 3.1: Optimization of random mutagenesis by error-prone PCR.
 165 
 
7.3 Optimization of E ectodomain mutant library surface expression 
Induction for expression of the E ectodomain library mutants was initially 
carried out by the same conditions used in the induction of wildtype (WT) E 
ectodomain. Transformants carrying unmodified pCTCON2 vector was used 
as an expression control. At 30oC, expression of the CD20 gene encoded in the 
pCTCON2 vector was observed in >70% cells.  In contrast, less than 20% 
cells expressed E ectodomain mutants on the surface. We hypothesized that 
the expression of mutant proteins may be temperature sensitive. A comparison 
was made in which cells were induced for E mutant protein expression at 30oC, 
RT and 20oC. As hypothesized, expression levels of the mutant library were 
improved with each successive drop in induction temperature. Expression 
levels were significantly improved to ~50% when induced at 20oC, a more 
than 2-fold increase from when induction was carried out at 30oC. 
Interestingly, induction temperature had minimal effects on the expression 











Figure 7.5: Detection of E ectodomain mutant library surface expression by flow 
cytometry. Surface expression was induced by switching cells into media 
containing galactose. Induction was carried out for 48 h with shaking at 250 rpm. 
The induced cells were collected and stained with chicken anti-c-myc IgY.  
Following primary antibody staining, cells were then stained with anti-chicken IgY-
Alexa Fluor 488. Cell surface expression was analyzed by flow cytometry on the 
MACSQuant VYB. (A, B, C) pCTCON2 expression at 30oC, RT and 20oC respectively, 
(D, E, F) Mutant Library expression at 30oC, RT and 20oC respectively. Expression 
level of mutant library is dependent on temperature at induction, in contrast to 








Chapter 8: Discussion 
The journey in search for an effective dengue vaccine has been an arduous one. 
Complications stem from the presence of four serologically similar but 
antigenically distinct virus serotypes. Infection with any of the four dengue 
virus (DENV) serotypes induces a life-long homologous protection with only 
transient heterologous protection. During the life-time of any individuals, 
he/she can be infected more than once with any of the four DENV serotypes. 
Epidemiological studies have suggested a strong correlation between 
secondary heterologous infections with disease exacerbation via the widely 
accepted antibody dependent enhancement (ADE) mechanism. A safe and 
effective vaccine candidate therefore, has to elicit a balanced immune 
response to all four serotypes concurrently. 
 
To add fuel to the fire, the human immune response to dengue remains elusive 
and is poorly defined with conflicting findings. Although studies with the 
polyclonal serum and monoclonal antibodies obtained from humans are in 
consensus in that a major fraction of the antibody response is made up of 
broadly cross-reactive but weakly neutralizing antibodies, and potent serotype-
specific neutralizing antibodies are rare. However, it is noted that the memory 
B cell response in Dengue infection has been the focus of the studies described 
to date. The targets of these antibodies are heterogeneous and consists of those 
against both structural (C, prM, E) and non-structural proteins (NS1, NS3). 
The weakly neutralizing antibodies have been implicated in disease 
exacerbation via the widely accepted mechanism termed antibody dependent 
enhancement (ADE).  
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In this study, a bold approach is undertaken to dissect the immune response in 
the acute phase of disease backed by the presence of transient immunity to 
heterologous infections where high titers of DENV specific neutralizing 
antibodies coinciding with the presence of plasmablasts found in large 
numbers. While potent serotype-specific neutralizing antibodies have been 
isolated, an antibody that possesses potent neutralization capacity against all 
four DENV serotypes has rarely been described. Alongside the 
characterization of the acute immune response, an attempt to construct an 
antibody with desirable neutralizing properties was made in parallel in this 
work.  
 
Although a large panel of human antibodies have been isolated to date, epitope 
mapping studies have not caught up with its pace. Alanine scanning 
mutagenesis and cryo-EM are two techniques that have been frequently 
described for epitope mapping studies. However, both are laborious and time-
consuming techniques. Although cryo-EM remains the preferred method, the 
entire process calls for personnel with highly trained skills in experiment set 
up, data analysis, and structure interpretation. In this study, we established the 
yeast surface display technology to assess its feasibility for use as a platform 
for epitope mapping studies. 
 
To date, the majority of monoclonal antibodies available for the study of the 
human antibody response to Dengue infections have been obtained from 
Epstein Barr Virus (EBV) immortalized B cells from convalescent patients. 
The major disadvantage of EBV immortalization is the biasness in the 
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transformation of only certain B cell subsets (Aman, Ehlin-Henriksson et al. 
1984, Chan, Stein et al. 1986) and the potential loss of antibody production 
over time. In addition, generation of monoclonal antibodies by EBV 
immortalization is time-consuming and labor intensive with low efficiency. 
Here, we describe a novel high-throughput and unbiased single B cell PCR 
method to isolate antibodies from the plasmablasts of naturally infected 
Dengue patients.  
 
From the sorted single B cells, a gene amplification efficiency of 75% and 60% 
by PCR was achieved for heavy and light chain, respectively. The lower 
amplification efficiency observed in light chains is attributed to the fact that 
only the kappa chain specific primers were used for single B cell PCR cloning 
in this study. From a total 176 sorted B cells, successful amplification of both 
heavy and light chain gene pairs was found in 78 cells.  Of these, 65 (~80%) 
were successfully cloned into the mammalian cell expression vector pTT5 
plasmid by homologous recombination. Cloning by employing homologous 
recombination proved to be a highly efficient and time-saving process 
compared to the conventional cloning by ligation as the method does not 
require the time-consuming restriction enzyme digestion as well as the 
subsequent purification of the PCR product. This simplified protocol makes 
high throughput cloning feasible when handling large number of clones.  
Transient expression of recombinant antibodies was achieved by the 
mammalian HEK293-6E cells in suspension culture.  Antibodies are 
subsequently purified from the culture supernatant by standard Protein G 
affinity chromatography. Heterogeneity in expression level was observed 
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among various clones. In this study, the expression yields ranged from 5 to 
100 mg/liter culture, and 10% clones were at negligible level.  
 
In summary, the streamlined process of Ig gene amplification, cloning, and 
antibody expression led to the generation of a panel of 65 recombinant 
antibodies from a total of 176 sorted plasmablast B cells. Assuming a 60% 
kappa clones in this plasmablast B cell population, our protocol yielded an 
overall 65% success rate. The limiting factor of this technology is the 
efficiency of homologous recombination associated with the amount of gene 
amplification products. This can be circumvented by increasing the number of 
PCR cycles for further amplification. 
 
Of the 65 successfully cloned and expressed antibodies, 75% was found to be 
specific to DENV.  This was probably not too surprising since patients were at 
the acute phase of disease when blood was drawn. Hence, a major advantage 
of isolating antibodies from plasmablasts is the amplification and 
concentration of target specificity which significantly reduces the laborious 
and time-consuming screening process to eliminate non-target specific 
antibodies. About 10% clones expressed no detectable levels of antibodies 
while the remaining 15% non-DENV specific clones likely derived from by-
stander B cell activation (Lanzavecchia, 2002, Wilson, 2008, Lee, 2011).  
 
The entire panel, except for one antibody, demonstrated cross-reactivity to all 
four DENV serotypes suggesting that these antibodies are DENV complex 
reactive, although they have not been tested for reactivity to the other common 
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flaviviruses such as the West Nile Virus (WNV) that also infect humans. None 
of the antibodies isolated in this study was serotype specific. The only 
antibody which demonstrated cross-reactivity to DENV1, 2 and 3 is defined as 
DENV sub-complex reactive. 
 
From the panel of 65 antibodies, 27 antibodies were identified for further 
characterization based on their binding capacity to inactivated viral particles. 
To facilitate the antigenic target identification of these antibodies, recombinant 
envelope ectodomain (rE) protein from all four DENV serotypes were 
constructed and expressed in the S2 insect cell line. E was co-expressed with 
prM which acts as a molecular chaperone to aid in the folding and secretion 
(Konishi and Mason 1993). prM is cleaved prior to rE secretion. The 
conformation of rE was accounted for by testing its reactivity with the mouse 
monoclonal antibody 4G2 that recognizes a conformational epitope on the E 
protein.  
 
It was observed from our panel that all but three antibodies recognized the 
soluble rE protein. This is in accordance with the report by Lai et al (2008) 
documenting the dominance of a strong antibody response towards E; 
antibodies to prM and NS1 follow after the antibody response to E have been 
made in the acute phase sera of Dengue patients. Thus, the presence of an 
antibody response dominated by E specificity in this work may be explained 




Various studies have described the dominance of broadly cross-reactive anti-
EDI/II antibodies with low to modest neutralization capacity whereas 
serotype-specific antibodies with potent neutralization capacity that target DIII 
of E were rare. Here, the panel of antibodies were assigned to their relative 
epitope-binding groups by conducting a competition ELISA and validated 
with another technique utilizing surface plasmon resonance (SPR). Antibody 
binding characteristics revealed the presence of four distinct epitope 
competing groups, with a dominant group consisting of more than 50% of the 
antibodies. This dominant group was subsequently identified as fusion loop 
reactive in another competition assay with the mouse monoclonal antibody 
4G2 that is known to recognize the highly conserved fusion loop. This finding 
is in agreement with a study that describes the predominance of epitopes 
around the fusion loop in polyclonal sera (Lai, Tsai et al. 2008, Crill, Hughes 
et al. 2009). This observation is also mirrored in studies involving human 
monoclonal antibodies demonstrating the immunodominance of EDI/II 
evidenced by the presence of a major fraction of the EDI/II antibodies that 
make up the total anti-E antibody response (Smith, Zhou et al. 2012, Costin, 
Zaitseva et al. 2013, Smith, de Alwis et al. 2013, Smith, de Alwis et al. 2014).  
 
Interestingly, we observed that binding of 4G2 was slightly enhanced by the 
binding of two antibodies from one epitope group, Group B.  Antibody 
binding to viral particles can induce a conformational change and influence 
binding by another antibody (Heinz, Mandl et al. 1984, Henchal, McCown et 
al. 1985). The increase in binding capacity by the two antibodies may also be 
attributed to the greater accessibility of their epitopes followed by the induced 
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conformational change. However, the presence of an avidity effect cannot be 
disregarded. The observed binding enhancement phenomenon could also be 
due to the preferential binding of more avid antibodies over the less avid 
antibodies. Such antibody induced conformational changes may have 
consequential effects on virus biology in terms of neutralization or infection 
enhancement. It would be interesting to decipher if the same effect is observed 
between different antibody pairs among the panel of isolated antibodies and to 
explore whether this phenomenon can be exploited for cocktail therapeutics 
approach if synergy in neutralization enhancement occurs. 
 
Subsequent epitope mapping studies of these antibodies by alanine scanning 
mutagenesis confirmed the findings of the competition ELISA assays. The 
major residue identified for the fusion loop reactive group D was W101. This 
importance of this residue along with L107 and F108 has been described by 
Lai et al who showed that the polyclonal sera E binding activity was greatly 
affected by mutations in these fusion loop residues. This is not surprising as 
tryptophan (Hammon, Rudnick et al.) is the largest hydrophobic residue and 
often contributes the largest binding energy in the antibody/antigen interaction. 
Hence, mutation to the small alanine often results in reduced or even loss of 
binding.  
 
The panel of antibodies isolated in this study can be further classified into 2 
main groups, one that only recognizes the whole viral particles but not the rE 
protein and the other that is reactive to both whole viral particles and the rE 
protein. The latter group dominates the immune response which makes up ~90% 
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of the antibodies tested. The presence of antibodies that recognizes epitopes 
that are only preserved on intact virions have also been shown by various 
investigators previously (Beltramello, Williams et al. 2010, Dejnirattisai, 
Jumnainsong et al. 2010, de Alwis, Beltramello et al. 2011).  
 
The in-vitro neutralization capacity of the rE reactive antibodies can be further 
segregated by their epitope competing groups. The neutralization capacity of 
the Group D fusion loop reactive antibodies are highly similar, cross-
neutralizing all four DENV serotypes with the same potency, albeit poor. In 
contrast, the neutralization capacity of the antibodies in the remaining Groups 
A, B, and C was highly variable marked by a plateau between 40-60% in 
neutralization capacity. This is suggestive of a virus population that is resistant 
to neutralization.  
 
Nelson et al described the dependence of neutralizing activity on stage of virus 
maturation with the closely related flavivirus, West Nile Virus (WNV). 
Neutralization of flaviviruses has been proposed to be a ‘multi-hit’ mechanism 
directly proportional to antibodies occupancy (Della-Porta and Westaway 
1978, Pierson and Diamond 2008). The number of antibody molecules 
required to dock on the viral surface simultaneously is dependent on epitope 
accessibility. Neutralization is the interplay between antibody affinity and 
epitope accessibility and occurs when the occupancy threshold is exceeded. 
The E protein of flaviviruses assumes a pseudo-icosahedral symmetry on virus 
surface exposing them to three distinct chemical environments defined by T=2, 
T=3 or T=5 symmetry. Not all epitopes are equally accessible due to stearic 
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hindrance imposed by their corresponding epitopes on the neighboring E 
protein (Kaufmann, Nybakken et al. 2006). Epitope accessibility is therefore 
determined by its location on the virion surface. Epitopes that are poorly 
accessible requires the simultaneous docking of much more antibody 
molecules to reach the stoichiometry necessary for neutralization. Therefore, 
any minute changes in epitope accessibility greatly impact its neutralization 
capacity.  
 
Along this line, epitope mapping studies of our poorly neutralizing antibodies 
of Group A and B revealed the presence of epitopes in EDII that are buried 
and hence poorly accessible on the mature virion.  Without detailed studies we 
can only speculate some possibilities as to why the epitopes of antibodies in 
these groups are mapped to the non-solvent exposed residues in the E protein.  
One possibility is the stage of virus maturation, although it is also plausible to 
hypothesize that these amino acids induce conformational changes in either 
nearby or distal surface residues of the true epitope thus affecting the binding 
of antibodies in this group. Another possibility is based on the observation that 
the structure of the virion is dynamic, a phenomenon described as breathing 
(Pierson and Kuhn 2012), thus giving antibodies only limited access 
opportunity. This may then explain the plateau in neutralization capacity 
observed despite saturating concentrations of antibody.  
 
As discussed previously, highly potent cross-serotypes neutralizing antibodies 
from natural infection in humans are rarely described.   In an attempt for the 
hunt of such antibodies, we turned our attention to those that only recognize 
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the quaternary structure of the virus as they have been shown to be highly 
potent.  Interestingly, screening using live whole viral particles identified three 
antibodies that were not found using inactivated viral particle or the 
recombinant E protein. Further characterization of these three antibodies in a 
neutralization assay by plaque reduction neutralization test (PRNT) led to the 
discovery of an antibody that possessed potent neutralization capacity towards 
all four dengue serotypes in vitro.  This is the first human antibody described 
that can cross-neutralize all four serotypes with high potency in the following 
order of neutralization EC50: DV2 (0.001 µg/ml) >> DV1 (0.059 µg/ml) > 
DV4 (0.075 µg/ml) >DV3 (0.223 µg/ml). In agreement with the antibody that 
neutralizes WNV potently (CR4354), this antibody also recognizes epitopes 
that are found only on intact whole viral particles (Kaufmann, Vogt et al. 2010) 
and is thought to inhibit infection by cross-linking E proteins and blocking 
structural changes required for entry and membrane fusion. This antibody 
demonstrated neutralization at both the pre-attachment and post-attachment 
stage with only a four-fold difference in EC50 at 0.001 ug/ml and 0.0037 ug/ml, 
respectively.  
 
Virus neutralization by antibodies can occur at various stages of their life 
cycle that includes but not limited to virus attachment and fusion. A major 
characteristic of flaviviruses is the exhibition of broad tissue tropism. 
Although several candidate receptors have been suggested, there is no single 
molecule solely responsible for cellular attachment and entry. Virus entry is 
therefore a complex process that requires interplay among different receptors 
and factors. DC-SIGN (CD 209) – the calcium dependent C-type lectin is a 
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well-characterized receptor implicated in the infection of immature monocyte 
derived dendritic cells. In vitro, the capacity to support DENV infection is 
increased in cell lines transfected with DC-SIGN (Navarro-Sanchez, Altmeyer 
et al. 2003, Tassaneetrithep, Burgess et al. 2003).  Antibodies that block 
infection of flaviviruses at the attachment stage have been shown to target 
domain III of the envelope protein (EDIII) (He et al, 1995).  
 
Viral particles coated with antibodies at neutralizing concentrations can be 
internalized by target cells (Gollins and Porterfield 1986), demonstrating the 
capacity of antibodies to neutralize virus infectivity at a stage post-attachment. 
Conformational changes in E associated with virus-host cell membrane are 
inhibited by the bound antibodies presumably through the imposed stearic 
constraints, although antibodies that bind to specific epitopes on E to directly 
block fusion have also been recorded (Stiasny, Brandler et al. 2007).  
 
Virus neutralization can be a result of antibody cooperative effects that target 
different stages of the virus life cycle simultaneously. A classic example is the 
neutralization of West Nile Virus (WNV) by the monoclonal antibody E16. 
Neutralization of WNV by E16 has been shown to directly block membrane 
fusion (Thompson, Moesker et al. 2009) while demonstrating the capacity to 
impede virus attachment at saturating concentrations simultaneously. 
 
Similar to the neutralization of WNV by E16, the mechanism of DENV 
neutralization by 50_3C at both pre- and post-attachment stages is therefore 
hypothesized to be a simultaneous occurrence. This hypothesis remains to be 
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answered since the direct blocking of fusion by 50_3C has yet to be 
determined in this study. 
 
 The current infecting serotype of patient 10/50, from whom 50_3C was 
isolated, was identified to be DENV3 by RT-PCR. In addition, the pre-
immune status of 10/50 is suggestive of a previous DENV2 infection by a 
flow-cytometry based neutralization assay. 50_3C demonstrated the highest 
neutralization potency against the previous infecting serotype, DENV2. This is 
consistent with the original antigenic sin phenomenon (OAS) that describes 
the preferential reactivation of the immune responses from the previous 
infection by the current infecting serotype that shares highly similar but non-
identical antigenic properties.  Such responses often elicit stronger 
neutralization capacity towards the previous infecting DENV serotype than 
current infecting serotype (Halstead, Rojanasuphot et al. 1983, Midgley, 
Bajwa-Joseph et al. 2011). 
 
50_3C was isolated from a naturally infected Dengue patient at the acute 
phase of disease. This antibody not only possessed a potent neutralization 
capacity against all four DENV serotypes in vitro, but also demonstrated 
paralleled potency to at least two DENV serotypes in the AG129 murine 
models. The presence of a strong antibody response against E at the acute 
phase of disease along with the transient protection against heterologous 
DENV serotypes has been documented. The isolation of such antibodies was 
probably not a matter of chance but rather the search of a needle in the 
haystack. The observation of transient heterologous immunity led to the 
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postulation of the corresponding re-activation of memory B cells that 
possessed cross-reactivity to all four DENV serotypes. However, infection 
with a heterologous DENV serotype led to the sustenance of antibodies that 
were weakly neutralizing resulting from the expansion of naïve B cell clones.  
Independent studies with either the polyclonal human immune sera or human 
monoclonal antibodies by various groups illustrated the dominance of prM 
specific antibodies that constitute 40-60% of the memory response in 
secondary infected individuals (Lai, 2008, Crill, 2009, Beltramello, 2010, 
Dejnirattisai, 2010, de Alwis, 2011, Smith, 2012, 2014). Heterogeneity has 
been observed in dengue virus due to the low efficacy of prM cleavage by the 
host enzyme furin. Three populations of DENV have been documented: (1) 
immature viral particles with relatively high levels of prM that are inherently 
non-infectious, (2) partially immature viral particles with intermediate prM 
density that are infectious and (3) mature viral particles with prM absence 
(Cherrier, Kaufmann et al. 2009). In the study by Dejnirattisai et al, it was 
shown that anti-prM antibodies were highly cross-reactive across all four 
DENV serotypes but were unable to fully neutralize infection even at high 
antibody concentrations. Instead, a plateau in their neutralization capacity was 
observed between 10% and 60%.  Furthermore, the antibodies to prM are 
thought to improve infectivity of the immature particles by promoting virus 
uptake via the antibody dependent enhancement (ADE) mechanism.   
 
Antibodies that bind prM possess poor neutralization capacity and leads to the 
formation of virus-antibody complexes. These complexes enter susceptible 
host cells through interaction of the virus-bound antibodies and their 
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respective host cell receptors. Enhancement is also observed with neutralizing 
antibodies, albeit at much lower concentrations compared to non-neutralizing 
antibodies. The potent cross-reactive antibody 50_3C mediates ADE in all 
four DENV serotypes. However, the ADE effect is only observed over a 
relatively small window at very low antibody concentrations. Also, the 
maximum enhancement was only 3-fold in contrast to the 10 - 800 fold 
enhancement increase seen with the non-neutralizing anti-prM antibodies 
(Dejnirattisai, 2010).  
 
ADE is proposed to occur through the interaction of the antibody Fc region 
with their respective FcR on host cells. A study by Balsitis et al (Balsitis, 
Williams et al. 2010) demonstrated that Fc modification at the N-linked 
glycosylation site N297 residue impaired lethal enhancement of dengue 
disease in mice. This effect is attributed to the loss of Fc receptors (FcRs) 
binding by the antibody as a result of aglycosylation at this site.  We expected 
that the native form of antibody 3C would also cause ADE, and would like to 
test if this can be prevented by eliminating FcRs binding capability of the 
antibody.  We decided to use Fc with mutations at sites other N297 because 
glycosylation at N297 not only facilitates FcRs binding but also contributes to 
the overall stability of the antibody (Kayser, Chennamsetty et al. 2011). 
Deglycosylation at this site has been shown to reduce thermal stability of the 
antibody, a feature that is unfavorable for therapeutics development (Kayser, 




In this study, we modified Fc by introducing two mutations to replace the 
leucine residues at positions 234 and 235 with alanine residues in the CH2 
region.  The resulting modification is often referred to as the LALA mutant. 
LALA mutations have been shown to result in a dramatic decrease in FcᵧR 
binding (Hessell, Hangartner et al. 2007). A neutralizing antibody with such 
mutations has also demonstrated a lack of ADE in a mouse model, suggesting 
a better therapeutic format (Beltramello, Williams et al. 2010). Indeed, the 
ADE effect seen in vitro with native 3C_50 IgG was abolished when the 
corresponding LALA mutations were introduced. 
 
The stoichiometry of antibody binding appears to draw a thin line between the 
phenomena of neutralization and infection enhancement (Figure 8.1). It is 
therefore not too surprising to find that many antibodies regardless of their 
neutralization capacities are able to promote ADE. The only difference 
perhaps, is the extent of ADE. A highly potent neutralizing while mediating 
ADE at a much smaller scale, our antibody 50_3C appears to paint the same 
phenomenon that fit the ‘multi-hit’ neutralization mechanism of flaviviruses. 
However, the exact epitope of 50_3C remains unknown. Complete 
neutralization of DENV2 occurs at 0.01 µg/ml suggesting that the epitope of 
50_3C is highly accessible on the virion surface and perhaps independent of 





Figure 8.1: Effect of epitope accessibility and antibody occupancy on virus 
neutralization. The relationship between epitope accessibility and antibody 
occupancy is demonstrated with two distinct antibodies on the mature West 
Nile Virus (WNV). E proteins are colored blue, green and yellow according to 
their twofold, threefold or fivefold symmetry axes respectively. Red solid 
spheres indicate antigenic residues. Neutralization threshold identified as the 
red line is plotted against number of accessible epitopes. The number of 
antibody molecules required to simultaneously dock on the virus surface with 
high epitope accessibility to exceed neutralization threshold is much smaller 
compared to poor epitope accessibility. Adapted from Pierson & Diamond, 
Molecular mechanisms of antibody-mediated neutralization of flavivirus 
neutralization, Expert Rev Mol Med, 2008. 
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A recent study by (Dejnirattisai, Jumnainsong et al. 2010) described the 
identification of a novel epitope termed envelope dimer epitope (EDE) 
recognized by a group of broadly cross-reactive highly potent antibodies that 
neutralize in the low picomolar range. Several findings from this study were 
similar to ours: (1) the human monoclonal antibody collection was also 
obtained from plasmablasts of naturally infected Dengue patients. (2) DENV 
complex reactive antibodies occupied a large fraction (~84%) of the acute 
immune response to Dengue infection. (3) The coincidence that antibodies 
recognized quaternary structure epitopes preserved on intact virions and 
possessed highly potent cross-serotype neutralization capacity.  
 
With these observations, it is postulated that our antibody 50_3C also 
recognizes the same EDE. Clone 50_3C failed to react with rE, albeit it 
reacted strongly to the whole DENV viral particles suggesting recognition of a 
structural protein in the context of the virion but not isolated protein. E is the 
major structural surface glycoprotein although the possibility of 50_3C 
binding to prM cannot be disregarded. Another line of evidence to suggest E 
protein as the target of 50_3C came from the sequence of the heavy chain 
CDR3 loop. Antibody diversity arises from what is known as the 
complementary determining regions (CDRs) termed CDR1, 2 and 3. Of note, 
the heavy chain CDR3 (CDRH3) sequence is highly diverse and has been 
implicated as a critical component in determining binding strength (Rock et al, 
1994, Barrios et al, 2004), and its length has been associated with antigen 
specificity in the context of various antigens such as the tumor associated 
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antigen CD227, HIV and pneumococcus (Carlos et al, 1993, Barrios et al, 




   
 
A striking observation is the CDR3 length of 50_3C and the EDE-specific 
antibody (Dejnirattisai, Jumnainsong et al. 2010), differing by only an amino 
acid residue in length at 25 and 26 residues, respectively (Figure 8.2). In 
addition, a high degree of sequence similarity, including the number of 
identical/similar amino acids and a conserved (Y/F)YDS motif give a reason 
to speculate a common or similar epitope that these antibodies share. 
Therefore, based on the association of CDRH3 length and antigenic specificity, 
it is plausible to postulate that 50_3C also recognizes E. Concurrently, epitope 
mapping studies for 50_3C by cryo-EM is in underway and it is of great 
interest to show whether or not 50_3C also recognizes EDE.  
 
Vaccine development and anti-viral initiatives have been severely impeded by 
the lack of suitable animal models since humans and mosquitos are the only 
natural hosts of dengue virus. Development of small animal models to mirror 
the pathogenesis seen in humans has been met with difficulties. The 
immunocompetent rodents are resistant to infection by DENV clinical isolates 
Clone Sequence Length 
EDE 1 ARDGVRYYYDSTGYY-PDNFFQYGLDV 26 
EDE 2 ARDGVRFYYDSTGYY-PDPYFQYGLDV 26 
50_3C ARGGRALFYDS--YTTPRDGGSWWFDP 25 
**.*   :***  *  *    .: :*  
Figure 8.2: Sequence alignment of Ig heavy chain CDR3 region between 50_3C 
and EDE specific antibody. Similarity in CDR3 lengths was observed.  
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and do not display any signs of overt disease. Establishing an infection in 
these rodents requires the inoculation of high virus titers intracranially. This 
often leads to irrelevant clinical symptoms especially the display of neurologic 
abnormalities not usually seen in human pathology.  
 
In contrast to immunocompetent mice, the type I and II interferon receptors 
deficient AG129 mice have been widely used as the preferred model for 
DENV infection. Despite the deficiency in IFN signaling, AG129 mice boast 
an intact adaptive immune system, an important aspect since the adaptive 
immune system has been implicated in the modulation of DENV infection in 
humans. DENV replicates to high levels in the peripheral tissues of AG129 
mice due to their inability to support IFN production necessary to limit DENV 
infection (Johnson and Roehrig 1999). However, intraperitoneal infection with 
mouse-adapted DENV strains is still necessary for the lethal infection model. 
Recently, a non-mouse adapted DENV2 clinical isolate that leads to similar 
clinical symptoms observed in humans upon intraperitoneal infection of 
AG129 mice have been described (Tan, Ng et al. 2010). Animal models that 
faithfully recapitulate signs of disease are important for testing hypotheses 
formulated by in vitro findings.  
 
In this study, we employed both pre- and post- virus challenge models to 
assess the protective capacity of 50_3C in vivo. 50_3C possesses potent 
neutralization capacity against all four DENV serotypes with the highest 
potency observed against DENV2 in vitro. Pre-exposure of AG129 mice to 
50_3C IgG 24 h prior to challenge (the pre-virus challenge model) with both 
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non-lethal DENV2 strain TSV01 and lethal DENV2 strain D2Y98P resulted in 
a dose-dependent reduction in viral loads. Remarkably, a reduction in viremia 
by 4-logs was observed with 100 µg in both groups of mice. This dose, 
equivalent to 5 mg/kg, is well within the standard range of therapeutic 
antibody used in clinic. Similar degree of reduction in viremia was also 
observed with 10 µg.  
 
It appears that administration of 50_3C at 1 µg in the lethal D2Y98P challenge 
group resulted in a slight increase in viral loads suggestive of an ADE effect 
routinely documented in vitro. The in vivo ADE effect has been documented 
by Balsitis et al (Balsitis, Williams et al. 2010) who showed that passive 
transfer of homotypic sera induced enhancement at low concentrations 
although a higher dose was protective. Transfer of cross-neutralizing 
antibodies mediated ADE in spite of neutralizing concentrations in vitro. Since 
50_3C appeared to mediate ADE in vivo, we would expect that the 
corresponding LALA mutant should abolish this phenomenon. Indeed, similar 
to the administration of native 50_3C IgG at 1 µg, 50_3C LALA at the same 
dose abolished ADE while promoting survival of these mice up to 7 days post 
infection. This is in contrast to the groups of mice treated with 50_3C IgG or 
the isotype control antibody HA4 where complete lethality was observed at 4 
and 5 days post infection respectively.  In contrast, a 1-log reduction in 
viremia is observed in the non-lethal DENV2 challenge group with 1 µg of 




The prophylactic efficacy of 50_3C was also assessed with another serotype, 
DENV1. When 50_3C was administered at 100 µg, 10 µg and 1 µg, similar to 
the non-lethal DENV2 TSV01challenge group, a dose-dependent reduction in 
viremia was observed. Viremia was not detectable with 10 µg of the antibody 
and with as little as 1 µg of the antibody resulting in 1-log reduction in viral 
load.  
 
In addition to prophylaxis, 50_3C IgG also showed intriguing therapeutic 
potential. Administration of 100 µg 50_3C IgG 48 h post challenge with the 
lethal DENV2 D2Y98P strain resulted in a reduction in viremia by 2-log and 
conferred 100% protection in these mice. Survival of the 50_3C treated mice 
was prolonged to at least 20 days as compared to the isotype control treated 
group in which complete lethality was observed 4 days post infection. Death 
of the last mouse occurred at 35 days post infection. It is currently unclear at 
this stage the reasons for death of the animals at this time point. Various 
studies have documented the exponential increase in virus titers in the brain 
despite clearance in the blood and peripheral tissues (Johnson and Roehrig 
1999, Balsitis, Williams et al. 2010) and have been implicated as the cause of 
death in the animals. It is likely that the inability of the antibody molecule to 
cross the blood brain barrier resulted in the escape of virus neutralization in 
the brain.  
 
Achieving reduction in viral load is deemed essential for any anti-viral drugs.  
Evidences for this include clinical studies demonstrating that viral load in 
patients with severe DHF/DSS is at least 1- to 2- logs higher than patients with 
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less severe DF (Vaughn et al, 2000). 50_3C is the most potent patient-derived 
cross-neutralizing antibody ever reported so far:  it neutralized all four DENV 
serotypes with EC50 in the 0.001 to 0.2 µg/ml (7 pM to 1.3 nM) range.  This 
is slightly more potent than the EDE antibodies that showed similar heavy 
chain CDR motif reported by (Dejnirattisai, Wongwiwat et al. 2015). 
Furthermore, the in vitro neutralization capability of 50_3C translated to in 
vivo protection for at least 2 DENV serotypes in both prophylactic and 
therapeutic murine models, which remains to be seen for the antibodies 
reported by (Dejnirattisai, Wongwiwat et al. 2015). A reduction in viral load 
by at least 2 logs was observed in both pre- and post-viral challenge models 
suggesting its efficacy as a potential prophylactic and therapeutic.  
 
Highly potent cross-neutralizing antibodies have also been obtained via 
rational design.  One recent attempt was described by Tharakaraman et al 
(Tharakaraman, Robinson et al. 2013).  The authors reported improvement in 
neutralization potency accompanied by the affinity maturation of a mouse 
monoclonal antibody 4E11 isolated previously. While 4E11 demonstrates 
cross-reactivity to all four DENV serotypes, its potency against DENV4 is 
much lower as compared to the other 3 DENV serotypes. Based on 
computational chemistry and the known E protein structure, mutations that 
lead to enhanced affinity were predicted. This resulted in an affinity matured 
molecule 4E5A with a 450 fold improvement in affinity and 75-fold increment 




Table 4.1: Comparison of EC50 µg/ml values (neutralization capacity) between the 
affinity improved mouse monoclonal antibody 4E5A and our 50_3C. 
 
In comparison, 50_3C is still a notch above the affinity matured 4E5A in 
terms of neutralization potency both in vitro and in vivo. 50_3C exhibits a 3-
30 fold higher potency in vitro for all 4 DENV serotypes. While the affinity 
matured 4E5A demonstrates an improvement in DENV4 neutralization by 75-
fold, 50_3C outperforms it by 50-fold (Table 5.1). Also, 50_3C is superior to 
4E5A in a DENV2 challenge mouse model in which 50_3C led to a 4-logs 
reduction in viremia while the same dose of 4E5A only resulted in a 1-log 
reduction. This observation further reiterated the potency of 50_3C. 
 
Although an antibody that possesses potent neutralization capacity against all 
four DENV serotypes was successfully isolated, an attempt to engineer one 
that can do the job was made in this study based on the structural knowledge 
of the virus. The antibody engineering approach took advantage of the 
structural conformational changes that were necessary to mediate fusion 
between the virus membrane and the host cell’s endosome membrane upon 
endosomal acidification that occurs during the course of infection.  
 
The format of our engineered antibody resembled that of a regular human IgG 
except that each antigen-binding arm is in the ScFv format replacing the 
natural Fab, and is connected to the Fc by a synthetic linker.  Based on the 
Antibody 
clone 
DENV1 DENV2 DENV3 DENV4 
EC50 µg/ml 
4E5A 0.19 0.028 0.77 4.0 
50_3C 0.059 0.001 0.223 0.075 
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crystal structure of the E dimer, a linker length of 20 amino acid residues was 
required to reach the potential epitopes located at the two farthest ends of the 
E dimer.  As the exact locations of the epitopes of our antibodies are yet 
determined, several linkers of various lengths were incorporated in the 
bispecific antibody design to allow for binding to two epitopes of different 
distance. With an optimal length of the linker, simultaneous binding of the 
each arm of the bispecific antibody to each subunit of the E protein dimer 
would lock the E protein in the dimer form and prevent it from undergoing the 
drastic conformational change (dissociation of the dimers followed by the 
formation of trimers) in the low pH environment in the endosome.  
 
An important characteristic of a suitable antibody candidate would be its 
stability at pH 5 to withstand the lower endosomal pH that triggers structural 
changes in E. We found that the majority of the antibodies in our panel tested 
displayed stability at pH 7, with most of them displaying equal or higher 
stability at pH 5. The assembly of bsAbs was facilitated by employing the 
knobs-into-holes technology described in 1996 by Ridgway et al (Ridgway, 
Presta et al. 1996). The primary advantage of this technology is to encourage 
heterodimerization over homodimerization. Although expression levels varied 
among different clones, the bsAb preparations were relatively clean with the 
complete assembled dimeric form represented as the major band 
corresponding to ~100 kDa. A minor fraction of non-assembled chains is 
represented at ~50 kDa. Due to the minor difference in length between the 
‘knob’ and ‘hole’ chains, homodimerization and heterodimerization was 
indistinguishable by SDS-PAGE. The minority of non-assembled chains 
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observed could be the result of an over-expression in one of the chains or 
homodimerization between two ‘hole’ chains to a certain degree leading to an 
excess in ‘knob’ chains. Homodimerization is possible between two ‘hole’ 
chains despite energetically less favorable as compared to nob-hole 
heterodimers, however, the possibility of homodimerization between two 
‘knob’ chains is low due to steric repulsion (Ridgway, Presta et al. 1996).  
 
bsAb were shown to retain their binding capacity when assessed in a binding 
ELISA in comparison to their respective parent clones. However, when 
assessed for their neutralization capacity in vitro, the bsAb with a 20 amino 
acids linker did not further enhance the low potency of their parent IgGs. We 
then suspected if the linker length was too long and overly flexible such that 
the bsAb were unable to ‘lock’ the E monomers in place to prevent subsequent 
conformational changes. However, shorter linker lengths ranging from 5 to 15 
amino acids in length did not appear to improve the potency of the bsAb and, 
in fact, these seemed to have a negative effect on its neutralization capacity 
with an overall increase in EC50. We then hypothesized if the lack of 
improvement in neutralization capacity was due to binding by only a single 
arm at any one time and hence unable “lock” the E dimer.  
 
We set out to determine the binding capacity of the bi-specific antibodies by 
comparing the avidity effect of the bi-specific antibodies versus that of a 
single arm dengue binding control antibody of identical design by SPR 
analysis illustrated in Figure 8.3.   
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Figure 8.3: Illustration of bi-specific antibody binding capacity by assessing 
affinity/avidity effect using surface plasmon resonance. Recombinant envelope 
(rE) protein is immobilized to the floor of a GLC chip followed by the addition of 
bi-specific antibody (bsAb). The hypothetical results of bsAb binding is illustrated 
as (A) bsAb binding with a single arm of either specificity (B) bsAb binding with 
both arms simultaneously with avidity conferred slow dissociation rate. The 




SPR analysis showed similar binding profile by both bsAb variants with dual 
specificities and the single DENV specificity with no significant dissociation 
rate difference to suggest avidity effect. It was however noted that binding by 
their respective parent antibodies in combination at equimolar concentrations 
resulted in a binding capacity difference marked by an increase of about 2-fold 
in response. It is thus hypothesized that bsAb binding is mediated by both 
arms which would otherwise result in a binding capacity similar to that seen 
with the parent antibodies in combination (Figure 6.13). 
  
The lack in epitope information of the antibody candidates proved to be 
daunting in engineering an antibody with a pre-defined function. This piece of 
information could have led to a better understanding in the lack of 
neutralization capacity improvement by bsAb and facilitate a successful 
design by a more rational way.  
 
As an alternative to epitope mapping by cryo-EM, this study also explored the 
feasibility of using yeast surface display for epitope mapping studies. The use 
of yeast display for epitope mapping is not new and has been described with 
success where EDI/EDII or EDIII was displayed (Lisova, Hardy et al. 2007, 
Sukupolvi-Petty, Austin et al. 2007, Brien, Austin et al. 2010, Sukupolvi-Petty, 
Austin et al. 2010).  However, epitope mapping on the full length E 
ectodomain has not been described to date. In this study, we attempted to 
clone and express the full length E ectodomain instead since we now learn that 
the occurrence of antibodies that can bind across domains (interdomain 
epitopes) are present more frequently than previously appreciated (Lin, Tsai et 
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al. 2012, Teoh, Kukkaro et al. 2012, Fibriansah, Tan et al. 2014). Surface 
expression of E ectodomain was detected by double-labeling yeast cells with 
an antibody against the c-myc tag designed at the carboxy terminus of the E 
protein and 4G2. The mouse monoclonal antibody 4G2 recognizes a 
conformational epitope on E and is used to control for proper protein folding. 
Expression of the full length, structurally intact E protein on the yeast surface 
was detected and quantified by flow cytometry.  A double positive population 
was observed as a ‘smear’, indicating differential expression levels on 
individual yeast cells. These data validated the feasibility of using full length 
E ectodomain for epitope mapping studies. 
 
A full length E mutant library was constructed by introducing random 
mutations using error-prone PCR. The mutation rate was aimed at one 
nucleotide change per gene to achieve single amino acid replacement per E 
protein gene by optimizing PCR conditions. The optimal parameters were 
determined to be 3.5 µg of template with 25 PCR cycles of amplification. 
Mutations were observed in about 70% of the genes with about 57% harboring 
one mutation per gene with the rest of 13% containing 2 or more mutations. 
Upon electroporation, a library diversity of approximately 100-fold excess of 
the theoretical library size (based on 1 nucleotide mutation per gene) was 
obtained at 1.676 x 106 individual yeast clones. The expression of the mutant E 
protein on yeast surface was induced by adding galactose in the culture 




Interestingly, we observed that expression of the mutants was dependent on 
induction temperature. The initial attempt to induce expression at 30oC led to 
expression in not more than 20% of yeast cells. This is in contrast to 
expression of the CD20 gene encoded in the same plasmid, which yielded 
least 70% of the cells expression the gene. When the induction temperature 
was lowered to 25oC, expression increased to 30%. Further increase to about 
50% was observed when the induction temperature was lowered to 20oC. Such 
temperature dependency often suggests folding as the rate limiting step in 
protein expression.  Lowering temperature slows down both transcription and 
translation, allowing time for the nascent proteins to fold into correct structure 
before forming unproductive aggregates.   
 
The major limitation of yeast surface display is the inability to map quaternary 
structure epitopes. However, this technology is still useful in the elucidation of 
structure independent conformational interdomain epitopes that occupy a large 
fraction of the human immune response to Dengue infection in humans. 
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Chapter 9: Final conclusions and future work 
Dengue is the leading arthropod-borne disease that puts half of the world’s 
population at risk of infection. To date, neither vaccines nor therapeutics are 
available to counter Dengue infections. Recovery relies solely on palliative 
care. Although mortality is relatively low, morbidity has a huge impact on the 
economy arising from the need for vector control and healthcare personnel. 
Vaccine development has been confounded by the presence of four 
serologically related but antigenically diverse DENV serotypes. While 
homologous protection is life-long, heterologous protection is only transient.  
Secondary infections have been associated with disease exacerbation via the 
widely accepted mechanism termed antibody mediated enhancement (ADE). 
Weakly neutralizing antibodies facilitate uptake of the otherwise non-
infectious viral particles into susceptible cells that express FcR. This process 
leads to an increase in viral replication and thus the higher viral load observed 
in patients with the more severe form of the disease. Thus, an effective 
vaccine is one that can elicit equal immune response to all four DENV 
serotypes simultaneously.  
 
The human memory antibody response to Dengue infection has been the focus 
of various studies to date. Cross-reactive but weakly neutralizing antibodies 
occupy a major fraction of the memory response. The occurrence of type-
specific antibodies that mediate life-long homologous protection is rare. In this 
study, we approach from a different perspective to analyze the antibody 
response at the acute phase of disease. 
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A panel of 65 recombinant monoclonal antibodies was obtained by 
amplification of immunoglobulin (Ig) genes from the plasmablasts of two 
naturally infected Dengue patients. Preliminary characterization of these 
antibodies suggests that the acute phase of human DENV infection is made up 
of antibodies that are primarily complex-specific. These antibodies are E 
reactive with varying neutralization capacities dominated by weak, cross-
serotype neutralizing antibodies, a major fraction of which recognizes fusion 
loop.  
 
A unique antibody designated 50_3C that possesses potent neutralization 
capacity across all four DENV serotypes is present amidst the pool of broadly 
cross-reactive but weakly neutralizing antibodies. Unlike all other antibodies 
in this study, 50_3C does not recognize the recombinant E protein but only 
binds to the quaternary structure of the epitope in the context of the virion. It   
neutralized DENV in the following order: DV2>DV1>DV4>DV3, with a 200-
fold difference in neutralization capacity between DV2 and DV3. Encouraged 
by a recent report in which a weak DENV4 neutralizing antibody was 
substantially improved by increasing its binding affinity, we are planning to 
further enhance the potency of 50_3C, in particular for DENV3 and DENV4, 
through a robust antibody affinity maturing technology developed in our lab. 
Further, 50_3C was shown to mediate neutralization at two stages of the virus 
life cycle by blocking virus attachment and fusion post-attachment. 
Mechanistically, these observations are not immediately understandable and 
therefore deserve further investigation.  
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The correlates of protection mediated by 50_3C in vitro are mirrored in both 
the DENV1 and DENV2 in AG129 animal model. The effects of 50_3C on 
survival, viral load and pathogenesis in various tissues are of interest to 
decipher lethality mechanisms. Re-challenge studies with homologous or 
heterologous DENV serotypes will also be carried out to understand if 
memory induction by 50_3C occurs in the animals. Unfortunately, clinical 
isolates of DENV3 and 4 that replicate efficiently in the AG129 mice are 
currently lacking.  As soon as the models become available, the repertoire of 
in vivo protection of 50_3C will be examined. In addition, elucidating the 
epitope of 50_3C would be of high interest as it is the first natural antibody 
described to date that possesses highly potent neutralization capacity against 
all four DENV serotypes both in the in vitro assays and in the animal models.  
 
Along with the attempt to understand the human antibody response to Dengue 
infection in humans, this study also looked at the feasibility of constructing a 
‘customized’ antibody with pre-defined functions. We proposed the 
construction of an antibody to possess dual specificities with the ability to 
prevent structural changes required by DENV to mediate membrane fusion. 
However, this approach was impeded by the lack of information pertaining to 
the parent antibody relative epitopes.  
 
In an effort to advance epitope mapping studies, the feasibility of employing 
full-length DENV envelope (E) ectodomain display on yeast cell surface as a 
platform for epitope mapping was established. The surface display and 
conformation of E ectodomain was supported by the binding of mouse 
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monoclonal antibody (mAb) 4G2. The mAb 4G2 recognizes a conformational 
epitope on the E protein. A collection of E mutants has been generated by 
error prone PCR and displayed to facilitate epitope mapping. Upon validation 
by an antibody of known epitopes, this system will be employed to map the 
epitope of clone 50_3C as well as those to be incorporated in the bispecific 
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Appendix 1 Media and buffer formulation 
 
NTE buffer 
 100 mM NaCl 
 10 mM Tris-HCl, pH 7.4 
 1 mM EDTA 
 
Overlay media 
1g   Carboxy Methyl Cellulose (CMC) 
20ml   Fetal Bovine Serum 
15ml  Sodium bicarbonate 7.5% solution 
in 1 liter RPMI 1640 
 
5X Crystal violet stain 
1 g       Crystal Violet 
20 ml  Absolute Ethanol 
80 ml  PBS 
 
1X Crystal violet stain 
200 ml  5X      Crystal Violet 
800 ml  4% (w/v) Paraformaldehyde 
 
1X TE buffer 
 10 mM Tris-HCl, pH 8.0 




1X LB (Luria Bertani) plates 
 10 g Tryptone 
 5 g yeast extract 
 5 g NaCl 
 20 g agar 
 100 µg/ml Ampicillin 
 
Coomassie Blue stain 
 0.1% Coomassie Brilliant Blue R-250 
 50% methanol 
 10% glacial acetic acid 
 
Destaining solution 
 40% methanol 
 10% glacial acetic acid 
 
Blocking Buffer 
 5% skim milk 
 
PBST 







1X PBS, pH 7.4 
 137 mM NaCl 
 2.7 mM KCl 
 10 mM Na2HPO4 
 2 mM KH2PO4 
 
Catch buffer 
 10 mM Tris-HCl 
 40 U/µl RNase inhibitor (Promega) 
 
Wash buffer pH 8.0 
 600 mM KCl 
 100 mM KH2PO4 
 10 mM   Imidazole 
 
Elution buffer pH 8.0 
 600 mM KCl 
 100 mM KH2PO4 
500 mM Imidazole 
 
Coating buffer, pH 9.6 
3.56 g Na2CO3 
8.4 g NaHCO3 





100 ml  10X DPBS  
20 ml  FBS 
10 ml  0.5 M EDTA 
1 g  Sodium azide 
in 1 L deionized water. 
 
FACS permeabilization buffer 
100 ml  10X DPBS  
20 ml  FBS 
10 ml  0.5 M EDTA 
1 g  Sodium azide 
1 g  Saponin 
in 1 L deionized water 
 
YPD media 
20 g dextrose 
20 g peptone 
10 g yeast extract 









20 g dextrose 
6.7 g Difco yeast nitrogen base 
5 g Bacto casamino acids, 
5.4 g Na2HPO4 
8.56 g NaH2PO4 




182 g sorbitol 




20 g galactose 
6.7 g Difco yeast nitrogen base 
5 g Bacto casamino acids, 
5.4 g Na2HPO4 
8.56 g NaH2PO4.H2O 






0.39 g 1,4-dithiothreitol 
1 ml 1 M Tris 
prepared fresh and filter sterilized 
 
E buffer, pH 7.5 
1.2 g Tris base 
92.4 g Sucrose 
0.2 g MgCl2 
in 1 L deionized water and filter sterilized 
 
PBSF buffer, pH 7.4 
8 g NaCl 
0.2 g KCl 
1.44 g Na2HPO4 
0.24 g KH2PO4 
1 g bovine serum albumin (BSA) 




Table 5.1: RT-PCR conditions for cDNA synthesis of human IgG variable regions.  
Step Cycling Temperature Duration No of cycles 
1 50
oC 30 min 1 95oC 15 min 
2 
95oC 30 s 
40 55oC 30 s 
72oC 1 min 
3 72oC 10 min 1 
 
 
Table 5.2: PCR conditions for introduction of restriction enzymes sites for human 
recombinant IgG1 cloning. 
Step Cycling Temperature Duration No ofcycles 
1 92oC 3 min 1 
2 
92oC 30 s 
30 55oC 30 s 
72oC 1 min 
 
 
Table 5.3: Oligonucleotides used for screening by colony PCR and DNA sequencing of 
human recombinant IgG1 plasmid. 
Primer Sequence (5’ --  3’) 
Vec 1146 TGTCCACTCCCAGGTCCAAG 
Vec 2312 TTTCCTTTATTAGCCAGAGG 
 
Table 5.4: Oligonucleotides used for the cloning of dengue serotype 2, strain TSV01 
envelope protein into pMT/BiP/V5-HisA vector. Underlined sequences denote 
restriction sites. 










Table 5.5: PCR cycling conditions for TSV01 envelope amplification. 
Step Cycling Temperature Duration No of cycles 
1 95oC 3min 1 
2 
95oC 60 s 
20 62oC 30 s 






Table 5.6: Oligonucleotides used for screening by colony PCR and DNA sequencing of 
DENV2 TSV01 E protein plasmid. 
Primer Sequence (5’ --  3’) 
MT Forward CATCTCAGTGCAACTAAA 
BGH Reverse TAGAAGGCACAGTCGAGG 
 
Table 5.7: Oligonucleotides used for site-directed mutagenesis of the human IgG1 Fc 
region, replacing leucine residues at positions 234 and 235 to alanine for 
abolishment of FCγRIIb binding. Underlined sequences denote mutation sites. 










Table 5.8: Cycling conditions used for site-directed mutagenesis of the human IgG1 
Fc region. 
Step Cycling Temperature Duration 
No of 
cycles 
1 95oC 1 min 1 
2 
95oC 1 min 
16 55oC 1 min 
68oC 10 min 
 
Table 5.9: Oligonucleotides used for amplification of ScFv for bi-specific cloning into 
the pTT5 vector. Underlined sequences denote restriction sites. 














Table 5.10: Cycling conditions used for amplification and introduction of restriction 
sites into ScFv. 
Step Cycling Temperature Duration 
No of 
cycles 
1 95oC 3 min 1 
2 
95oC 60 s 
25 65oC 30 s 
72oC 90 s 




Table 5.11: Oligonucleotides used for amplification and cloning of DENV2 TSV01 E 
protein into the yeast surface display vector pCTCON2. 












Table 5.12: Cycling conditions used for amplification of DENV2 TSV01 E protein. 
Step Cycling Temperature Duration No of cycles 
1 95oC 3 min 1 
2 
95oC 60 s 
20 62oC 30 s 
72oC 90 s 
 
Table 5.13: Oligonucleotides used for the generation of DENV2 TSV01 E protein 
mutant library. 










Table 5.14: Cycling conditions for DENV2 TSV01 E protein mutant library 
construction. 
Step Cycling Temperature Duration No of cycles 
1 94oC 3 min 1 
2 
94oC 45 s 
25 60oC 30 s 
72oC 90 s 





Table 5.15: List of oligonucleotides for RT-PCR 
  






























Primer Sequence (5’ --  3’) 
HuVH1B/7A-
BACK-SalI GGGTTCCAGGGTCGACTGGCCAGRTGCAGCTGGTGCARTCTGG 
HuVH1C-
BACK-SalI GGGTTCCAGGGTCGACTGGCSAGGTCCAGCTGGTRCAGTCTGG 
HuVH2B-
BACK-SalI GGGTTCCAGGGTCGACTGGCCAGRTCACCTTGAAGGAGTCTGG 
HuVH3B-
BACK-SalI GGGTTCCAGGGTCGACTGGCSAGGTGCAGCTGGTGGAGTCTGG 
HuVH3C-
BACK-SalI GGGTTCCAGGGTCGACTGGCGAGGTGCAGCTGGTGGAGWCYGG 
HuVH4B-
BACK-SalI GGGTTCCAGGGTCGACTGGCCAGGTGCAGCTACAGCAGTGGGG 
HuVH4C-
BACK-SalI GGGTTCCAGGGTCGACTGGCCAGSTGCAGCTGCAGGAGTCSGG 
HuVH5B-
BACK-SalI GGGTTCCAGGGTCGACTGGCGARGTGCAGCTGGTGCAGTCTGG 
HuVH6A-
BACK-SalI GGGTTCCAGGGTCGACTGGCCAGGTACAGCTGCAGCAGTCAGG 
HuVk1B-
BACK-SalI GGGTTCCAGGGTCGACTGGCGACATCCAGWTGACCCAGTCTCC 
HuVk2 -
BACK-SalI GGGTTCCAGGGTCGACTGGCGATGTTGTGATGACTCAGTCTCC 
HuVk3B-
BACK-SalI GGGTTCCAGGGTCGACTGGCGAAATTGTGWTGACRCAGTCTCC 
HuVk4B-
BACK-SalI GGGTTCCAGGGTCGACTGGCGATATTGTGATGACCCACACTCC 
HuVk5 -
BACK-SalI GGGTTCCAGGGTCGACTGGCGAAACGACACTCACGCAGTCTCC 
HuVk6 -
BACK-SalI GGGTTCCAGGGTCGACTGGCGAAATTGTGCTGACTCAGTCTCC 
HuIgG-NheI 
reverse+4 TCTTGGAGGAGGGTGCTAGCGGGAAGACCGATGGGCCCT 
HuIgK-NotI 
reverse 
CGGCCTCGAGCGGCCGCTTAACACTCTCCCCTGTTGAAGC 
HuIgL2-NotI 
reverse 
CGGCCTCGAGCGGCCGCTTATGAACATTCTGTAGGGGCCA 
HuIgL7-NotI 
reverse 
CGGCCTCGAGCGGCCGCTTAAGAGCATTCTGCAGGGGCCA 
